Nothing Special   »   [go: up one dir, main page]

WO1995005363A1 - Amidine derivatives with nitric oxide synthetase activities - Google Patents

Amidine derivatives with nitric oxide synthetase activities Download PDF

Info

Publication number
WO1995005363A1
WO1995005363A1 PCT/GB1994/001767 GB9401767W WO9505363A1 WO 1995005363 A1 WO1995005363 A1 WO 1995005363A1 GB 9401767 W GB9401767 W GB 9401767W WO 9505363 A1 WO9505363 A1 WO 9505363A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
thiophenecarboximidamide
amino
ethyl
compound
Prior art date
Application number
PCT/GB1994/001767
Other languages
French (fr)
Inventor
Robert James Gentile
Robert John Murray
James Edwin Macdonald
William Calvin Shakespeare
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939316806A external-priority patent/GB9316806D0/en
Priority claimed from GB939319835A external-priority patent/GB9319835D0/en
Priority claimed from GB939325410A external-priority patent/GB9325410D0/en
Priority claimed from GB9401580A external-priority patent/GB9401580D0/en
Priority claimed from GB9411700A external-priority patent/GB9411700D0/en
Priority to EP94923776A priority Critical patent/EP0713483B1/en
Priority to JP7506814A priority patent/JPH09501918A/en
Priority to RU96104356A priority patent/RU2130017C1/en
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Priority to US08/586,761 priority patent/US5807885A/en
Priority to PL94312961A priority patent/PL180081B1/en
Priority to AT94923776T priority patent/ATE231126T1/en
Priority to DE69432019T priority patent/DE69432019T2/en
Priority to SK163-96A priority patent/SK16396A3/en
Priority to AU73875/94A priority patent/AU682381B2/en
Priority to BR9407515A priority patent/BR9407515A/en
Publication of WO1995005363A1 publication Critical patent/WO1995005363A1/en
Priority to NO960534A priority patent/NO306459B1/en
Priority to FI960628A priority patent/FI960628A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • This invention relates to amidine derivatives, processes for their preparation, compositions containing them and their use in therapy.
  • Amidine derivatives have been described for use as herbicides in German Patent Application DE-OS-2321330 (Bayer). N-phenyl amidine derivatives have also been described for use in the treatment of diabetes in US Patent 3669974 (USV).
  • D represents phenyl, pyridinyl or a 5 membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, S and N, which three groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, halogen and perfluoroalkyl C1 to 6; or perfluoroalkyl C1 to 6;
  • R 1 represents hydrogen, alkyl C1 to 6 or halogen
  • R 2 represents -X(CH 2 ) n ZCONR 3 R 4 , -X(CH 2 ) n NHCO(CH 2 ) s NR 3 R 4 ,
  • R 3 and R 4 independently represent hydrogen, alkyl C1 to 6, -(CH 2 ) r A, -(CH 2 ) m OA or -CH(CH 3 )(CH 2 ) t A;
  • R 4 together represent 1-indanyl, piperonylamino-, piperidinyl, morpholinyl, pyrrolidinyl, 1,2,3,4-tetrahydroisoquinolinyl; or piperazinyl optionally 4-substituted by alkyl C1 to 6;
  • R 5 represents alkyl C1 to 6, perfluoroalkyl C1 to 6, -(CH 2 ) r A or
  • A represents phenyl, pyridinyl, pyrimidinyl, or a 5 membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, S and N, which four groups are optionally substituted by one or more groups selected from alkyl C1 to 6, halogen, nitro, cyano and trifluoromethyl;
  • R 6 represents phenyl, pyridinyl or a 5 membered heterocyclic aromatic ring contaimng 1 to 4 heteroatoms selected from O, S and N, which three groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, halogen and perfluoroalkyl C1 to 6; or perfluoroalkyl C1 to 6;
  • n and r independently represent an integer in the range 0 to 6 inclusive;
  • p and w independently represent an integer in the range 1 to 5 inclusive;
  • n represents an integer in the range 2 to 5 inclusive
  • q and t independently represent an integer in the range 0 to 5 inclusive;
  • s represents an integer in the range 1 to 3 inclusive;
  • X represents O or a bond
  • Z represents O, NR 7 or a bond
  • R 7 represents hydrogen or alkyl C1 to 6
  • D represents phenyl, pyridinyl or a 5 membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, S and N,
  • three groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, halogen or perfluoroalkyl C1 to 6.
  • D represents phenyl, thiophene, furan, pyrrole or thiazole, which five groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, halogen or perfluoroalkyl C1 to 6.
  • D represents thiophene, pyrrole, furan or thiazole which four groups are optionally substituted by alkyl C1 to 6 or halogen.
  • D represents thiophene, furan or pyrrole, most especially thiophene.
  • D represents 2-thiophene.
  • R 1 represents hydrogen.
  • R 2 represents -X(CH 2 ) n ZCONR 3 R 4 ,
  • -NR 3 R 4 represents piperidinyl, morpholinyl, pyrrolidinyl, 1,2,3,4-tetrahydroisoquinolinyl or 1-indanyl, or that at least one of R 3 and R 4 represents -(CH 2 ) r A or -(CH 2 ) m OA.
  • -NR 3 R 4 represents 1,2,3,4-tetrahydroisoquinolinyl or 1-indanyl or that one of R 3 and R 4 represents -(CH 2 ) r A and the other represents hydrogen or methyl.
  • one of R 3 and R 4 represents -(CH 2 ) r A and the other represents hydrogen or methyl.
  • R 2 represents -X(CH 2 ) n NHCOR 5
  • R 5 represents -(CH 2 ) r A.
  • R 2 represents -X(CH 2 ) n ZCONR 3 R 4 , -X(CH 2 ) n NHCO(CH 2 ) s NR 3 R 4 , -X(CH 2 ) P NR 3 R 4 or -X(CH 2 ) n NHCOR 5 , we prefer X to represent a bond.
  • R 7 represents hydrogen
  • R 2 represents -X(CH 2 ) n ZCONR 3 R 4 we prefer Z to represent a bond.
  • R 6 represents phenyl or a 5-membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, S and N, which two groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6 and halogen.
  • R 2 represents -(CH 2 ) q NHC(NH)R 6
  • R 6 represents phenyl or thiophene, which two groups are optionally substituted by one or more groups selected from alkyl C1 to 6 and halogen.
  • R 2 represents -(CH 2 ) q NHC(NH)R 6
  • q represents 0, 1 or 2.
  • q represents 0 or 2, especially 0.
  • R 2 represents -(CH 2 ) q NHC(NH)R 6
  • q represents 0
  • R 6 represents phenyl optionally substituted by halogen, alkyl C1 to 6, or alkoxy C1 to 6 or R 6 represents pyridinyl
  • D does not have the same definition as R 6 .
  • R 2 represents -(CH 2 ) q NHC(NH)R 6 and q represents 0, then we generally prefer than R 6 does not have the same definition as D.
  • R 2 represents -X(CH 2 ) p NR 3 R 4 we prefer that p represents an integer in the range 1 to 4 inclusive, particularly 1, 2 or 3, especially 1 or 2.
  • n represents 1, 2 or 3, especially 2 or 3.
  • R 3 , R 4 or R 5 represent -(CH 2 ) r A
  • r to represent an integer in the range 0 to 4 inclusive, particularly 0, 1 or 2, more particularly 1 or 2, especially 1.
  • R 3 or R 4 represent -(CH 2 ) m OA
  • R 5 represents -O(CH 2 ) w A
  • w we prefer w to represent 2, 3 or 4.
  • R 3 or R 4 represent -CHMe(CH 2 ) t A
  • t we prefer t to represent 0, 1 or 2, especially 0 or 1.
  • A represents phenyl, pyridinyl, pyrimidinyl, thiophenyl or furanyl, which five groups are optionally substituted by one or more groups selected from alkyl C1 to 6 and halogen.
  • A represents phenyl optionally substituted one or more groups selected from alkyl C1 to 6 and halogen.
  • D or R 5 represent perfluoroalkyl C1 to 6 we prefer that they represent pentafluoroethyl or trifluoromethyl, especially trifluoromethyl.
  • R 2 represents -X(CH 2 ) p NR 3 R 4 or -(CH 2 ) q NHC(NH)R 6 .
  • R 1 and R 2 are as defined above,
  • R 1 and R 2 are as defined above and HA is an acid
  • R 3 and R 4 represents alkyl C1 to 6, -(CH 2 ) A -(CH 2 ) m OA or
  • R 8 represents alkyl C1 to 6, -(CH 2 ) r A, -(CH 2 ) m OA or -CH(CH 3 )(CH 2 ) t A and L is a leaving group
  • R 6 is as defined above and L is a leaving group
  • R 6 is as defined above
  • R 3 and R 4 are as defined above,
  • R 3 , R 4 and s are as defined above and L is a leaving group
  • R 5 is as defined above and L is a leaving group
  • R 7 is as defined above and L is a leaving group
  • R 1 , D, p and X are as defined above,
  • R 1 , D, X and n are as defined above and Z represents O or NR 7 , with a compound of formula XX
  • R 4 is as defined above
  • R 5 represents -O(CH 2 ) w A by reacting a compound of formula XXI wherein R 1 , D, X and n are as defined above,
  • R 1 , R 4 , D, X and p are as defined above,
  • R 1 , A, D, r and p are as defined above,
  • R 1 , A, D, p and m are as defined above,
  • R 1 , A, D, p and r are as defined above, or
  • R 1 , A, D, p and m are as defined above,
  • the reaction will take place on stirring a mixture of the reactants in a suitable solvent, for example a lower alkanol e.g. ethanol, isopropanol or tertiary butanol, at a temperature between room temperature and the reflux temperature of the solvent.
  • a suitable solvent for example a lower alkanol e.g. ethanol, isopropanol or tertiary butanol.
  • the reaction time will depend inter alia on the solvent and the nature of the leaving group, and may be up to 48 hours, however it will typically be from 1 to 5 hours.
  • Suitable leaving groups that L may represent include thioalkyl, sulphonic acid, trifluorocarbon sulphonic acid, halide, alkyl and aryl alcohols and tosyl groups; others are recited in 'Advanced Organic Chemistry', J. March (1985) 3rd Edition, McGraw-Hill on page 315 and are well known in the art.
  • the reaction is preferably performed by refluxing a mixture of the two compounds for several hours in the presence of a suitable solvent whereby the reaction temperature is high enough so that condensation takes place readily, but not sufficiently high to decompose the amidine formed.
  • the reaction temperature can vary from room temperature to about 250 °C, although it is preferable to perform the reaction at temperatures from about 100 °C to 200 °C.
  • o-dichlorobenzene is a particularly suitable solvent and it is useful to add 4-dimethylaminopyridine as a catalyst.
  • the solvent may be decanted, and the reaction worked up by addition of aqueous base.
  • the solvent may be evaporated off under vacuum and the reaction mixture worked up by addition of water.
  • the acid HA may be an organic or inorganic acid, for instance,
  • hydrochloric hydrobromic, hydroiodic, sulphuric, nitric, phosphoric, acetic, lactic, succinic, fumaric, malic, maleic, tartaric, citric, benzoic or methanesulphonic acid.
  • process (c) the reaction will take place under standard conditions, for example by reacting the two materials in an inert solvent under basic conditions at room temperature for a period of up to 12 hours.
  • L represents halide, particularly bromide.
  • Process (d) may be performed under conditions analogous to those described above for process (a).
  • Process (e) may be performed under conditions analogous to those described above for process (b).
  • Processes (f), (g) and (h) may be performed under the standard conditions well known in the art for condensation of an amine and a carboxylic acid or an activated carboxylic acid to form an amide.
  • reaction of compounds to form the amide may be achieved on stirring the reactants for 12-24 hours at a
  • Process (i) may be performed under standard conditions analogous to those given above for process (c).
  • the reduction may be perfomed by treatment with diborane in an inert solvent e.g. THF.
  • an inert solvent e.g. THF.
  • Alternative although less preferred reagents which may be suitable include lithium aluminium hydride and reagents for catalytic hydrogenation e.g. H 2 on Pd/C. Further details of the reaction conditions for use of these reactions may be obtained by reference to J. March “Advanced Organic Chemistry" on page 1099, including the references cited therein.
  • the reduction reaction may be performed under a number of conditions, for example those described in J March "Advanced Organic Chemistry" on pages 1103-1104.
  • reaction (1) and (m) the reaction may be performed by stirring the reactants in the presence of an inert solvent at a temperature between room temperature and the reflux temperature of the solvent for up to 24 hours.
  • Process (n) may be performed under conditions analogous to those described above for processes (f), (g) and (h).
  • the reduction may be performed by treating the compound with sodium borohydride under standard conditions.
  • the reaction may be performed under conditions analogous to those described above for process (j).
  • Salts of compounds of formula I may be formed by reacting the free acid, base or a salt, enantiomer, tautomer or protected derivative thereof, with one or more equivalents of the appropriate base or acid.
  • the reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, eg water, dioxan, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed in vacuo or by freeze drying.
  • the reaction may be a metathetical process or it may be carried out on an ion exchange resin.
  • the compounds of formula III may be prepared by reduction of a
  • the reduction reaction may be performed under analogous conditions to those described above for process (k).
  • Certain compounds of formula XXX are either known or may be prepared by conventional methods known per se. Other compounds of formula XXX may be prepared from known compounds with simpler side-chains by following analogous processes to those described above for processes (c) to (s).
  • Compounds of formula V may be prepared by analogous processes to those described for the preparation of compounds of formula III.
  • Compounds of formula V may be converted to corresponding compounds of formula III by treatment with a base.
  • Compounds of formula HI may be converted to corresponding compounds of formula V by treatment with a protic acid HA, for example one of those listed above.
  • XXVI, XXVII and XXVIII may be prepared by analogous processes to those described for the preparation of compounds of formula I.
  • Compounds of formula VIII are either known or may be prepared by an analogous process to that described above for preparation of compounds of formula II.
  • Compounds of formula IV, VI, X, XII, XVI, XX, XXII, XXIII and XXIX are either known or may be prepared by conventional methods known per se.
  • hydroxy, amine or other reactive groups in intermediate compounds may be protected using a protecting group as described in the standard text "Protecting groups in Organic Synthesis", 2nd Edition (1991) by Greene and Wuts.
  • the compounds of the invention and intermediates may be isolated from their reaction mixtures by standard techniques.
  • alkyl C1 to 6 includes straight chain, branched, saturated,
  • the compounds of formula I may exist in tautomeric, enantiomeric or
  • optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, e.g. fractional crystallisation, or HPLC. Alternatively the individual enantiomers may be made by reaction of the appropriate optically active starting materials under reaction conditions which will not cause racemisation.
  • Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures.
  • the compounds of general formula I possess useful pharmacological activity in animals. In particular, they possess useful nitric oxide synthetase inhibiting activity, and are expected to be useful in the treatment or prophylaxis of human diseases or conditions in which the synthesis or oversynthesis of nitric oxide forms a
  • hypoxia e.g. in cases of cardiac arrest and stroke
  • neurodegenerative disorders including nerve degeneration and/or nerve necrosis in disorders such as hypoxia, hypoglycemia, epilepsy, and in external wounds (such as spinal cord and head injury), hyperbaric oxygen convulsions and toxicity
  • dementia e.g. pre-senile dementia, Alzheimer's disease and AIDS-related dementia
  • Compounds of formula I may also be expected to show activity in the prevention and reversal of tolerance to opiates and diazepines, treatment of drug addiction, relief of pain and treatment of migraine and other vascular headaches.
  • the compounds of the present invention may also show useful immunosuppressive activity, be useful in the treatment or prophylaxis of
  • Compounds of formula I are expected to be particularly useful in the treatment of neurodegenerative disorders or of migraine or for the prevention and reversal of tolerance to opiates and diazepines or for the treatment of drug addiction and especially in the treatment of neurodegenerative disorders.
  • the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered to a human at a daily dosage of between 1 mg and 2000 mg (measured as the solid form) per day.
  • the compounds of formula I, and pharmaceutically acceptable salts thereof, may be used on their own, or in the form of appropriate medicinal preparations for enteral or parenteral administration.
  • a pharmaceutical formulation including preferably less than 80% and more preferably less than 50% of a compound of formula I, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable diluent or carrier.
  • compositions in a form suitable for oral, i.e. oesophageal administration include: tablets, capsules and dragees; sustained release compositions include those in which the active ingredient is bound to an ion exchange resin which is optionally coated with a diffusion barrier to modify the release properties of the resin.
  • nitric oxide synthetase has a number of isoforms and compounds of formula I, or pharmaceutically acceptable salts thereof, may be screened for nitric oxide synthetase activity by procedures based on those of Bredt and Snyder in Proc. Natl. Acad. Sci. (1990) 87, 682-685 and Förstermann et. al. (1992) Eur. J. Pharm. 225,161-165 as follows.
  • Nitric oxide synthetase converts 3 H-L-arginine to 3 H-L-citrulline which can be separated by cation exchange chromatography and
  • Enzyme was isolated from rat hippocampus or cerebellum.
  • the cerebellum or hippocampus of a male Sprague-Dawley rat (250-275g) is removed following CO 2 anaesthesia of the animal and decapitation.
  • Cerebellar or hippocampal supernatant is prepared by homogenisation in 50 mM Tris-HCl with 1 mM EDTA buffer (pH 7.2 at 25 °C) and centifugation for 15 minutes at 20,000 g. Residual L-arginine is removed from the supernatant by chromatography through Dowex AG-50W-X8 sodium form and hydrogen form columns successively, and further centrifugation at 1000 g for 30 seconds.
  • 25 ⁇ l of the final supernatant is added to each of 12 test tubes containing 25 ⁇ l L-arginine solution (of concentration 18 ⁇ M 1 H-L-arginine, 96 nM 3 H-L-arginine) and either 25 ⁇ l of an assay buffer (50 mM HEPES, 1 mM EDTA, 1.5 mM CaCl 2 , pH 7.4) or 25 ⁇ l of test compound in the buffer at 22 °C.
  • an assay buffer 50 mM HEPES, 1 mM EDTA, 1.5 mM CaCl 2 , pH 7.4
  • each test tube was added 75 ⁇ l of complete assay buffer (50 mM HEPES, 1 mM EDTA, 1.5 mM CaCl 2 , 1 mM DTT, 100 ⁇ M NADPH, 10 ⁇ g/ml calmodulin, pH 7.4) to initiate the reaction and the reaction is stopped after 10 minutes by addition of 2 ml of a termination buffer (20 mM HEPES, 2 mM EDTA pH 5.5).
  • complete assay buffer 50 mM HEPES, 1 mM EDTA, 1.5 mM CaCl 2 , 1 mM DTT, 100 ⁇ M NADPH, 10 ⁇ g/ml calmodulin, pH 7.4
  • Labelled L-citrulline is separated from labelled L-arginine by chromatography over a Dowex AG-50W-X8 200-400 mesh column. 1 ml of each terminated reaction is added to an individual 1 ml column and the eluant combined with that from two 1 ml distilled water washes and 16 ml of scintillation cocktail. The L-citrulline is then quantified by scintillation counting.
  • Enzyme is prepared, after induction, from the cultured murine macrophage cell line J774A-1 (obtained from laboratories of the Imperial Cancer Research Fund). J774A-1 cells are cultured in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% foetal bovine serum, 4 mM L-glutamine and antibiotics (100 units/ml penicillin G, 100 ⁇ g/ml streptomycin & 0.25 ⁇ g/ml amphotericin B). Cells are routinely grown in 225 cm 2 flasks containing 35 ml medium kept at 37 °C and in a humidified atmosphere containing 5% CO 2 .
  • DMEM Dulbecco's Modified Eagles Medium
  • Nitric oxide synthetase is produced by cells in response to interferon- ⁇ (IFN7) and lipopolysaccharide (LPS).
  • IFN7 interferon- ⁇
  • LPS lipopolysaccharide
  • the medium from confluent culture flasks is removed and replaced with 25 ml (per flask) of fresh medium containing 1 ⁇ g/ml LPS and 10 units/ml IFN7. After a period of 17-20 hours in culture, harvesting of cells is accomplished by scraping the cell sheet from the flask surface into the culture medium.
  • Cells are collected by centrifugation (1000g for 10 minutes) and lysate prepared by adding to the cell pellet a solution containing 50 mM Tris-HCl (pH 7.5 at 20 °C), 10% (v/v) glycerol, 0.1% (v/v) Triton-X-100, 0.1 ⁇ M dithiothreitol and a cocktail of protease inhibitors comprising leupeptin (2 ⁇ g/ml), soya bean trypsin inhibitor (10 ⁇ g/ml), aprotinin (5 ⁇ g/ml) & phenylmethylsulphonyl fluoride (50 ⁇ g/ml).
  • 25 ⁇ l substrate cocktail 50 mM Tris-HCl (pH 7.5 at 20 °C), 400 ⁇ M NADPH, 20 ⁇ M flavin adenine dinucleotide, 20 ⁇ M flavin mononucleotide, 4 ⁇ M tetrahydrobiopterin, 12 ⁇ M L-arginine and 0.025 ⁇ Ci L-[ 3 H] arginine
  • substrate cocktail 50 mM Tris-HCl (pH 7.5 at 20 °C), 400 ⁇ M NADPH, 20 ⁇ M flavin adenine dinucleotide, 20 ⁇ M flavin mononucleotide, 4 ⁇ M tetrahydrobiopterin, 12 ⁇ M L-arginine and 0.025 ⁇ Ci L-[ 3 H] arginine
  • the reaction is started by adding 50 ⁇ l of cell lysate (prepared as above) and after incubation for 1 hour at room temperature is terminated by addition of 50 ⁇ l of an aqueous solution of 3 mM nitroarginine and 21 mM EDTA.
  • Labelled L-citrulline is separated from labelled L-arginine using Dowex AG- 50W.
  • 150 ⁇ l of a 25% aqueous slu ⁇ y of Dowex 50W (Na + form) is added to the assay after which the whole is filtered into 96 well plates.
  • 70 ⁇ l of filtrate is sampled and added to wells of 96 well plates containing solid scintillant. After allowing the samples to dry the L-citrulline is quantified by scintillation counting.
  • basal activity is 300 dpm per 70 ⁇ l sample which is increased to 1900 dpm in the reagent controls.
  • Aminoguanidine which gives an IC 50 (50% inhibitory concentration) of 10 ⁇ M, is tested as a standard to verify the procedure.
  • Enzyme may be isolated from human umbilical vein endothelial cells (HUVECs) by a procedure based on that of Pollock et al (1991) Proc. Nat. Acad. Sci., 88, 10480-10484.
  • HUVECs were purchased from Clonetics Corp (San Diego, CA, USA) and cultured to confluency. Cells can be maintained to passage 35-40 without significant loss of yield of nitric oxide synthetase.
  • cells When cells reach confluency, they are resuspended in Dulbecco's phosphate buffered saline, centrifuged at 800 rpm for 10 mins, the cell pellet homogenised in ice-cold 50 mM Tris-HCl, 1 mM EDTA, 10% glycerol, 1 mM phenylmethylsulphonylfluoride, 2 ⁇ M leupeptin at pH 4.2. Following centrifugation at 34,000 rpm for 60 mins, the pellet is solubilised in the homogenisation buffer which also contains 20 mM CHAPS. After a 30 min incubation on ice, the suspension is centrifuged at 34,000 rpm for 30 mins.
  • the resulting supernatant is stored at -80 °C until use.
  • 25 ⁇ l of the final supernatant is added to each of 12 test tubes containing 25 ⁇ l L-arginine solution (of concentration 12 ⁇ M 1 H-L-arginine, 64 nM
  • Labelled L-citrulline is separated from labelled L-arginine by chromatography over a Dowex AG-50W-X8 200-400 mesh column. 1 ml of each terminated reaction is added to an individual 1 ml column and the eluant combined with that from two 1 ml distilled water washes and 16 ml of scintillation cocktail. The L-citrulline is then quantified by scintillation counting.
  • basal activity is increased by 5,000 dpm/ml of sample above a reagent blank which has an activity of 1500 dpm/ml.
  • Compounds may also be tested in an ex-vivo assay to determine the extent of brain penetration.
  • mice Male Sprague-Dawley rats (250-275g) were dosed intravenously at 10mg/kg with test compound dissolved in 0.9% saline or with saline alone as control. At a predetermined time (typically 2-24 hours) after treatment, the animals were sacrificed, the cerebellum removed and the supernatant prepared and assayed for nitric oxide synthetase activity as described in Screen A
  • IC 50 the concentration of drug substance which gives 50% enzyme inhibition in the assay.
  • IC 50 values for test compounds were initially estimated from the inhibiting activity of 1, 10 and 100 ⁇ M solutions of the compounds.
  • Example 1 In Screen A above (a screen for activity against the neuronal isoform of nitric oxide synthetase), the compound of Example 1 below gave an IC 50 of less than 10 ⁇ M indicating that it is expected to show useful therapeutic activity. In Screens B and C (the screens for activity against the macrophage and endothelial isoforms of nitric oxide synthetase) the compound of Example 1 gave IC 50 values more than 10 times that obtained in Screen A indicating that it shows desirable selectivity.
  • Example 2-20, 21(a)-(n), 22(a)-(e), 23(a)-(f), 24-26, 27(a), (b), 28-47 and 49-71 were tested in Screen A and also gave IC 50 values of less than 10 ⁇ M.
  • Example 48 was tested in Screen A and gave an IC 50 value of less than 100 ⁇ M.
  • Example 72 was tested in Screen A and gave 17% inhibition at 10 ⁇ M. Thus these compounds are also expected to show useful therapeutic activity.
  • Compounds of formula I, and pharmaceutically acceptable salts thereof, may also have the advantage that they are more selective for the neuronal isoform of nitric oxide synthetase enzyme and are therefore expected to show useful therapeutic activity with a reduced side-effect profile associated with inhibition of the other isoforms.
  • the invention is illustrated by the following examples:
  • step (a) To a stirred solution of the product of step (a) (0.89 g, 3.40 mmol) in THF (5 ml) at 0 °C was added NaH (60%, 0.18 g, 4.42 mmol) followed by benzyl bromide (0.50 ml, 4.10 mmol). The mixture was stirred at room temperature for 6 h, quenched with water, and extracted with ethyl acetate ( 3 X 30 ml).
  • step (b) To a stirred solution of the product of step (b) (0.52 g, 1.48 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 1 hr, filtered through celite, and concentrated to give N(2-(4-aminophenyl)ethyl)-N-(phenylmethyl)trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction.
  • step (a) To a stirred solution of the product of step (a) (1.0 g, 4.03 mmol) in THF (10 ml) at 0 °C was added NaH (60%, 0.21 g, 5.24 mmol) followed by benzyl bromide (0.72 ml, 4.84 mmol). The mixture was stirred at room temperature for 12 h, quenched with water, and extracted with ethyl acetate( 3 X 30 ml).
  • step (b) To a stirred solution of the product of step (b) (1.76 g, 5.16 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 0.5 hr, filtered through celite, and concentrated to give N((4-aminophenyl)methyl)-N-(phenylmethyl)trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction.
  • Example 1 step (d)) (1.47 g, 5.16 mmol). The mixture was stirred for 24 hr at 40 °C, diluted with methanol (5 ml) and 2 N NaOH (15 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml).
  • step (a) To a stirred solution of the product of step (a) (2.0 g, 9.26 mmol) in THF (10 ml) at 0 °C was added NaH (60%, 0.37 g, 9.26 mmol) followed by 4-nitrobenzyl bromide (1.0 g, 4.63 mmol). The mixture was stirred at room temperature for 1 hr, quenched with water, and extracted with ethyl acetate (3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered,
  • step (b) To a stirred solution of the product of step (b) (1.60 g, 4.54 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 0.75 hr, filtered through celite, and concentrated to give N-(2-phenylethyl)-N-((4-aminophenyl)methyl)trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction.
  • step (d) N-(4-(1-((2-phenylethyl)amino )methyl)phenyl)-2-thiophenecarboximidamide
  • step (c) N-(4-(1-((2-phenylethyl)amino )methyl)phenyl)-2-thiophenecarboximidamide
  • isopropanol 5 ml
  • Example 1 step (d)) (1.30 g,4.54 mmol). The mixture was stirred for 24 hr at 40 °C, diluted with methanol (5 ml) and 2 N NaOH (10 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml).
  • step (c) N-(4-(2-((2-chlorophenylmethyl )amino)ethyl)iphenyl)-2-thiophenecarboximidamide
  • step (b) To a solution of the product of step (b) (2.1 g, 5.96 mmol) in isopropanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (1.7 g, 5.96 mmol). The mixture was stirred for 24 hr, diluted with methanol (10 ml) and 2 N NaOH (6 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, concentrated and
  • step (a) To a stirred solution of the product of step (a) (1.63 g, 4.40 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 1 hr, filtered through celite, and concentrated to give N- (2-(4-aminophenyl)ethyl)-N-((3-fluorophenyl)methyl)trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction,
  • step (b) To a solution of the product of step (b) (1.5 g, 4.40 mmol) in methanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (1.3 g, 4.40 mmol). The mixture was stirred for 2 hr, diluted with methanol (5 ml) and 2 N NaOH (8 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml).
  • step (a) N-(2-(4-aminophenyl)ethyl)-N-((2-methylphenyl)methyl)-trifluoroacetamide
  • step (b) To a solution of the product of step (b) (1.62 g, 4.82 mmol) in methanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (1.37 g, 4.82 mmol). The mixture was stirred for 2 hr, diluted with 2 N NaOH (8 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml).
  • step (b) N-methyl-N-(2-(4-aminophenyl)ethyl)trifluoroacetamide
  • step (a) N-methyl-N-(2-(4-aminophenyl)ethyl)trifluoroacetamide
  • THF/MeOH 100 ml, 1:1
  • step (b) To a solution of the product of step (b) (1.32 g, 5.37 mmol) in methanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of
  • Example 1 step (d)) (1.53 g, 5.37 mmol). The mixture was stirred for 2 hr, diluted with 2 N NaOH (8 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml).
  • Example 1 step (a)) (1.00 g, 3.81 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 1 hr, filtered through celite, and concentrated to give N-(2-(4-aminophenyl)ethyl)trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction.
  • step (a) To a solution of the product of step (a) (0.88 g,3.81 mmol) in methanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (1.09 g, 3.81 mmol). The mixture was stirred for 12 hr, diluted with 2 N
  • step (b) To a stirred solution of the product of step (b) (0.68g; 0.0035 mol) and 15.0ml isopropyl alcohol was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (0.99g; 0.0035 mol). The mixture was stirred at 35C. To this mixture was added 10.0ml methanol along with 2M hydrochloric acid in isopropyl alcohol added dropwise until all of the reactants were in solution. The reaction was allowed to stir for 48 hours. The reaction was then diluted in 50ml saturated sodium chloride and extracted with (3 ⁇ 75mL) ethyl acetate. The organic layers were collected, dried over magnesium sulfate, and the solvent evaporated. The crude product was separated on a silica gel column eluted with 10% methanol in methylene chloride. The solvent was evaporated and the crude solid
  • step (a) To a solution of the product of step (a) (2.85 g, 11.1 mmol) in 50 ml of anhydrous tetrahydrofuran at 0 °C under nitrogen was added 18.6 ml of a 1.0 M borane in THF solution (18.6 mmol). The reaction mixture was then heated to reflux for 5.5 h. The solution was allowed to cool overnight and was then quenched by the successive addition of 2 ml of methanol and 10 ml of 6 M hydrochloric acid. The reaction mixture was again heated to reflux for 1 h. Upon cooling to ambience, the reaction mixture was basified and extracted into ether. The dried (MgSO 4 ) was concentrated to afford an oil.
  • step (b) To a solution of the product of step (b) (1.21 g, 3.58 mmol) dissolved in a solution of 100 ml of methanol was added 20 ml of a saturated solution of hydrogen chloride in isopropanol and 0.1 g of 5% Pd/C. The resulting solution was hydrogenated at 50 psi for one hour. The catalyst was removed by filtration and the filtrate was concentrated in vacuo sohd. Trituration of this solid with ether afforded 1.15 g (93%) of the title compound as the hydrochloride salt, m.p. 169-74 °C.
  • Example 11 An alternative synthesis for the compound of Example 2.
  • This compound benzyl-(4-nitrobenzyl)amine was prepared using the method described in Example 10, step (b) for the preparation of benzyl-3-(nitrobenzyl)amine. From 2.49 g (9.36 mmol) of N-(4-nitrobenzyl)-benzamide and 18.6 ml of 1.0 M borane in THF was obtained 3.12 g of the crude benzyl-(4-nitrobenzyl)amine, which was used without further purification. This crude product was mixed with 4.3 ml of triethylamine in 40 ml of methylene chloride at 0oC under nitrogen. To this solution was added dropwise 3.6 ml of trifluoroacetic anhydride. The solution was stirred for 10 minutes and was poured into water and separated. The dried organic phase was dried (MgSO 4 ) and concentrated to give 3.1 g (94%) of the title compound as an oil.
  • step (b) To a stirred solution of the product of step (b) (2.2 g, 10.6mmol) in tetrahydrofuran (50ml) under nitrogen, was added dropwise 1.0M borane-tetrahydrofuran (42ml, 42mmol). Reaction was heated at reflux for 1.5 hours, cooled on ice bath, then aqueous 6N HCl (75ml) added dropwise. The resulting mixture was refluxed for 1 hour, basified to pH 11 with 20% aqueous sodium hydroxide, extracted twice with ether. Combined extracts were dried over magnesium sulfate, filtered,
  • the hydrochloride salt of the crude was made from isopropanol and ethyl acetate to yield ethyl-(2-(3-nitrophenyl)ethyl)amine hydrochloride as a light yellow solid: (1.7g, 70%); m.p. 186-188 °C.
  • step (c) To a solution of the product of step (c) (1.7g, 7.0mmol) in methanol (30ml) was added a catalytic amount of 10% palladium on carbon. The mixture was hydrogenated at 50 psi for 30 minutes, filtered through celite, concentrated to yield 3-(2-ethylamino-ethyl)phenylamine hydrochloride as an off-white solid: (1.4g, 100%); m.p. 192-194 °C.
  • step (e) N-(3-(2-(Ethylamino)ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride
  • S-methyl-2-thiophenethiocarboximide hydroiodide 2.5g, 8.8mmol
  • the mixture was stirred for 16 hours, diluted with 20% aqueous sodium hydroxide, and extracted twice with ethyl acetate. The combined extracts were washed twice with water, dried over magnesium sulfate, filtered, and concentrated to give 2.7g of an oil.
  • the dihydrobromide salt was made from isopropanol and ethyl acetate, recrystallized from isopropanol, methanol, and ethyl acetate to yield N-(3-(2-(ethylamino)ethyl)-phenyl)-2-thiophenecarboximidamide dihydrobromide as a tan solid: (1.72g, 49%); m.p. 192-194 °C (dec).
  • step (a) To a solution of the product of step (a) (3.0 g, 9.17 mmol) and S-methyl-2-thiophenethiocarboximide hydroiodide (3.3 g, 11.5 mmol) in isopropanol (25ml) and dimethylformamide (25ml) was added pyridine (0.74 ml, 9.17 mmol) in one portion. The mixture was stirred for 16 hours, diluted with 20% aqueous sodium hydroxide, and extracted twice with ethyl acetate. The combined extracts were washed twice with water, dried over magnesium sulfate, filtered, and concentrated.
  • the dioxalate salt of the crude was made from ethanol and ether, recrystallized from ethanol to yield N-(3-(3-((phenylethyl)amino)propyl)phenyl)-2-thiophenecarboximidamide dioxalate as the white solid: (2.3 g, 44%); m.p. 102-105 °C.
  • step (a) To a solution of the product of step (a) (5.45 g, 15.6 mmol) in 85% glacial acetic acid (400 ml) was added in one portion the zinc dust (10.2 g, 156 mmol). Reaction was stirred for 30 minutes, filtered, and concentrated. The residue was partitioned with 20% aqueous sodium hydroxide and dichloromethane, the organic layer was dried over magnesium sulfate, filtered, concentrated to yield N-(2-bromobenzyl)-2-(3-aminophenyl)acetamide as a white solid: (4.7 g, 94%); m.p. 110-112 °C.
  • the organic phase was washed with 1 ⁇ 100 ml of 1 N hydrochloric acid and the dried over magnesium sulfate. The solvent evaporated to yield a yellow solid.
  • the solid was dissolved in 100 ml of methanol and 250 mg of 10% palladium on carbon was added, the reaction was hydrogenated over a 4 hour period. The product was found to be unreduced, and was then dissolved in 100 ml of methanol. 10 ml of a saturated solution of HCl in isopropanol was added, followed by 250 mg of 10% palladium on carbon. The mixture was hydrogenated for 4 hours. The catalyst was removed by filtration and the solvent evaporated.
  • step (a) To a stirred suspension of the product of step (a) (1.00 g; 0.0037 moles) in approximately 5ml of isopropanol was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (1.01g, 0.0035 moles). This mixture was refluxed for 1 hr and then allowed to cool giving solids. The product was filtered and allowed to dry under vacuum overnight giving N-(4-(3-((phenylamino)carbonyl)propyl)phenyl)-2-thiophenecarboximidamide. 1.76 g yield. m.p. 229-231 °C.
  • 4-(4-nitrophenyl)butyric acid (2.25 g, 0.01076 moles) was dissolved in 40 ml dichloromethane and cooled to -5 °C on an ice/acetone bath. Triethylamine (1.09 g, 0.01076 moles) and ethyl chloroformate (1.17 g, 0.01076 moles) were added and the mixture was stirred for 10 minutes before pyrrolidine (0.92 g, 0.01291 moles) was added dropwise whilst maintaining the temperature below 0 °C. After 10 minutes the cold bath was removed and the reaction stirred for 16 hours at room temperature.
  • the dichloromethane solution was washed with 2 ⁇ 75 ml saturated sodium bicarbonate and 2 ⁇ 75 ml water.
  • the dichloromethane layer was dried over magnesium sulfate and the solvent evaporated under vacuum to leave 2.19 g of a clear brown oil.
  • the clear brown oil was reduced under 50 psi hydrogen; ethanol was the solvent and 10% palladium on carbon was used as a catalyst. After 4 hours the catalyst was filtered off and the solvent evaporated under vacuum to provide 4-(3-((1-pyrrolidinyl)carbonyl)propyl)aniline, an oil that solidified on standing (this was used as is).
  • step (a) The product of step (a), 4.4 g, was dissolved in 200 ml of water.
  • the mixture was made basic with 50 % sodium hydroxide solution, and extracted with 2 X 50 ml of ethyl acetate.
  • the ethyl acetate extracts were combined, dried with magnesium sulfate, and evaporated in vacuo, giving a solid.
  • the solid was dissolved in hot ethyl acetate and hexane, and crystals of 4-(2-(((4-morpolinyl)carbonyl)amino)
  • step (b) The product of step (b), 1.0 g, and S-methyl-2-thiophenethiocarboximide
  • step (b) The product of step (b), 1.0 g, and S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)), 1.01 g, were combined in a minimal amount of isopropanol and the mixture refluxed for one hour. The resulting clear solution was cooled, solids precipitated and were collected by filtration, giving N-(4-(3-(((phenyl)amino)carbonyl)propyloxy)phenyl)-2-thiophenecarboximidamide hydroiodide, 1.76 g, m.p. 229-231 °C.
  • step (a) To a stirred solution of the product of step (a) (0.52 g, 1.98 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 1 hr, filtered through celite, and concentrated to give 4-(2-(((trifluoromethyl)carbonyl)amino)-ethyl)aniline which was homogeneous by TLC and used immediately in the next reaction.
  • step (b) To a solution of the product of step (b) (0.30 g, 1.29 mmol) in isopropanol (6 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of
  • Example 1 step (d)) (0.37 g, 1.29 mmol).
  • the mixture was stirred for 4 hr, turned into a solution of saturated NaCl (50 ml) and 50% NaOH (4 ml), and extracted with ethyl acetate (3 X 20 ml).
  • the combined extracts were washed with water, dried over magnesium sulfate, filtered and concentrated to a solid which was recrystallized from hexane/ethyl acetate to yield N-(4-(2-(((trifluoromethyl) carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide as a slightly yellow solid: 0.19 g (43% yield), m.p. 181-182 °C.
  • Example 30 step (a) The above compound was made by the mothod of Example 30 step (a) except that trifluoroacetic anhydride was replaced by acetic anhydride. 1.28 g of a pale yellow solid was obtained that was used immediately in the next reaction.
  • step (b) 4-(2-(((methyl)carbonyl)amino )ethyl)aniline
  • THF/MeOH 100 ml, 1:1
  • a stirred solution of the product of step (a) (0.82 g, 3.94 mmol) in THF/MeOH (100 ml, 1:1) was added 4 ml of 1 N HCl and a catalytic amount of 10% Pd/C.
  • the mixture was hydrogenated at 50 psi for 4 hr, filtered through celite, and
  • step (a) To a pressure bottle charged with the product of step (a) (8.6 g, 0.024 moles) in 200 ml of methanol was added 20 ml of isopropanol/HCl and 0.5 g of 10% palladium on carbon. The reaction was hydrogenated for six hours; the catalyst was removed by filtration and the solvent evaporated. To the residue was added 50 ml of isopropanol and 100 ml of ethyl acetate, the solid was slurried and then collected by filtration to yield 10.6 g of N-(4-aminophenyl)benzenecarboximidamide hydrochloride.
  • N-(4-aminophenyl)benzenecarboximidamide hydrochloride was dissolved in 100 ml of water and 20 ml of 50% sodium hydroxide. The aqueous phase was extracted (3x100 ml) of ethyl acetate, and dried over magnesium sulfate. Evaporation of the solvent gave solid product N-(4-aminophenyl)benzene carboximidamide, yield 7.6 g.
  • step (b) To a stirred suspension of the product of step (b) (1.1g, 0.0052 moles) in 5 ml of isopropanol was added S-methyl-2-thiophenecarboxthioimide hydroiodide (the product of Example 1, step (d)) (1.5 g, 0.0054 moles) and the reaction was stirred for 48 hours. The solid was collected by filtration, this was dissolved in a solution containing 100 ml of water and 10 ml of 50% sodium hydroxide and the aqueous phase was extracted three times with ethyl acetate (100ml). The organic phase was dried over magnesium sulfate and subsequent evaporation of the solvent gave a crude oil.
  • S-methyl-2-thiophenecarboxthioimide hydroiodide the product of Example 1, step (d)
  • step (c) N-(4-((bis(phenylmethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide
  • S-methyl-2-thiophenethiocarboximide hydroiodide the product of Example 1, step (d)
  • the mixture was stirred for 14 hr, quenched with 2 N NaOH (2 ml) and extracted with ethyl acetate ( 3 X 30 ml).
  • the combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to a solid which was recrystallized from ethyl
  • step (a) To a stirred solution of the product of step (a) (1.00g, 3.29 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 0.5 hr, filtered through celite, and concentrated to give 3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)aniline hydrochloride which was homogeneous by TLC and used immediately in the next reaction.
  • step (c) N-(3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)phenyl)-2-thiophenecarboximidamide
  • step (b) N-(3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)phenyl)-2-thiophenecarboximidamide
  • S-methyl-2-thiophenethiocarboximide hydroiodide (0.94 g, 3.29 mmol).
  • the mixture was stirred for 14 hr, quenched with 2 N NaOH (2 ml) and extracted with ethyl acetate ( 3 X 30 ml).
  • dichloromethane was treated with benzylamine, 1.07 g, giving suspended solids.
  • the mix was treated with diphenylphosphorylazide, 2.75 g, and 20 ml of dioxane and on stirring for 4 hours it became clear.
  • the mix was diluted with 100 ml of ethyl acetate and washed twice with 100 ml of 2 M potassium carbonate, then 100 ml of 1 M hydrochloric acid.
  • the organic layer was dried with magnesium sulfate and evaporated to give solids.
  • step (a) A sample of the product of step (a), 0.80 g in 20 ml of ethanol and 20 ml of ethyl acetate was treated with 0.4 g of 5 % paladium on carbon and placed under 50 psi of hydrogen. TLC after one hour showed a new spot, Rf 0.2 with 15% acetone in methylenechloride. The mix was evaporated to dryness, and then treated with 30 ml of toluene. The residue was dissolved in 10 ml of THF and treated with 5 ml of 1 M lithium aluminium hydride in THF (Aldrich) giving a clear solution.
  • step (b) A sample of the product of step (b) was suspended in 5 ml of THF and treated with 5 ml of 1 M lithium aluminium hydride in THF (Aldrich) giving a clear solution. The mixture was warmed to reflux for 5 hours, then cooled. The semisolid mass was diluted with diethyl ether to 20 ml, and then 1 ml of 2M sodium
  • step (c) A sample of the product of step (c), 0.50 g, and S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)), 0.44g were combined in 4 ml of isopropanol and warmed to 60 °C. After 2 hours, TLC with 15 % methanol in chloroform on silica showed that the starting aniline was mostly consumed, and that there had developed a new spot of lower Rf. The mix was diluted with 20 ml of 1M potassium carbonate, and extracted with ethyl acetate. The ethyl acetate extract was dried with 10 g of potassium carbonate and treated with 0.150 g of maleic acid, giving a gummy precipitate.
  • TLC of the precipitate versus the supernatant showed the precipitate to be a mix of the starting amine and product, and that the supernatant contained mostly product.
  • the supernatant was then treated again with 0.150 g of maleic acid, giving a gummy precipitate, and the remaining supernatant was decanted.
  • the solids were dissolved in 5 ml of methanol and precipitated with 100 ml of diethylether.
  • the resulting gummy precipitate was reacted with 1 ml of water, diluted with acetone to 200 ml giving a clear solution, diluted with diethyl ether to 275 ml and cooled to -20 °C.
  • the fumaric acid salt was made from isopropanol and methanol, to yield (2.0g) of N-(4-(((2-thiophenyl)iminomethyl)amino)methyl)phenyl)-2- thiophenecarboximidamide difumarate, m.p. 200-201 °C
  • Example 43 The following compounds were prepared by a process analogous to that of Example 17:
  • step (b) N-(2-phenylethyl)-2-(3-nitrophenyl)ethylamine
  • step (a) N-(2-phenylethyl)-2-(3-nitrophenyl)ethylamine
  • dichloromethane was added 1.99g (0.0197 moles) of triethylamine and the mix was cooled to 0 °C before 2.34g (0.111 moles) of trifluoroacetic anhydride was added dropwise. After 45 minutes, the mixture was quenched with 50ml water and the product extracted with 3x50ml dichloromethane. The organic layers were combined, dried over magnesium sulfate and evaporated to leave N-(2-phenylethyl)-N-(2-(3-nitrophenyl)ethyl)trifluoroacetamide, 3.3g, as an oil.
  • step (c) To a solution of the product of step (c), 3.3g, in 75ml each of THF and methanol was added a catalytic amount of 10% Pd on carbon. After 1 hour under 50 psi hydrogen, the reaction was complete. The catalyst was filtered off and the solvents evaporated to leave N-(2-phenylethyl)-N-(2-(3-aminophenyl)ethyl)
  • isopropanol was added 2.94g of S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)). The mixture was stirred at room temperature for 16 hours then a solid yellow residue was filtered off and discarded. The wash was evaporated and the residue dissolved in minimal methanol; the solution was basified with 2M NaOH and heated to 50 °C for 30 minutes. The deprotected product was extracted with 3 ⁇ 50ml ethyl acetate, the organic layers were combined, washed with 2 ⁇ 50ml water, dried over magnesium sulfate and evaporated to leave an oil. The free base was dissolved in an isopropanol solution of HBr.
  • step (b) 4-(((phenylmethoxy)carbonyl)aminomethyl)aniline
  • step (a) The product of step (a), 6.0 g was treated with 10 ml of acetic acid and 100 ml of methanol. The mixture was treated with platinum sulfide on carbon, 0.97 g, and treated with 50 psi of hydrogen gas; after 20 hours, the mixture was filtered and evaporated in vacuo. The residue was dissolved in 50 ml of ether, and diluted with hexanes to 200 ml. The mixture was then stirred for five days and filtered to give 4-(((phenylmethoxy)carbonyl)aminomethyl)aniline, m.p. 60-64 °C
  • step (b) The product of step (b), 0.89 g, and S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)), 1.0 g, were combined in 6 ml of isopropanol, and stirred at 30 °C. After 4 hours, the mixture was precipitated with ether, giving gummy solids which were taken up in 100 ml of hot water, treated with cellite and filtered. The mix was cooled, giving gummy white solids which were treated with 50 ml of ethyl acetate and 5 g sodium bicarbonate. The ethyl acetate layer was dried with magnesium sulfate, and cooled to -20 °C.
  • step (a) A sample of the product of step (a), 3.74 g, was taken up in 100 ml of methanol and 100 ml of ethyl acetate. The mix was treated with 0.4 g of 10 % palladium on carbon and placed under 50 psi hydrogen. After one hour the mix was filtered, and concentrated in vacuo to provide crude 4-aminophenoxy-N-(phenylmethyl) acetamide: CHN calculated: C 70.29, H 6.29, N 10.93, found C 69.97, H 6.3, N 10.90
  • step (a) To a solution of the product of step (a) (0.49 g, 1.62 mmol) in isopropanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (0.46 g, 1.62 mmol). The mixture was stirred for 48 hr, dumped into basic water and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to an oil.
  • S-methyl-2-thiophenethiocarboximide hydroiodide the product of Example 1, step (d)
  • This compound was prepared following the procedure of Example 26, step (b) and was recrystallized from water, m.p. 234-5 °C.
  • This compound was prepared following a process analogous to that of Example 49, step (a), m.p. 172-82 °C.
  • This compound was prepared following the procedure of Example 56, step (a), m.p. 105-7 °C.
  • the dihydrochloride salt was crystallised from isopropanol and ether, m.p. 256-61
  • This compound was prepared following the procedure of Example 55, step (a), m.p.
  • This compound was prepared following the procedure of Example 34, step (c), m.p. 300 °C (dec).
  • step (a) The compound of step (a) (4.28 g) and benzylamine (2.5 ml) were combined in DMF (10 ml) with potassium carbonate (3.2 g) and stirred at room temperature for 3 hours. The solids were filtered off, and washed with methanol (2 X 10 ml). The combined filtrates were slowly diluted with water to 150 ml to give yellow solids, which were collected by filtration, and air dried to give 4-((((phenylmethyl)amino)methylcarbonyl)amino)nitrobenzene, MS 286 (M+H).
  • step (b) The compound of step (b) (4.9 g) trifluoroacetic anhydride (2.5 ml) and
  • step (d) 4-((((phenylmethyl)(trifluoromethylcarbonyl)amino )methylcarbonyl)amino )aniline
  • step (d) (1.05 g) and S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1 step (d)) (0.85 g) were treated with methanol (2 ml). After 15 minutes the solids had dissolved and the mixture was blown down with nitrogen to remove methanethiol. TLC with 10 % isopropanol in chloroform on silica showed starting amine consumed and new spot of lower Rf. The mixture was dissolved in methanol (6 ml), and treated with potassium
  • the resulting sohds were taken up in a solution of 7% methanol/methylene chloride, and purified on a silica gel column eluted with the same solvent. The product was collected and concentrated. The solid was taken up in THF (50 ml) and treated with 1M Borane/THF (50 ml). The solution was refluxed for 15 hours. The mixture was cooled to 0 °C and was slowly made acidic with 4N hydrochloric acid. The mixture was reheated to reflux and stirred for 4 hours.
  • the crude product was purified on a silica gel column eluted with 20% methanol/methylene chloride. The product was collected and concentrated to an oil, which was taken up in isopropyl alcohol and treated with 2.5 equivalents of oxalic acid. The white sohds were filtered and washed with ether to leave N-(4-(2-(((2-Furanyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide dioxalate (580 mg) m.p. decomposes >220 °C.
  • Example 64 This compound was prepared following the procedure of Example 26, step (b). The salt was recrystallized from 30% isopropanol in water, m.p. 236 °C (dec).
  • Example 64
  • step (b) To a solution of the compound of step (b) (1.24 g, 3.90 mmol) in isopropanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (1.06 g, 3.70 mmol). The mixture was stirred for 18 hr, dumped into basic water and extracted with chloroform ( 3 X 30 ml). The combined extracts were washed with water, dried (MgSO 4 ), filtered, concentrated, and chromatographed over silica (6% methanol/methylene chloride) to an oil which solidified upon standing. A small amount was isolated as the oxalate salt: (48 mg); m.p. (dec) 150 °C.
  • step (a) A mixture of the compound of step (a) (1.6 g 1.3 mmol) and S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (4.4 g, 1.5 mmol) in of DMF (10 ml) was warmed to 40 °C for 72 hours. The mixture was then diluted with 20% aqueous sodium hydroxide, and the solid collected by filtration to yield (2.5g) of crude N-(4-((((2-thiophenyl)iminomethyl)amino)methyl)phenyl)-2-thiophenecarboxamidine. The difumarate salt was made from methanol and isopropanol. m.p. 200-201 °C.
  • step (a) To a solution of the compound of step (a) (2.0 g, 8.2 mmol) was added S-methyl-(3-methylphenyl)thiocarboximide hydroiodide (2.8 g, 9.2 mmol) in isopropanol (10 ml). The mixture was stirred at 40 °C for 18 hours, diluted with 20% aqueous sodium hydroxide, and extracted twice with ethyl acetate. The organic layer was washed with water (100 ml), dried (MgSO 4 ) filtered and concentrated to give an oil.
  • the difumarate salt was made from methanol, isopropanol, and ethyl acetate to yield N(4-((((3-methylphenyl)iminomethyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine difumarate: m.p. 200-201 °C.
  • step (a) To a solution of the compound of step (a) in acetic acid (100 ml) was added zinc dust (3.0 g). The reaction mixture was stirred for 30 minutes, filtered and concentrated. The residue was partitioned with 20% aqueous sodium hydroxide and dichloromethane and the organic layer was dried (MgSO 4 ), filtered and concentrated to yield 1.3g of [2-(4-aminophenyl)-ethyl]pyrimidi-2-ylamine.
  • step (b) To a solution of the compound of step (b) (1.3 g, 6.6 mmol) in (10 ml) of dimethylformamide was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)). The reaction was stirred for 72 hours, diluted with 20% sodium hydroxide and extracted twice with ethyl acetate. The combined extracts were washed twice with water, dried (MgSO 4 ), filtered and concentrated. The hydrochloride salt was made from methanol and isopropanol to yield N-(4-(2-((pyrimidin-2-yl)amino)ethyl)phenyl)-2-thiophenecarboxamide dihydrochoride. m.p. 191-192 °C.
  • step (a) A sample of the compound of step (a) (2.84 g) was dissolved in dry THF (100 ml), then methylmorpholine (1.45 ml) was added and the mix stirred at 0 °C. Ethyl chloroformate, (1.26 ml) was added, and the mixture stirred for 2 minutes.
  • step (b) was converted to N-(4-(2-((phenylmethyl)amino)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Compounds of formula (I) wherein D represents phenyl, pyridinyl or a 5-membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, S and N, which three groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, halogen and perfluoroalkyl C1 to 6; or perfluoroalkyl C1 to 6; R1 represents hydrogen, alkyl C1 to 6 or halogen; R2 represents a group -X(CH¿2?)nZCONR?3R4¿, -X(CH¿2?)nNHCO(CH2)sNR?3R4¿, -X(CH¿2?)pNR?3R4¿, -X(CH¿2?)nNHCOR?5¿ or -(CH¿2?)qNHC(NH)R?6¿; and X, Z, R?3, R4, R5, R6¿, n, s, p and q are defined in the specification are described, together with processes for their preparation and compositions containing them. Compounds of formula (I) have nitric oxide synthetase inhibitory activity.

Description

Amidine derivatives wi th n itric oxide synthetase activiti es
This invention relates to amidine derivatives, processes for their preparation, compositions containing them and their use in therapy.
Certain nitrogen containing compounds have been described as neuroprotective agents. International Patent Application WO 91/12797 (State of Oregon) teaches tri- and tetrasubstituted guanidines as neuroprotective agents. US Patent 5266594 (Dawson et al) (published after the earliest priority date of this application) describes the use of arginine derivatives in the treatment of stroke and other neurodegenerative diseases. Also European Patent Application 547558
(Washington University) describes the use of aminoguanidine in the treatment of immunological and other disorders.
The use of inhibitors of nitric oxide synthetase in the treament of disease has also been described, for example, in International Patent Applications WO 94/12163 (Abbott) and WO 94/12165 (Wellcome) (both published after the earliest priority date of this application) and European Patent Application 446699 (Merrell Dow).
Amidine derivatives have been described for use as herbicides in German Patent Application DE-OS-2321330 (Bayer). N-phenyl amidine derivatives have also been described for use in the treatment of diabetes in US Patent 3669974 (USV
Pharmaceutical Corp.) and UK Patent Application 2226562 (Boots). N'N"-disubstituted amidines are described for use in the treatment of hypertension, depression and halliconogenic states in International Patent Application WO
92/04054 (University of Oregon). The use of certain symmetric bisamidines as analgesics, in the treatment of inflammation and in the treatment of hypertension is described in UK Patent No. 1180629 (Delalande).
A number of. patent documents describe processes for the preparation of amidines or describe the use of amidines as intermediates without disclosing any pharmaceutical use for these compounds. Simple amidine derivatives are described in UK Patent No. 1088095 (Merck) as intermediates in the preparation of useful benzimidazole derivatives. Processes for preparation of other simple N-aryl and N-heteroaryl amidines are described in US Patent 3299081 (Merck) and fluorine containing amidine derivatives are described as chemical intermediates in Japanese Patent Application No. 2229147 (Nissan) and in Japanese Patent Application No. 58057357 (Daikin). We have now found a new group of amidine derivatives that possesses useful pharmaceutical activity.
According to a first aspect of the invention, we provide a compound of formula I
Figure imgf000004_0001
wherein
D represents phenyl, pyridinyl or a 5 membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, S and N, which three groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, halogen and perfluoroalkyl C1 to 6; or perfluoroalkyl C1 to 6;
R1 represents hydrogen, alkyl C1 to 6 or halogen;
R2 represents -X(CH2)nZCONR3R4, -X(CH2)nNHCO(CH2)sNR3R4,
-X(CH2)pNR3R4, -X(CH2)nNHCOR5 or -(CH2)qNHC(NH)R6;
R3 and R4 independently represent hydrogen, alkyl C1 to 6, -(CH2)rA, -(CH2)mOA or -CH(CH3)(CH2)tA;
or -NR3R4 together represent 1-indanyl, piperonylamino-, piperidinyl, morpholinyl, pyrrolidinyl, 1,2,3,4-tetrahydroisoquinolinyl; or piperazinyl optionally 4-substituted by alkyl C1 to 6;
R5 represents alkyl C1 to 6, perfluoroalkyl C1 to 6, -(CH2)rA or
-O(CH2)w A;
A represents phenyl, pyridinyl, pyrimidinyl, or a 5 membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, S and N, which four groups are optionally substituted by one or more groups selected from alkyl C1 to 6, halogen, nitro, cyano and trifluoromethyl;
R6 represents phenyl, pyridinyl or a 5 membered heterocyclic aromatic ring contaimng 1 to 4 heteroatoms selected from O, S and N, which three groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, halogen and perfluoroalkyl C1 to 6; or perfluoroalkyl C1 to 6;
n and r independently represent an integer in the range 0 to 6 inclusive;
p and w independently represent an integer in the range 1 to 5 inclusive;
m represents an integer in the range 2 to 5 inclusive;
q and t independently represent an integer in the range 0 to 5 inclusive;
s represents an integer in the range 1 to 3 inclusive;
X represents O or a bond;
Z represents O, NR7 or a bond;
R7 represents hydrogen or alkyl C1 to 6;
provided that:
(a) when D contains a heteroatom, it is not connected to the remainder of the compound of formula I through the heteroatom;
(b) when R2 represents -X(CH2)nZCONR3R4 and neither X nor Z represent a bond, then n represents an integer in the range 2 to 6 inclusive;
(c) when R2 represents -X(CH2)nNHCO(CH2)sNR3R4 or -X(CH2)nNHCOR5, and X represents O, then n represents an integer in the range 2 to 6 inclusive;
(d) when R2 represents -X(CH2)pNR3R4 and X represents O, then p represents an integer in the range 2 to 5 inclusive;
(e) when R2 represents -(CH2)qNHC(NH)R6, R1 represents hydrogen, D represents phenyl and R6 represents phenyl, then q does not represent 0;
(f) when R2 represents -(CH2)qNHC(NH)R6, R1 represents hydrogen, D and R6 represent 2-chlorophenyl, then q does not represent 0;
(g) when R2 represents -(CH2)qNHC(NH)R6, R1 represents hydrogen, D and R6 represent 3-pyridinyl, then q does not represent 0; and
(h) when R2 represents -(CH2)qNHC(NH)R6, R1 represents hydrogen, D and R6 represent 4-pyridinyl, then q does not represent 0; or a pharmaceutically acceptable salt thereof.
We prefer that D represents phenyl, pyridinyl or a 5 membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, S and N,
which three groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, halogen or perfluoroalkyl C1 to 6.
We particularly prefer that D represents phenyl, thiophene, furan, pyrrole or thiazole, which five groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, halogen or perfluoroalkyl C1 to 6.
We more particularly prefer that D represents thiophene, pyrrole, furan or thiazole which four groups are optionally substituted by alkyl C1 to 6 or halogen. We especially prefer than D represents thiophene, furan or pyrrole, most especially thiophene.
We prefer most of all that D represents 2-thiophene. We prefer that R1 represents hydrogen.
When R2 represents -X(CH2)nZCONR3R4,
-X(CH2)nNHCO(CH2)sNR3R4 or -X(CH2)pNR3R4, we prefer that -NR3R4 represents piperidinyl, morpholinyl, pyrrolidinyl, 1,2,3,4-tetrahydroisoquinolinyl or 1-indanyl, or that at least one of R3 and R4 represents -(CH2)rA or -(CH2)mOA. We particularly prefer that -NR3R4 represents 1,2,3,4-tetrahydroisoquinolinyl or 1-indanyl or that one of R3 and R4 represents -(CH2)rA and the other represents hydrogen or methyl. We especially prefer that one of R3 and R4 represents -(CH2)rA and the other represents hydrogen or methyl.
When R2 represents -X(CH2)nNHCOR5, we prefer that R5 represents -(CH2)rA.
When R2 represents -X(CH2)nZCONR3R4, -X(CH2)nNHCO(CH2)sNR3R4, -X(CH2)PNR3R4 or -X(CH2)nNHCOR5, we prefer X to represent a bond.
When R2 represents -X(CH2)nZCONR3R4 and Z represents NR7, we prefer R7 to represent hydrogen.
When R2 represents -X(CH2)nZCONR3R4 we prefer Z to represent a bond.
When R2 represents -(CH2)qNHC(NH)R6, we prefer that R6 represents phenyl or a 5-membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, S and N, which two groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6 and halogen.
When R2 represents -(CH2)qNHC(NH)R6, we particularly prefer that R6 represents phenyl or thiophene, which two groups are optionally substituted by one or more groups selected from alkyl C1 to 6 and halogen. When R2 represents -(CH2)qNHC(NH)R6, we prefer that q represents 0, 1 or 2.
We particularly prefer that q represents 0 or 2, especially 0.
When R2 represents -(CH2)qNHC(NH)R6, q represents 0 and R6 represents phenyl optionally substituted by halogen, alkyl C1 to 6, or alkoxy C1 to 6 or R6 represents pyridinyl, then we prefer that D does not have the same definition as R6.
When R2 represents -(CH2)qNHC(NH)R6 and q represents 0, then we generally prefer than R6 does not have the same definition as D. When R2 represents -X(CH2)pNR3R4 we prefer that p represents an integer in the range 1 to 4 inclusive, particularly 1, 2 or 3, especially 1 or 2.
When R2 represents -X(CH2)nZCONR3R4, -X(CH2)nNHCO(CH2)sNR3R4 or -X(CH2)nNHCOR5, we prefer n to represent 1, 2 or 3, especially 2 or 3.
When R3, R4 or R5 represent -(CH2)rA, we prefer r to represent an integer in the range 0 to 4 inclusive, particularly 0, 1 or 2, more particularly 1 or 2, especially 1.
When R3 or R4 represent -(CH2)mOA, we prefer m to represent 2, 3 or 4.
When R5 represents -O(CH2)wA, we prefer w to represent 2, 3 or 4. When R3 or R4 represent -CHMe(CH2)tA, we prefer t to represent 0, 1 or 2, especially 0 or 1.
We prefer that A represents phenyl, pyridinyl, pyrimidinyl, thiophenyl or furanyl, which five groups are optionally substituted by one or more groups selected from alkyl C1 to 6 and halogen. We particularly prefer that A represents phenyl optionally substituted one or more groups selected from alkyl C1 to 6 and halogen.
When D or R5 represent perfluoroalkyl C1 to 6 we prefer that they represent pentafluoroethyl or trifluoromethyl, especially trifluoromethyl.
We prefer that R2 represents -X(CH2)pNR3R4 or -(CH2)qNHC(NH)R6.
We prefer that the orientation of R2 is meta or para to the nitrogen atom of the amidine moiety. According to the invention, we further provide a process for the preparation of compounds of formula I, and pharmaceutically acceptable salts thereof, which comprises:
(a) preparing a compound of formula I, by reacting a corresponding compound of formula II
Figure imgf000009_0004
wherein D is as defined above and L is a leaving group,
with a compound of formula III
Figure imgf000009_0003
wherein R1 and R2 are as defined above,
(b) preparing a compound of formula I, by reacting a corresponding compound of formula IV
Figure imgf000009_0002
wherein D is as defined above,
with a compound of formula V
Figure imgf000009_0001
wherein R1 and R2 are as defined above and HA is an acid,
(c) preparing a compound of formula I in which R2 represents
-X(CH2)nZCONR3R4, -X(CH2)nNHCO(CH2)sNR3R4 or -X(CH2)pNR3R4 and at least one of R3 and R4 represents alkyl C1 to 6, -(CH2) A -(CH2) mOA or
-CH(CH3)(CH2)tA by reacting a corresponding compound of formula I in which one or both of R3 and R4 represents hydrogen with a compound of formula VI,
Figure imgf000010_0005
wherein R8 represents alkyl C1 to 6, -(CH2)rA, -(CH2)mOA or -CH(CH3)(CH2)tA and L is a leaving group,
(d) preparing a compound of formula I in which R2 represents
-(CH2)qNHC(NH)R6 by reacting a corresponding compound of formula VII
Figure imgf000010_0004
wherein D, R1 and q are as defined above,
with a compound of formula VIII
Figure imgf000010_0003
wherein R6 is as defined above and L is a leaving group,
(e) preparing a compound of formula I in which R represents
-(CH2)qNHC(NH)R6 by reacting a corresponding compound of formula IX
Figure imgf000010_0002
wherein D, R1, q and HA are as defined above,
with a compound of formula X
Figure imgf000010_0001
wherein R6 is as defined above,
(f) preparing a compound of formula I in which R2 represents
-X(CH2)nZCONR3R4 by reacting a corresponding compound of formula XI,
Figure imgf000011_0001
wherein D, R1, X, n, Z and L are as defined above,
with a compound of formula XII,
Figure imgf000011_0002
wherein R3 and R4 are as defined above,
(g) preparing a compound of formula I in which R2 represents
-X(CH2)nNHCO(CH2)sNR3R4, by reacting a compound of formula XIII
Figure imgf000011_0003
wherein D, R1, X and n are as defined above,
with a compound of formula XIV
Figure imgf000011_0004
wherein R3, R4 and s are as defined above and L is a leaving group,
(h) preparing a compound of formula I in which R2 represents
-X(CH2)nNHCORs, by reacting a compound of formula XIII with a compound of formula XV
Figure imgf000011_0005
wherein R5 is as defined above and L is a leaving group,
(i) preparing a compound of formula I in which R2 represents
-X(CH2)nZCONR3R4 and Z represents NR7 by reacting a corresponding compound of formula I in which R2 represents -X(CH2)nZCONR3R4 and Z represents -NH with a compound of formula XVI
Figure imgf000011_0006
wherein R7 is as defined above and L is a leaving group, (j) preparing a compound of formula I in which R2 represents -X(CH2)pNR3R4, and p is not less than 2, by reduction of a compound of formula XVII
Figure imgf000012_0005
wherein D, X, R1, R3, R4 and p are as defined above,
(k) preparation of a compound of formula I wherein R2 represents
-X(CH2)pNR3R4 and both R3 and R4 represent hydrogen, by reduction of a corresponding compound of formula XVHI
Figure imgf000012_0004
wherein R1, D, p and X are as defined above,
(1) preparing a compound of formula I wherein R2 represents
-X(CH2)nZCONR3R4, Z represents O or NR7 and R3 represents hydrogen by reacting a compound of formula XIX
Figure imgf000012_0003
wherein R1, D, X and n are as defined above and Z represents O or NR7, with a compound of formula XX
Figure imgf000012_0002
wherein R4 is as defined above,
(m) preparing a compound of formula I wherein R2 represents
-X(CH2)nNHCOR5 and R5 represents -O(CH2)wA by reacting a compound of formula XXI
Figure imgf000012_0001
wherein R1, D, X and n are as defined above,
with a compound of formula XXII
Figure imgf000013_0004
wherein A and w are as defined above,
(n) preparing a compound of formula I wherein R2 represents
-X(CH2)-ZCONR3R4 and Z represents O or NR7 by reacting a compound of formula XIX with a compound of formula XXIII
Figure imgf000013_0001
wherein R3 and R4 are as defined above,
(o) preparing a compound of formula I wherein R2 represents -X(CH2)pNR3R4, R3 represents hydrogen and p represents an integer 2 to 5, by reduction of a compound of formula XXIV
Figure imgf000013_0002
wherein R1, R4, D, X and p are as defined above,
(p) preparing a compound of formula I wherein R2 represents -X(CH2)pNR3R4, one of R3 and R4 represents hydrogen, and the other represents -(CH2)rA in which r represents an integer 2 to 6, by reduction of a compound of formula XXV
Figure imgf000013_0003
wherein R1, A, D, r and p are as defined above,
(q) preparing a compound of formula I wherein R2 represents -
X(CH2)pNR3R4, one of R3 and R4 represents hydrogen, and the other represents (CH2)mOA, by reduction of a compound of formula XXVI
Figure imgf000014_0001
wherein R1, A, D, p and m are as defined above,
(r) preparing a compound of formula I wherein R2 represents -X(CH2)pNR3R4, one of R3 and R4 represents hydrogen, and the other represents -(CH2)rA in which r represents an integer 2 to 6, by reduction of a compound of formula XXVII
Figure imgf000014_0002
wherein R1, A, D, p and r are as defined above, or
(s) preparing a compound of formula I wherein R2 represents -X(CH2)pNR3R4, one of R3 and R4 represents hydrogen, and the other represents -(CH2)mOA, by reduction of a compound of formula XXVIII
Figure imgf000014_0003
wherein R1, A, D, p and m are as defined above,
and where desired or necessary converting the resultant compound of formula I, or another salt thereof, to a pharmaceutically acceptable salt thereof, or vice versa.
In process (a), the reaction will take place on stirring a mixture of the reactants in a suitable solvent, for example a lower alkanol e.g. ethanol, isopropanol or tertiary butanol, at a temperature between room temperature and the reflux temperature of the solvent. The reaction time will depend inter alia on the solvent and the nature of the leaving group, and may be up to 48 hours, however it will typically be from 1 to 5 hours. Suitable leaving groups that L may represent include thioalkyl, sulphonic acid, trifluorocarbon sulphonic acid, halide, alkyl and aryl alcohols and tosyl groups; others are recited in 'Advanced Organic Chemistry', J. March (1985) 3rd Edition, McGraw-Hill on page 315 and are well known in the art.
In process (b), the reaction is preferably performed by refluxing a mixture of the two compounds for several hours in the presence of a suitable solvent whereby the reaction temperature is high enough so that condensation takes place readily, but not sufficiently high to decompose the amidine formed. The reaction temperature can vary from room temperature to about 250 °C, although it is preferable to perform the reaction at temperatures from about 100 °C to 200 °C. We find that o-dichlorobenzene is a particularly suitable solvent and it is useful to add 4-dimethylaminopyridine as a catalyst. On cooling, two layers form, the solvent may be decanted, and the reaction worked up by addition of aqueous base.
Alternatively, where the reactants are soluble in the solvent, the solvent may be evaporated off under vacuum and the reaction mixture worked up by addition of water. The acid HA may be an organic or inorganic acid, for instance,
hydrochloric, hydrobromic, hydroiodic, sulphuric, nitric, phosphoric, acetic, lactic, succinic, fumaric, malic, maleic, tartaric, citric, benzoic or methanesulphonic acid.
In process (c), the reaction will take place under standard conditions, for example by reacting the two materials in an inert solvent under basic conditions at room temperature for a period of up to 12 hours. We have frequently found it desirable to treat the amine with NaH before reacting with the compound of formula II. We prefer that L represents halide, particularly bromide. Process (d) may be performed under conditions analogous to those described above for process (a).
Process (e) may be performed under conditions analogous to those described above for process (b). Processes (f), (g) and (h) may be performed under the standard conditions well known in the art for condensation of an amine and a carboxylic acid or an activated carboxylic acid to form an amide. For example, reaction of compounds to form the amide may be achieved on stirring the reactants for 12-24 hours at a
temperature between 0 °C and 25 °C in water or a mixture of water and a less polar solvent, for example dioxan, tetrahydrofuran or ethanol. We prefer to perform the reaction under basic conditions, e.g. in the presence of aqueous sodium carbonate or sodium bicarbonate. Process (i) may be performed under standard conditions analogous to those given above for process (c).
In process (j), the reduction may be perfomed by treatment with diborane in an inert solvent e.g. THF. Alternative although less preferred reagents which may be suitable include lithium aluminium hydride and reagents for catalytic hydrogenation e.g. H2 on Pd/C. Further details of the reaction conditions for use of these reactions may be obtained by reference to J. March "Advanced Organic Chemistry" on page 1099, including the references cited therein. In process (k), the reduction reaction may be performed under a number of conditions, for example those described in J March "Advanced Organic Chemistry" on pages 1103-1104. These include catalytic hydrogenation, use of Zn, Sn or Fe metal, AlH3-AlCl3, sulphides and others. We prefer to perform the reaction by hydrogenation at atmospheric pressure for 3-6 hours in the presence of a palladium and carbon catalyst.
In process (1) and (m), the reaction may be performed by stirring the reactants in the presence of an inert solvent at a temperature between room temperature and the reflux temperature of the solvent for up to 24 hours. Process (n) may be performed under conditions analogous to those described above for processes (f), (g) and (h).
In processes (o), (p) and (q), the reduction may be performed by treating the compound with sodium borohydride under standard conditions.
In processes (r) and (s), the reaction may be performed under conditions analogous to those described above for process (j). Salts of compounds of formula I may be formed by reacting the free acid, base or a salt, enantiomer, tautomer or protected derivative thereof, with one or more equivalents of the appropriate base or acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, eg water, dioxan, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed in vacuo or by freeze drying. The reaction may be a metathetical process or it may be carried out on an ion exchange resin.
It will be apparent to a person skilled in the art that it may be desirable to protect a hydroxy, amine or other reactive group using a protecting group as described in the standard text "Protecting groups in Organic Synthesis", 2nd Edition (1991) by Greene and Wuts. Amine-protecting groups which may be mentioned include alkyloxycarbonyl C2 to 7, eg t-butyloxycarbonyl, phenylalkyloxycarbonyl C8 to 13, eg benzyloxycarbonyl or preferably trifluoroacetate. Deprotection will normally take place on treatment with aqueous base.
Compounds of formula II are either known or may be prepared by known methods. For example, compounds of formula II in which L represents thioalkyl may be prepared by treatment of the corresponding thiamide of formula XXIX
Figure imgf000017_0001
wherein D is as defined above,
with an alkyliodide.
The compounds of formula III may be prepared by reduction of a
corresponding compound of formula XXX
Figure imgf000018_0001
wherein R1 and R2 are as defined above.
The reduction reaction may be performed under analogous conditions to those described above for process (k).
Certain compounds of formula XXX are either known or may be prepared by conventional methods known per se. Other compounds of formula XXX may be prepared from known compounds with simpler side-chains by following analogous processes to those described above for processes (c) to (s).
Compounds of formula V may be prepared by analogous processes to those described for the preparation of compounds of formula III. Compounds of formula V may be converted to corresponding compounds of formula III by treatment with a base. Compounds of formula HI may be converted to corresponding compounds of formula V by treatment with a protic acid HA, for example one of those listed above. Compounds of formula VII, IX, XI, XIIl, XVII, XVIII, XIX, XXI, XXIV, XXV,
XXVI, XXVII and XXVIII may be prepared by analogous processes to those described for the preparation of compounds of formula I.
Compounds of formula VIII are either known or may be prepared by an analogous process to that described above for preparation of compounds of formula II. Compounds of formula IV, VI, X, XII, XVI, XX, XXII, XXIII and XXIX are either known or may be prepared by conventional methods known per se.
Compounds of formula XIV and XV are either known or may readily be prepared from the corresponding carboxylic acid which is either known or may be prepared by conventional methods known per se.
Where necessary, hydroxy, amine or other reactive groups in intermediate compounds may be protected using a protecting group as described in the standard text "Protecting groups in Organic Synthesis", 2nd Edition (1991) by Greene and Wuts.
The compounds of the invention and intermediates may be isolated from their reaction mixtures by standard techniques.
The term "alkyl C1 to 6" includes straight chain, branched, saturated,
unsaturated, aliphatic and cyclic alkyl groups containing 1 to 6 carbon atoms.
The compounds of formula I may exist in tautomeric, enantiomeric or
diasteriomeric forms, all of which are included within the scope of the invention. The various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, e.g. fractional crystallisation, or HPLC. Alternatively the individual enantiomers may be made by reaction of the appropriate optically active starting materials under reaction conditions which will not cause racemisation.
Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures. The compounds of general formula I possess useful pharmacological activity in animals. In particular, they possess useful nitric oxide synthetase inhibiting activity, and are expected to be useful in the treatment or prophylaxis of human diseases or conditions in which the synthesis or oversynthesis of nitric oxide forms a
contributory part; for example, hypoxia, e.g. in cases of cardiac arrest and stroke, neurodegenerative disorders including nerve degeneration and/or nerve necrosis in disorders such as hypoxia, hypoglycemia, epilepsy, and in external wounds (such as spinal cord and head injury), hyperbaric oxygen convulsions and toxicity, dementia e.g. pre-senile dementia, Alzheimer's disease and AIDS-related dementia,
Sydenham's chorea, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Korsakoffs disease, imbecility relating to a cerebral vessel disorder, sleeping disorders, schizophrenia, depression, seasonal affective disorder, jet-lag, depression or other symptoms associated with Premenstrual Syndrome (PMS), anxiety and septic shock. Compounds of formula I may also be expected to show activity in the prevention and reversal of tolerance to opiates and diazepines, treatment of drug addiction, relief of pain and treatment of migraine and other vascular headaches. The compounds of the present invention may also show useful immunosuppressive activity, be useful in the treatment or prophylaxis of
inflammation, in the treatment of of gastrointestinal motility disorders, and in the induction of labour. Compounds of formula I are expected to be particularly useful in the treatment of neurodegenerative disorders or of migraine or for the prevention and reversal of tolerance to opiates and diazepines or for the treatment of drug addiction and especially in the treatment of neurodegenerative disorders. Thus according to a further aspect of the invention we provide a compound of formula I, or a pharmaceutically acceptable salt thereof, for use as a
pharmaceutical.
According to another feature of the invention we provide the use of a compound of formula I, without provisos (e) to (h), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of the aforementioned diseases or conditions.
For the above mentioned therapeutic indications, the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered to a human at a daily dosage of between 1 mg and 2000 mg (measured as the solid form) per day. The compounds of formula I, and pharmaceutically acceptable salts thereof, may be used on their own, or in the form of appropriate medicinal preparations for enteral or parenteral administration.
According to the invention, there is provided a pharmaceutical formulation including preferably less than 80% and more preferably less than 50% of a compound of formula I, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable diluent or carrier.
There is also provided a method of treatment of one of the aforementioned diseases or conditions which comprises administering a therapeutically effective amount of a compound of formula I, without provisos (e) to (h), or a
pharmaceutically acceptable salt thereof, to a person suffering from such a disease or condition. Examples of such diluents and carriers are: for tablets and dragees: lactose, starch, talc, stearic acid; for capsules: tartaric acid or lactose; for injectable solutions: water, alcohols, glycerin, vegetable oils; for suppositories: natural or hardened oils or waxes. Compositions in a form suitable for oral, i.e. oesophageal administration include: tablets, capsules and dragees; sustained release compositions include those in which the active ingredient is bound to an ion exchange resin which is optionally coated with a diffusion barrier to modify the release properties of the resin.
The enzyme nitric oxide synthetase has a number of isoforms and compounds of formula I, or pharmaceutically acceptable salts thereof, may be screened for nitric oxide synthetase activity by procedures based on those of Bredt and Snyder in Proc. Natl. Acad. Sci. (1990) 87, 682-685 and Förstermann et. al. (1992) Eur. J. Pharm. 225,161-165 as follows. Nitric oxide synthetase converts 3H-L-arginine to 3H-L-citrulline which can be separated by cation exchange chromatography and
quantified by liquid scintillation counting.
Screen A
(A) Screen for neuronal nitric oxide synthetase activity
Enzyme was isolated from rat hippocampus or cerebellum. The cerebellum or hippocampus of a male Sprague-Dawley rat (250-275g) is removed following CO2 anaesthesia of the animal and decapitation. Cerebellar or hippocampal supernatant is prepared by homogenisation in 50 mM Tris-HCl with 1 mM EDTA buffer (pH 7.2 at 25 °C) and centifugation for 15 minutes at 20,000 g. Residual L-arginine is removed from the supernatant by chromatography through Dowex AG-50W-X8 sodium form and hydrogen form columns successively, and further centrifugation at 1000 g for 30 seconds.
For the assay, 25 μl of the final supernatant is added to each of 12 test tubes containing 25 μl L-arginine solution (of concentration 18 μM 1H-L-arginine, 96 nM 3H-L-arginine) and either 25 μl of an assay buffer (50 mM HEPES, 1 mM EDTA, 1.5 mM CaCl2, pH 7.4) or 25 μl of test compound in the buffer at 22 °C. To each test tube was added 75 μl of complete assay buffer (50 mM HEPES, 1 mM EDTA, 1.5 mM CaCl2 , 1 mM DTT, 100 μM NADPH, 10 μg/ml calmodulin, pH 7.4) to initiate the reaction and the reaction is stopped after 10 minutes by addition of 2 ml of a termination buffer (20 mM HEPES, 2 mM EDTA pH 5.5).
Labelled L-citrulline is separated from labelled L-arginine by chromatography over a Dowex AG-50W-X8 200-400 mesh column. 1 ml of each terminated reaction is added to an individual 1 ml column and the eluant combined with that from two 1 ml distilled water washes and 16 ml of scintillation cocktail. The L-citrulline is then quantified by scintillation counting.
In a typical experiment using the cerebellar supernatant, basal activity is increased by 20,000 dpm/ml of sample above a reagent blank which has an activity of 7,000 dpm/ml. A reference standard, N-nitro-L-arginine, which gives 60% inhibition of nitric oxide synthetase at a concentration of 1 μM, is tested in the assay to verify the procedure. Screen B
(B) Screen for macrophage nitric oxide synthetase activity
Enzyme is prepared, after induction, from the cultured murine macrophage cell line J774A-1 (obtained from laboratories of the Imperial Cancer Research Fund). J774A-1 cells are cultured in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% foetal bovine serum, 4 mM L-glutamine and antibiotics (100 units/ml penicillin G, 100 μg/ml streptomycin & 0.25 μg/ml amphotericin B). Cells are routinely grown in 225 cm2 flasks containing 35 ml medium kept at 37 °C and in a humidified atmosphere containing 5% CO2.
Nitric oxide synthetase is produced by cells in response to interferon-γ (IFN7) and lipopolysaccharide (LPS). The medium from confluent culture flasks is removed and replaced with 25 ml (per flask) of fresh medium containing 1 μg/ml LPS and 10 units/ml IFN7. After a period of 17-20 hours in culture, harvesting of cells is accomplished by scraping the cell sheet from the flask surface into the culture medium. Cells are collected by centrifugation (1000g for 10 minutes) and lysate prepared by adding to the cell pellet a solution containing 50 mM Tris-HCl (pH 7.5 at 20 °C), 10% (v/v) glycerol, 0.1% (v/v) Triton-X-100, 0.1 μM dithiothreitol and a cocktail of protease inhibitors comprising leupeptin (2 μg/ml), soya bean trypsin inhibitor (10 μg/ml), aprotinin (5 μg/ml) & phenylmethylsulphonyl fluoride (50 μg/ml).
For the assay, 25 μl substrate cocktail (50 mM Tris-HCl (pH 7.5 at 20 °C), 400 μM NADPH, 20 μM flavin adenine dinucleotide, 20 μM flavin mononucleotide, 4 μM tetrahydrobiopterin, 12 μM L-arginine and 0.025 μCi L-[3H] arginine) is added to wells of a 96 well filter plate (0.45μM pore size) containing 25 μl of a solution of test compound in 50 mM Tris-HCl. The reaction is started by adding 50 μl of cell lysate (prepared as above) and after incubation for 1 hour at room temperature is terminated by addition of 50 μl of an aqueous solution of 3 mM nitroarginine and 21 mM EDTA.
Labelled L-citrulline is separated from labelled L-arginine using Dowex AG- 50W. 150 μl of a 25% aqueous sluπy of Dowex 50W (Na+ form) is added to the assay after which the whole is filtered into 96 well plates. 70 μl of filtrate is sampled and added to wells of 96 well plates containing solid scintillant. After allowing the samples to dry the L-citrulline is quantified by scintillation counting.
In a typical experiment basal activity is 300 dpm per 70 μl sample which is increased to 1900 dpm in the reagent controls. Aminoguanidine, which gives an IC50 (50% inhibitory concentration) of 10 μM, is tested as a standard to verify the procedure.
Screen C
(C) Screen for endothelial nitric oxide synthetase activity
Enzyme may be isolated from human umbilical vein endothelial cells (HUVECs) by a procedure based on that of Pollock et al (1991) Proc. Nat. Acad. Sci., 88, 10480-10484. HUVECs were purchased from Clonetics Corp (San Diego, CA, USA) and cultured to confluency. Cells can be maintained to passage 35-40 without significant loss of yield of nitric oxide synthetase. When cells reach confluency, they are resuspended in Dulbecco's phosphate buffered saline, centrifuged at 800 rpm for 10 mins, the cell pellet homogenised in ice-cold 50 mM Tris-HCl, 1 mM EDTA, 10% glycerol, 1 mM phenylmethylsulphonylfluoride, 2 μM leupeptin at pH 4.2. Following centrifugation at 34,000 rpm for 60 mins, the pellet is solubilised in the homogenisation buffer which also contains 20 mM CHAPS. After a 30 min incubation on ice, the suspension is centrifuged at 34,000 rpm for 30 mins. The resulting supernatant is stored at -80 °C until use. For the assay, 25 μl of the final supernatant is added to each of 12 test tubes containing 25 μl L-arginine solution (of concentration 12 μM 1H-L-arginine, 64 nM
3H-L-arginine) and either 25 μl of an assay buffer (50 mM HEPES, 1 mM EDTA,
1.5 mM CaCl2, pH 7.4) or 25 μl of test compound in the buffer at 22 °C. To each test tube was added 25 μl of complete assay buffer (50 mM HEPES, 1 mM EDTA, 1.5 mM CaCl2, 1 mM DTT, 100 μM NADPH, 10 μg/ml calmodulin, 12 μM tetrahydrobiopterin, pH 7.4) to initiate the reaction and the reaction is stopped after 10 mins by addition of 2 ml of a termination buffer (20 mM HEPES, 2 mM EDTA, pH 5.5).
Labelled L-citrulline is separated from labelled L-arginine by chromatography over a Dowex AG-50W-X8 200-400 mesh column. 1 ml of each terminated reaction is added to an individual 1 ml column and the eluant combined with that from two 1 ml distilled water washes and 16 ml of scintillation cocktail. The L-citrulline is then quantified by scintillation counting.
In a typical experiment, basal activity is increased by 5,000 dpm/ml of sample above a reagent blank which has an activity of 1500 dpm/ml. A reference standard, N-nitro-L-arginine, which gives 70-90% inhibition of nitric oxide synthetase at a concentration of 1 μM, is tested in the assay to verify the procedure. Compounds may also be tested in an ex-vivo assay to determine the extent of brain penetration.
Screen D
(D) Ex vivo assay for neuronal nitric oxide synthetase activity
Male Sprague-Dawley rats (250-275g) were dosed intravenously at 10mg/kg with test compound dissolved in 0.9% saline or with saline alone as control. At a predetermined time (typically 2-24 hours) after treatment, the animals were sacrificed, the cerebellum removed and the supernatant prepared and assayed for nitric oxide synthetase activity as described in Screen A
As a further confirmatory test, a fraction of the cerebellar supernatant was applied to a 2'-5'-ADP Sepharose column (which binds nitric oxide synthetase) and subsequently eluted with NADPH. The eluant was tested for nitric oxide synthetase activity following the procedure of Screen A.
Compounds that penetrate the rat brain and inhibit neuronal nitric oxide synthetase resulted in reduced nitric oxide synthetase activity both in the
supernatant preparation and in the eluant from the 2'-5'-ADP Sepharose column.
In the screens for nitric oxide synthetase inhibition activity, compound activity is expressed as IC50 (the concentration of drug substance which gives 50% enzyme inhibition in the assay). IC50 values for test compounds were initially estimated from the inhibiting activity of 1, 10 and 100 μM solutions of the compounds.
Compounds that inhibited the enzyme by at least 50% at 10 μM were retested using more appropriate concentrations so that an IC50 could be determined.
In Screen A above (a screen for activity against the neuronal isoform of nitric oxide synthetase), the compound of Example 1 below gave an IC50 of less than 10 μM indicating that it is expected to show useful therapeutic activity. In Screens B and C (the screens for activity against the macrophage and endothelial isoforms of nitric oxide synthetase) the compound of Example 1 gave IC50 values more than 10 times that obtained in Screen A indicating that it shows desirable selectivity.
The compounds of Examples 2-20, 21(a)-(n), 22(a)-(e), 23(a)-(f), 24-26, 27(a), (b), 28-47 and 49-71 were tested in Screen A and also gave IC50 values of less than 10 μM. Example 48 was tested in Screen A and gave an IC50 value of less than 100 μM. Example 72 was tested in Screen A and gave 17% inhibition at 10 μM. Thus these compounds are also expected to show useful therapeutic activity.
Compounds of formula I, and pharmaceutically acceptable salts thereof, have the advantage that they are less toxic, more efficacious, more selective, are longer acting, have a broader range of activity, are more potent, produce fewer side effects, are more easily absorbed, or have other useful pharmacological properties than compounds previously known and used in the therapeutic fields mentioned above.
Compounds of formula I, and pharmaceutically acceptable salts thereof, may also have the advantage that they are more selective for the neuronal isoform of nitric oxide synthetase enzyme and are therefore expected to show useful therapeutic activity with a reduced side-effect profile associated with inhibition of the other isoforms. The invention is illustrated by the following examples:
Example 1
N-(4-(2-((phenylmethyl)amino)ethyl )phenyl)-2-thiophenecarboximidamide
(a) N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide
To a stirred solution of 4-nitrophenethylamine hydrochloride (1.84 g, 9.10 mmol) and triethylamine (3.03 ml, 21.70 mmol) in methanol (12 ml) was added
trifluoroacetic anhydride (1.51 ml, 10.66 mmol) dropwise. After stirring for 1 minute, the solvent was removed at reduced pressure and the remaining residue was mixed with water and extracted with methylene chloride (3 X 20 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to yield a solid which was recrystallized from methylene chloride/hexane to give N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide as a white solid: 1.92 g (80% yield); m.p. 103-104 °C.
(b) N-(2-(4-nitrophenyl)ethyl)-N-(phenylmethyl)trifluoroacetamide
To a stirred solution of the product of step (a) (0.89 g, 3.40 mmol) in THF (5 ml) at 0 °C was added NaH (60%, 0.18 g, 4.42 mmol) followed by benzyl bromide (0.50 ml, 4.10 mmol). The mixture was stirred at room temperature for 6 h, quenched with water, and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, concentrated, and chromatographed over silica gel (18% ethylacetate/hexane) to give N(2-(4- nitrophenyl)ethyl)-N-(phenylmethyl)trifluoroacetamide as a colourless oil: (0.52 g, 44%); M.S. (M+H)+= 353.
(c) N-(2-(4-aminophenyl)ethyl)-N-(phenylmethyl)trifluoroacetamide
To a stirred solution of the product of step (b) (0.52 g, 1.48 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 1 hr, filtered through celite, and concentrated to give N(2-(4-aminophenyl)ethyl)-N-(phenylmethyl)trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction.
(d) S-methyl-2-thiophenethiocarboximide hydroiodide
A solution of 2-thiophenecarboxthioamide (Maybridge Chemical) (11.1 g) in 60ml of acetone was treated with iodomethane (13.4g). After 6 hrs at 22 °C, the resulting yellow solids were collected by filtration, washed twice with 25ml of acetone and dried to provide 18.45 g of S-methyl-2-thiophenethiocarboximide hydroiodide, m.p.195 °C (dec).
(e) N-(4-(2-((phenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide
To a solution of N(2-(4-aminophenyl)ethyl)-N-(phenylmethyl)trifluoroacetamide (0.48 g, 1.48 mmol) in isopropanol (6 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (0.42 g, 1.48 mmol). The mixture was stirred for 4 hr, diluted with methanol (5 ml) and 2 N NaOH (6 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to give a solid which was recrystallized (ethyl acetate/hexane) to yield N-(4-(2-((phenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide as a white solid: (0.17 g, 34%); m.p. 116-118 °C.
Example 2
N-(4-(1-((phenylmethyl )amino)methyl )phenyl)-2-thiophenecarboximidamide
(a) N-((4-nitrophenyl)methyl)trifluoroacetamide
To a stirred solution of 4-nitrobenzylamine hydrochloride (4.06 g, 21.5 mmol) and triethylamine (6.60 ml, 47.4 mmol) in methylene chloride (30 ml) was added trifluoroacetic anhydride (3.34 ml, 23.7 mmol) dropwise. After stirring for 1 minute, water was added and the layers separated. The aqueous layer was further extracted with methylene chloride (3 X 20 ml) and the combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to yield a solid which was re crystallized from methylene chloride/hexane to give N-((4-nitrophenyl)methyl)trifluoroacetamide as a white solid: 3.9 g (73% yield); m.p. 97-
98 °C.
(b) N-((4-nitrophenyl)methyl)-N-(phenylmethyl)trifluoroacetamide
To a stirred solution of the product of step (a) (1.0 g, 4.03 mmol) in THF (10 ml) at 0 °C was added NaH (60%, 0.21 g, 5.24 mmol) followed by benzyl bromide (0.72 ml, 4.84 mmol). The mixture was stirred at room temperature for 12 h, quenched with water, and extracted with ethyl acetate( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, concentrated, and chromatographed over silica gel (16% ethylacetate/hexane) to give N-((4-nitrophenyl)methyl)-N-(phenylmethyl)trifluoroacetamide as a colorless oil: (0.50 g, 40%); M.S. (M+H)+= 339.
(c) N((4-aminophenyl)methyl)-N-(phenylmethyl)trifluoroacetamide
To a stirred solution of the product of step (b) (1.76 g, 5.16 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 0.5 hr, filtered through celite, and concentrated to give N((4-aminophenyl)methyl)-N-(phenylmethyl)trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction.
(d) N(-4-(1-((phenylmethyl)amino )methyl)phenyl)-2-thiophenecarboximidamide
To a solution of the product of step (c) (1.60 g, 5.16 mmol) in isopropanol (6 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of
Example 1, step (d)) (1.47 g, 5.16 mmol). The mixture was stirred for 24 hr at 40 °C, diluted with methanol (5 ml) and 2 N NaOH (15 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, concentrated and chromatographed over silica gel (8% methanol/ methylene chloride) to give a solid which was recrystallized (ethyl acetate/hexane) to yield N-(4-(1-((phenylmethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide as a white solid: (60 mg, 4%); m.p. 73-74 °C. Example 3
N-( 4-(1-((phenethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide
(a) N-(2-phenylethyl)trifluoroacetamide
To a stirred solution of phenethylamine (4.91 g, 40.5 mmol) and triethylamine (6.50 ml, 46.6 mmol) in methylene chloride (30 ml) was added trifluoroacetic anhydride (6.3 ml, 44.6 mmol) dropwise. After stirring for 1 minute, water was added and the layers separated. The aqueous layer was further extracted with methylene chloride (3 X 40 ml) and the combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to yield a solid which was
recrystallized from methylene chloride/hexane to give N-(2-phenylethyl)trifluoroacetamide as a white solid: 6.0 g 69% yield); m.p. 50-52 °C.
(b) N-(2-phenylethyl)-N-((4-nitrophenyl)methyl)trifluoroacetamide
To a stirred solution of the product of step (a) (2.0 g, 9.26 mmol) in THF (10 ml) at 0 °C was added NaH (60%, 0.37 g, 9.26 mmol) followed by 4-nitrobenzyl bromide (1.0 g, 4.63 mmol). The mixture was stirred at room temperature for 1 hr, quenched with water, and extracted with ethyl acetate (3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered,
concentrated, and chromatographed over silica gel (16% ethylacetate/hexane) to give N-(2- phenylethyl)-N-((4-nitrophenyl)methyl)trifluoroacetamide as a colorless oil: (1.60 g, 98%); M.S. (M+H)+= 353.
(c) N-(2-phenylethyl)-N-((4-aminophenyl)methyl)trifluoroacetamide
To a stirred solution of the product of step (b) (1.60 g, 4.54 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 0.75 hr, filtered through celite, and concentrated to give N-(2-phenylethyl)-N-((4-aminophenyl)methyl)trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction.
(d) N-(4-(1-((2-phenylethyl)amino )methyl)phenyl)-2-thiophenecarboximidamide To a solution of the product of step (c) (1.47 g,4.54 mmol) in isopropanol (5 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of
Example 1, step (d)) (1.30 g,4.54 mmol). The mixture was stirred for 24 hr at 40 °C, diluted with methanol (5 ml) and 2 N NaOH (10 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, concentrated and chromatographed over silica gel (10% methanol/methylene chloride) to give a solid which was recrystallized (ethyl acetate/hexane) to yield N-(4-(1-((2-phenylethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide as a white solid: (20 mg, 2%); M.S. (M+H)+= 336.
Example 4
N-(4-(2-((2-chlorophenylmethyl)amino )ethyl)phenyl)-2-thiophenecarboximidamide (a) N-(4-nitrophenyl)ethyl)-N-((2-chlorophenyl)methyl)trifluoroacetamide
To a stirred solution of N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide (the product of Example 1 step (a)) (2.0 g, 7.63 mmol) and a catalytic amount of 15-crown-5 in THF (10 ml) at 0 °C was added NaH (60%, 0.18 g, 4.42 mmol) followed by 2-chlorobenzyl bromide (1.49 ml, 11.45 mmol). The mixture was stirred at room temperature for 2 hr, quenched with water, and extracted with ethyl acetate( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, concentrated, and chromatographed over silica gel (18%
ethylacetate/hexane) to give N-(2-(4-nitrophenyl)ethyl)-N-((2-chlorophenyl)methyl)trifluoroacetamide as a colourless oil: (2.31 g, 78%); M.S.
(M+H)+= 353.
(b) N-(2-(4-aminophenyl)ethyl)-N-((2-chlorophenyl)methyl )trifluoroacetamide
To a stirred solution ofthe product of step (a) (2.31 g, 5.96 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 1 hr, filtered through celite, and concentrated to give N-(2-(4-aminophenyl)ethyl)-N-((2-chlorophenyl)methyl)trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction. (c) N-(4-(2-((2-chlorophenylmethyl )amino)ethyl)iphenyl)-2-thiophenecarboximidamide
To a solution of the product of step (b) (2.1 g, 5.96 mmol) in isopropanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (1.7 g, 5.96 mmol). The mixture was stirred for 24 hr, diluted with methanol (10 ml) and 2 N NaOH (6 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, concentrated and
chromatographed over silica gel (10% methanol/methylene chloride) to give a solid which was recrystallized (methylene chloride/hexane) to yield N-(4-(2-((2-chlorophenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide as a white solid: (0.21 g, 10%); m.p. 81-82 °C. Example 5
N-(4-(2-((3-fluorophenylmethyl )amino )ethyl )phenyl)-2-thiophenecarboximidamide
(a) N-((3-fluorophenyl)methyl)-N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide
To a stirred solution of N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide (the product of Example 1 step (a)) (1.5 g, 5.75 mmol) and a catalytic amount of 15-crown-5 in THF (10 ml) at 0 °C was added NaH (60%, 0.25 g, 6.34 mmol) followed by 3-fluorobenzyl bromide (1.40 ml, 11.45 mmol). The mixture was stirred at room temperature for 4 hr, quenched with water, and extracted with ethyl acetate( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, concentrated, and chromatographed over silica gel (18% ethyl
acetate/hexane) to give N-((3-fluorophenyl)methyl)-N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide as a colourless oil: (1.63 g, 77%); M.S.
(M+H)+= 371.
(b) N-(2-(4-aminophenyl)ethyl)-N-((3-fluorophenyl)methyl)trifluoroacetamide
To a stirred solution of the product of step (a) (1.63 g, 4.40 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 1 hr, filtered through celite, and concentrated to give N- (2-(4-aminophenyl)ethyl)-N-((3-fluorophenyl)methyl)trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction,
(c) N-(4-(2-((3-fluorophenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide
To a solution of the product of step (b) (1.5 g, 4.40 mmol) in methanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (1.3 g, 4.40 mmol). The mixture was stirred for 2 hr, diluted with methanol (5 ml) and 2 N NaOH (8 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to give a solid which was recrystallized (methylene chloride/hexane) to yield N-(4-(2-(((3-fluorophenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide as a white solid: (0.14 g, 8%); m.p.130-131 °C.
Example 6
N-(4-(2-(((2-methylphenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide
(a) N-((2-methylphenyl)methyl)-N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide
To a stirred solution of N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide (the product of Example 1 step (a)) (1.5 g, 5.75 mmol) and a catalytic amount of 15-crown-5 in THF (10 ml) at 0 °C was added NaH (60%, 0.25 g, 6.34 mmol) followed by 2-methylbenzyl bromide (1.53 ml, 11.45 mmol). The mixture was stirred at room temperature for 2 hr, quenched with water, and extracted with ethyl acetate( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, concentrated, and chromatographed over silica gel (18%
ethylacetate/hexane) to give N-((2-methylphenyl)methyl)-N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide as a colorless oil: (1.76 g, 84%); M.S.
(M+H)+= 367.
(b)N-(2-(4-aminophenyl)ethyl)-N-((2-methylphenyl)methyl)-trifluoroacetamide To a stirred solution of the product of step (a) (1.76 g, 4.82 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 1 hr, filtered through celite, and concentrated to give N(2-(4-aminophenyl)ethyl)-N-((2-methylphenyl)methyl)-trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction,
(c) N-(4-(2-(((2-methylphenyl)methyl)ammo)ethyl)phenyl)-2-thiophenecarboximidamide
To a solution of the product of step (b) (1.62 g, 4.82 mmol) in methanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (1.37 g, 4.82 mmol). The mixture was stirred for 2 hr, diluted with 2 N NaOH (8 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to give a solid which was recrystallized (methylene chloride/hexane) to yield N-(4-(2-(((2-methylphenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide as a white solid: (0.46 g, 28%); m.p.105-106 °C.
Example 7
N-(4-(2-(methylamino)ethyl )phenyl)-2-thiophenecarboximidamide
(a) N-methyl-N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide
To a stirred solution of N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide (the product of Example 1 step (a)) (1.5 g, 5.75 mmol) and a catalytic amount of 15-crown-5 in THF (10 ml) at 0 °C was added NaH (60%, 0.25 g, 6.34 mmol) followed by methyhodide (0.71 ml, 11.45 mmol). The mixture was stirred at room temperature for 4 hr, quenched with water, and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to yield N-methyl-N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide a colorless oil: (1.40 g, 88%); M.S. (M+H)+= 277.
(b) N-methyl-N-(2-(4-aminophenyl)ethyl)trifluoroacetamide To a stirred solution of the product of step (a) (1.45 g, 5.25 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 1 hr, filtered through celite, and concentrated to give N-methyl-N-(2-(4-aminophenyl)ethyl)trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction.
(c) N-(4-(2-(methylamino )ethyl)phenyl)-2-thiophenecarboximidamide
To a solution of the product of step (b) (1.32 g, 5.37 mmol) in methanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of
Example 1, step (d)) (1.53 g, 5.37 mmol). The mixture was stirred for 2 hr, diluted with 2 N NaOH (8 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to give a solid which was recrystallized (methylene chloride/hexane) to yield N-(4-(2-((2-methylphenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide as a white solid: (0.43 g, 31%); M.S. (M+H)+= 260.
Example 8
N-(4-(2-aminoethyl)phenyl)-2-thiophenecarboximidamide
(a) N-(2-(4-aminophenyl)ethyl)trifluoroacetamide
To a stirred solution of N-(2-(4-nitrophenyl)ethyl)trifluoroacetamide (the product of
Example 1 step (a)) (1.00 g, 3.81 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 1 hr, filtered through celite, and concentrated to give N-(2-(4-aminophenyl)ethyl)trifluoroacetamide which was homogeneous by TLC and used immediately in the next reaction.
(c) N-(4-(2-aminoethyl)phenyl)-2-thiophenecarboximidamide
To a solution of the product of step (a) (0.88 g,3.81 mmol) in methanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (1.09 g, 3.81 mmol). The mixture was stirred for 12 hr, diluted with 2 N
NaOH (8 ml) and heated to 70 °C for 1 hr. The solvents were removed at reduced pressure, and the residue was dumped into water and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to give a solid which was recrystallized (ethyl acetate/methanol) to yield N-(4-(2-aminoethyl)phenyl)-2-thiophenecarboximidamide as a white solid: (70 m g, 8%); m.p.134-137 °C.
Example 9
N-((4-morpholinylmethyl)phenyl)-2-thiophenecarboximidamide
(a) 4-(4-Nitrobenzyl)-morpholine.
To a stirred solution of (2.00g; 0.0093 mol) 4-nitrobenzyl bromide (Aldrich) and (0.736g; 0.011 mol) potassium carbonate anhydrous (Aldrich) in 20.0ml DMF was added (0.796ml; 0.0093 mol) morpholine. The reaction was heated to 50°C and stirred for 30 minutes, after which time and additional 0.1 equivalents of morpholine and potassium carbonate were added. After 30 minutes the reaction mixture was quenched with 100 ml water and extracted with (4×100ml) ethyl acetate. The organic layers were collected and dried over magnesium sulfate and the solvent evaporated. The resulting solids were recrystallized from ethly acetate and hexane to leave 1.90g of 4-(4-nitrobenzyl)-morpholine.
(b) (4-morpholinylmethyl )aniline
A (1.00g; 0.0045 mol) sample of 4-(4-nitrobenzyl)-morpholine was dissolved in 25ml each THF and methanol in a pressure bottle. A catalytic amount of 10% palladium on carbon was added and the reaction hydrogenated. When hydrogen uptake had ceased, the catalyst was removed by filtration and the solvents evaporated. The solids were dissolved in 30ml each ethyl acetate and water, and 30 ml 2N sodium hydroxide. The aqueous layer was extracted with (4×75ml) ethyl acetate. The organic layers were collected, dried, over magnesium sulfate, and the solvent evaporated under vacuum. The resulting solids were recrystallized from ethyl acetate and hexane to leave 0.68g of (4-morpholinylmethyl)aniline.
(c) N-((4-morpholinylmethyl)phenyl)-2-thiophenecarboximidamide
To a stirred solution of the product of step (b) (0.68g; 0.0035 mol) and 15.0ml isopropyl alcohol was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (0.99g; 0.0035 mol). The mixture was stirred at 35C. To this mixture was added 10.0ml methanol along with 2M hydrochloric acid in isopropyl alcohol added dropwise until all of the reactants were in solution. The reaction was allowed to stir for 48 hours. The reaction was then diluted in 50ml saturated sodium chloride and extracted with (3×75mL) ethyl acetate. The organic layers were collected, dried over magnesium sulfate, and the solvent evaporated. The crude product was separated on a silica gel column eluted with 10% methanol in methylene chloride. The solvent was evaporated and the crude solid
recrystallized twice from ethyl acetate and hexane to leave 60mg of N-((4-morpholinylmethyl)phenyl)-2-thiophenecarboximidamide, m.p. = 148-150°C.
Example 10
N-(3-(((phenylmethyl)amino)methyl )phenyl)-2-thiophenecarboximidamide bisoxalate
(a) N-(3-nitrobenzyl)benzamide
To a solution of 3-nitrobenzyl amine hydrochloride (2.45 g, 0.013 mol) in a solution of 50 ml of methylene chloride and 50 ml of half saturated aqueous potassium carbonate at 0 °C was added dropwise a solution of benzoyl chloride (2.1 g, 0.0149 mol) in 10 ml of methylene chloride. After addition was complete, the reaction mixture was stirred for 2 h at 0 °C and was then allowed to warm to ambience overnight. The organic layer was separated and was washed successively with dilute hydrochloric acid and water. The dried (MgSO4) organic phase was concentrated in vacuo to give 2.92 g (88%) of the title product, m.p. 136-8°C.
(b) N-benzyl-2,2,2-trifluoro-N-(3-nitrobenzyl)acetamide
To a solution of the product of step (a) (2.85 g, 11.1 mmol) in 50 ml of anhydrous tetrahydrofuran at 0 °C under nitrogen was added 18.6 ml of a 1.0 M borane in THF solution (18.6 mmol). The reaction mixture was then heated to reflux for 5.5 h. The solution was allowed to cool overnight and was then quenched by the successive addition of 2 ml of methanol and 10 ml of 6 M hydrochloric acid. The reaction mixture was again heated to reflux for 1 h. Upon cooling to ambience, the reaction mixture was basified and extracted into ether. The dried (MgSO4) was concentrated to afford an oil. This oil was chromatographed on silica gel using methylene chloride as eluent to give 1.95 g (72 %) of benzyl-3-(nitrobenzyl)amine as an oil. To a solution of the crude benzyl-3-(nitrobenzyl)amine (1.95 g, 8.05 mmol) and triethylamine (2.6 M1, 18 mmol) in 20 ml of methylene chloride under nitrogen at 0º C, was added dropwise triflluoroacetic anhydride (3.4 g, 16 mmol). The reaction mixture was stirred for 10 minutes before pouring into water. The organic layer was separated and dried over magnesium sulfate. The solution was filtered and concentrated to give an oil. Chromatography on silica gel, using 20% ethyl acetate in hexanes as eluent afforded 1.46 g (54%) of the product as an oil, mass spectra m/e 339 (100%, M+H).
(c) N-(3-aminobenzyl)-N-benzyl-2,2,2-trifluoroacetamide
To a solution of the product of step (b) (1.21 g, 3.58 mmol) dissolved in a solution of 100 ml of methanol was added 20 ml of a saturated solution of hydrogen chloride in isopropanol and 0.1 g of 5% Pd/C. The resulting solution was hydrogenated at 50 psi for one hour. The catalyst was removed by filtration and the filtrate was concentrated in vacuo sohd. Trituration of this solid with ether afforded 1.15 g (93%) of the title compound as the hydrochloride salt, m.p. 169-74 °C.
(d) N-(3-(((phenylmethyl )amino)methyl)phenyl)-2-thiophenecarboximidamide To a solution of 0.25 g (0.94 mmol) of S-methyl 2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) in 4 ml of isopropanol was added 0.41 g (1.3 mmol) of N-(3-aminobenzyl)-N-benzyl-2,2,2-trifluoroacetamide (prepared by taking the hydrochloride salt and neutralizing with 2.5 m NaOH and extracting into methylene chloride). The reaction mixture was stirred for 5 h. A solution (2 ml) of 2.5 M sodium hydroxide and about 5 drops of methanol was added and the resulting solution was heated at reflux for 1 h. The solution was concentrated and the product was extracted into ethyl acetate. The solution was dried and concentrated to give a solid. This solid was dissolved in ethanol and oxalic acid dihydrate (0.16 g, 1.3 mmol) was added. The resulting salt was collected and dried to give 0.26 g (55%) of the title compound as the bis oxalate salt, mp 178-183 °C.
Example 11 An alternative synthesis for the compound of Example 2.
N-(4-(((phenylmethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide
(a) N-(4-nitrobenzyl)benzamide)
This compound was prepared following the method of Example 10, step (a). From 4-nitrobenzyl amine (2.45 g, 0.013 mol) and benzoyl chloride (2.1 g, 0.0149 mol) was isolated 2.56 g (77%) of the title product, m.p. 150-3 °C.
(b) N-benzyl-2,2,2-trifluoro-N-(4-nitrobenzyl)acetamide
This compound benzyl-(4-nitrobenzyl)amine was prepared using the method described in Example 10, step (b) for the preparation of benzyl-3-(nitrobenzyl)amine. From 2.49 g (9.36 mmol) of N-(4-nitrobenzyl)-benzamide and 18.6 ml of 1.0 M borane in THF was obtained 3.12 g of the crude benzyl-(4-nitrobenzyl)amine, which was used without further purification. This crude product was mixed with 4.3 ml of triethylamine in 40 ml of methylene chloride at 0ºC under nitrogen. To this solution was added dropwise 3.6 ml of trifluoroacetic anhydride. The solution was stirred for 10 minutes and was poured into water and separated. The dried organic phase was dried (MgSO4) and concentrated to give 3.1 g (94%) of the title compound as an oil.
(c) N-(4-aminobenzyl)-N-benzyl-2,2,2-trifluoroacetamide
This compound was prepared using the method described in Example 10, step (c) for the preparation of N-(3-aminobenzyl)-N-benzyl-2,2,2-trifluoroacetamide. From N-benzyl-2,2,2-trifluoro-N-(4-nitrobenzyyl)acetamide (3.1 g, 9.2 mmol) was obtained 2.46 g (78%) of the title compound as the hydrochloride salt following
hydrogenation. Recrystallization from isopropanol and ether gave 1.74 g of pure material, mp 115-9 °C.
(d) N-(4-(((phenylmethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide From 0.60 g (1.9 mmol) of the free base of N-(4-aminobenzyl)-N-benzyl-2,2,2-trifluoroacetamide and 0.42 g (1.6 mmol) of S-methyl 2-thiophenethiocarboximide (prepared by taking the hydrochloride salt produced by following a method analogous to that of Example 1, step (d), and neutralizing with 2.5 m NaOH and extracting into methylene chloride) in 4 ml of isopropanol. The reaction mixture was stirred for 5 h. A solution (2 ml) of 2.5 M sodium hydroxide and about 5 drops of methanol was added and the resulting solution was heated at reflux for 1 h. The solution was concentrated and the product was extracted into ethyl acetate. The solution was dried and concentrated to give a sohd. This was converted to the bis oxalate in isopropanol and then recrystallized from 95% ethanol to give 110 mg (10%) of the title compound, mp 209-13 °C.
Example 12
The following compounds were prepared following the method of Example 1:
(a) N-(4-(2-(((2,6-dichlorophenyl )methyl )ammo )ethyl)phenyl)-2-thiophenecarboximidamide m.p. 104-105 °C
(b) N-(4-(2-(((2-bromophenyl)lmethyl )amino)ethyl )phenyl)-2-thiophenecarboximidamide m.p. 81-82 °C
(c) N-(3-(2-((Phenylmethyl)amino )ethyl)phenyl)-3-thiophenecarboximidamide dihydrochloride, m.p. 145-147 °C
(d) N-(4-(2-((2,6-dichlorophenylmethyl)amino)ethyl)phenyl)
-3-thiophenecarboximidamide free base, m.p. 109-110 °C
(e) N-(4-(2-aminoethyl)phenyl)-3-thiophenecarboximidamide dihydrochloride m.p. 158-170 dec
(f)
N-(4-(2-((2,6-dichlorophenylmethyl)amino)ethyl)phenyl)-2-furanocarboximidamide free base, m.p. 101-104 °C
(g) N-(3-(3-(1-pyrolidinyl)lpropyl)phenyl)-2-thiophenecarboximidamide free base, m.p. 110-111 °C
(h) N-(4-(2-aminoethyl )phenyl)-2-furocarboximidamide dioxalate, m.p. 162 °C dec
Example 13
The following compounds were prepared following the method of Example 9:
(a) N-(4-((1-piperidinyl)methyl)phenyl)-2-thiophenecarboximidamide dihydrochloride m.p. 277-278 °C
(b) N-(4-((i-pyrrolidinyl)methyl)phenyl)-2-thiophenecarboximidamide dihydrochloride m.p. 248-250 °C
Example 14
The following compound was prepared following the method of Example 10:
N-(3-(((phenylmethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide
dimaleate m.p. 171-173 °C
Example 15
The following compound was prepared following the general method of Example 1 starting at step (e) by reacting S-methyl-2-thiophenecarboximide hydroiodide with 3-(methylamino)phenylamine.
N-(3-((amino)methyl)phenyl)-2-thiophenecarboximidamide
dimaleate m.p. 145-148 °C Example 16
The following compound was prepared following the method of Example 10
N-(3-(2-((phenylmethyl)aminotethyl)phenyl)-2-thiophenecarboxamidine Dioxalate, m.p. 132-134 °C Example 17
N-(3-(2-(Ethylamino )ethyl)phenyl)-2-thiophenecarboximidamide
(a) (3-Nitrophenyl)acetyl chloride
A stirred solution of 3-nitrophenylacetic acid (10.0 g, 55.2 mmol) in thionyl chloride (100 ml, 1.37 mol) was heated at reflux for 2 hours, then concentrated to yield 11.1 g of (3-nitrophenyl)acetyl chloride as a tan solid.
(b) N-Ethyl-2-(3-nitrophenyl)acetamide
To a stirred solution of 70 wt % ethylamine in water (35 ml) cooled on an ice bath was added in one portion (3-nitrophenyl)acetyl chloride (3 g, 15.0 mmol). Resulting mixture was warmed to achieve a clear solution, allowed to cool. Resulting precipitate was filtered to yield N-ethyl-2-(3-nitrophenyl)acetamide as a yellow solid: (2.2 g, 71%); m.p. 115-117 °C. (c) Ethyl-(2-(3-nitrophenyl)ethyl)amine hydrochloride
To a stirred solution of the product of step (b) (2.2 g, 10.6mmol) in tetrahydrofuran (50ml) under nitrogen, was added dropwise 1.0M borane-tetrahydrofuran (42ml, 42mmol). Reaction was heated at reflux for 1.5 hours, cooled on ice bath, then aqueous 6N HCl (75ml) added dropwise. The resulting mixture was refluxed for 1 hour, basified to pH 11 with 20% aqueous sodium hydroxide, extracted twice with ether. Combined extracts were dried over magnesium sulfate, filtered,
concentrated. The hydrochloride salt of the crude was made from isopropanol and ethyl acetate to yield ethyl-(2-(3-nitrophenyl)ethyl)amine hydrochloride as a light yellow solid: (1.7g, 70%); m.p. 186-188 °C.
(d) 3-(2-Ethylamino-ethyl)phenylamine hydrochloride
To a solution of the product of step (c) (1.7g, 7.0mmol) in methanol (30ml) was added a catalytic amount of 10% palladium on carbon. The mixture was hydrogenated at 50 psi for 30 minutes, filtered through celite, concentrated to yield 3-(2-ethylamino-ethyl)phenylamine hydrochloride as an off-white solid: (1.4g, 100%); m.p. 192-194 °C.
(e) N-(3-(2-(Ethylamino)ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride To a solution of the product of step (d) (1.4g, 7.0mmol) in isopropanol (20ml) and dimethylformamide (20ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (2.5g, 8.8mmol). The mixture was stirred for 16 hours, diluted with 20% aqueous sodium hydroxide, and extracted twice with ethyl acetate. The combined extracts were washed twice with water, dried over magnesium sulfate, filtered, and concentrated to give 2.7g of an oil. The dihydrobromide salt was made from isopropanol and ethyl acetate, recrystallized from isopropanol, methanol, and ethyl acetate to yield N-(3-(2-(ethylamino)ethyl)-phenyl)-2-thiophenecarboximidamide dihydrobromide as a tan solid: (1.72g, 49%); m.p. 192-194 °C (dec).
Example 18
N-(3-(3-((Phenylethyl)amino)propyl)phenyl)-2-thiophenecarboximidamide dioxalate (a) 3-(3-Phenylethylamino-propyl)phenylamine dihydrochloride This was prepared following a method analogous to that of Example 17, steps (a)-
(d).
(b) N-(3-(3-((Phenylethyl)amino)propyl)phenyl)-2-thiophenecarboximidamide dioxalate
To a solution of the product of step (a) (3.0 g, 9.17 mmol) and S-methyl-2-thiophenethiocarboximide hydroiodide (3.3 g, 11.5 mmol) in isopropanol (25ml) and dimethylformamide (25ml) was added pyridine (0.74 ml, 9.17 mmol) in one portion. The mixture was stirred for 16 hours, diluted with 20% aqueous sodium hydroxide, and extracted twice with ethyl acetate. The combined extracts were washed twice with water, dried over magnesium sulfate, filtered, and concentrated. The dioxalate salt of the crude was made from ethanol and ether, recrystallized from ethanol to yield N-(3-(3-((phenylethyl)amino)propyl)phenyl)-2-thiophenecarboximidamide dioxalate as the white solid: (2.3 g, 44%); m.p. 102-105 °C. Example 19
N-(3-(2-(((2-Bromophenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide
(a) N-(2-Bromoben_zyl)-2-(3-nitrophenyl)acetamide
This was prepared following a method analogous to that of Example 17, steps (a)- (b).
(b) N-(2-Brornobenzyl)-2-(3-aminophenyl)acetamide
To a solution of the product of step (a) (5.45 g, 15.6 mmol) in 85% glacial acetic acid (400 ml) was added in one portion the zinc dust (10.2 g, 156 mmol). Reaction was stirred for 30 minutes, filtered, and concentrated. The residue was partitioned with 20% aqueous sodium hydroxide and dichloromethane, the organic layer was dried over magnesium sulfate, filtered, concentrated to yield N-(2-bromobenzyl)-2-(3-aminophenyl)acetamide as a white solid: (4.7 g, 94%); m.p. 110-112 °C.
(c) 3-(2-(2-Bromobenzylamino)ethyl)phenylamine dihydrochloride
This was prepared following a method analogous to that of Example 17, step (c). (d) N-(3-(2-(((2-Bromophenyl)methyl)amino)ethyl)phenyl)-2- thiophenecarboximidamide dioxalate
This was prepared following a method analogous to that of Example 18, step (b). m.p. 175-8 °C (dec)
Example 20
N-(3-(2-(Phenylamino)ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride (a) (2-(3-Nitrophenyl)ethyl)phenylamine
This was prepared following a process analogous to that of Example 17, steps (a)- (c).
(b) 2,2,2-Trifluoro-N-(2-(3-nitrophenyl )ethyl)-N-phenylacetamide
This was prepared following a process analogous to that of Example 1, step (a). (c) 2,2,2-Trifluoro-N-(2-(3-aminophenyl)ethyl)-N-phenylacetamide
This was prepared following a process analogous to that of Example 1, step (c).
(d) N-(3-(2-(Phenylamino)ethyl)phenyl)-2-thiophenecarboximidarnide
dihydrochloride
This was prepared following a process analogous to that of Example 1, step (e). m.p. 235-240 °C (dec).
Example 21
The following compounds were prepared following a process analogous to that of Example 17:
(a) N-(4-(2-(Ethylamino)ethyl)phenyl)-2-thiophenecarboximidarnide dihydrochloride. m.p. 176-178 °C
(b) N-(4-(2-(2-Propylamino)ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride, m.p. 240-242 °C (dec)
(c) N-(4-(2-)1-Propylamino)ethyl)phenvl)-2-thiophenecarboximidamide dihydrochloride, m.p. 233-235 °C (dec)
(d) N-(4-(2-(t-Butylamino)ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride, m.p. 241-242 °C
(e) N-(4-(2-(n-Butylamiπotethyl)phenyl)-2-thiophenecarboximidarnide dihydrochloride, m.p. 238-240 °C
(f) N-(3-(2-(Methylamino)ethyl)phenyl)-2-thiophenecarboximidamide
dihydrochloride. m.p. 219-223 °C (g) N-(3-(2-(1-Propylamino)ethyl)phenyl)-2-thiophenecarboximidarnidedihydrochloride, m.p. 72-75 °C (softened)
(h) N-(3-(2-(t-Butylamino)ethyl)phenyl)-2-thiophenecarboxirnidamidedihydrochloride, m.p. 232-235 °C (dec)
(i) N-(3-(2-(2-Propylamino)ethyl )phenyl)-2-thiophenecarboximidamide
dihydrochloride, m.p. 206-210 °C (dec)
(j) N-(3-(2-aminoethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride, m.p.
194-199 °C
(k) N-(3-(2-(Dimethylamino)ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride, m.p. 232-233 °C (dec)
(1) N-(3-(2-(Diethylamino)ethyl)phenyl)-2-thiophenecarboximidarnide
dihydrochloride.
m.p. 75-80 °C (softened)
(m) N-(3-(2-(2-(1,2,3,4-Tetrahydro )isoquinolinyl)ethyl)phenyl)-2-thiophenecarboximidamide dioxalate.
m.p. 172-175 °C (dec)
(n) N-(4-(3-(2-(1,2,3A-tetrahydro)isoquinolyl)propyl)phenyl)-2-thiophene carboximidamide dioxalate. m.p. 138-142°C
(o) N-(4-(2-(3,5-bistrifluoromethylphenylmethyl)amino)ethyl)phenyl-2-thiophenecarboximidamide free base, m.p. 98-100 °C
(p) N-(4-(2-(diethylamino)ethyI)phenyI-2-thiophenecarboxirnidarnide free base, m.p. 113-115 °C
(q) N-(4-(2-((3-chlorophenylmethyl)amino)ethyl)phenyl)-benzenecarboximidamide dihydrochloride, 253-254°C
(r) N-(4-(2-((3-chlorophenylmethyl)aminotethyl)phenyl)-3-chlorothiophene-2-carboximidamide dihydrochloride. 257°C
(s) N-(4-(2-((4-methylphenylmethyl )amino)ethyl )phenyl)-2-thiophenecarboxamidine dihydrochloride, 218-219°C
(t) N-(4-(2-(piperonylamino)ethyl)phenyl )-2-thiophenecarboxamidine
dihydrochloride, m.p. 205-6 °C Example 22
The following compounds were prepared following a process analogous to that of
Example 18:
(a) N-(3-(2-(((2-Chlorophenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide dioxalate,
m.p. 155-157 °C (dec)
(b) N-(3-(3-((Phenylmethyl)amino)propyl)phenyl)-2-thiophenecarboximidamide dioxalate,
m.p. 138-141 °C (dec)
(c) N-(4-(2-(((3-Chloronhenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine dioxalate, m.p. 216-217 °C
(d) N-(4-(2-(((4-Chloroohenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine dioxalate, m.p. 203-204 °C
(e) N-(4-(2-(((3-Chlorophenyl)methyl)amino)ethyl)phenyl)-3-chlorothiophene-2-carboximidamide dihydrochloride m.p. 257-258°C
(f) N-(4-(3-fethylamino)propyl)phenyl-2-thiophenecarboximidamide dioxalate, m.p. 98-100 °C
Example 23
The following compound was prepared following a process analogous to that of
Example 19:
(a) N-(3-(2-((N-Phenylmethyl-N-methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide. free-base
m.p. 85-87 °C
(b) N-(4-(2-((N-Phenylmethyl-N-methyl)amino)ethyl)phenyl)-2-thiophene carboximidamide. free base
m.p. 110-112 °C
(c) N-(3-(2-(((3-Chlorophenyl)methyl)amino )ethyl)phenyl)-2-thiophenecarboximidamide dioxalate, m.p. 185-88 °C (dec)
(d) N-(3-(2-(((3-fluorophenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide dioxalate, m.p. 183-4 °C (e) N-(4-(3-(((3-Chlorophenyl)methyl)amino)propyl)phenyl)-2-thiophene carboximidamide dioxalate, m.p. 212-215 °C
(f) N-(4-(3-((phenylmethyl-N-methynamino)propyl)phenyl)-2-thiophene
carboximidamide dihvdrobromide. m.p. 228-232°C(dec)
(g) N-(4-(2-((ethyl)(phenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide free base.
m.p. 87-89 °C
(h) N-(4-(2-((propyl)(phenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide free base.
m.p. 100-102 °C
(i) N-(4-(2-((1,1-dimethylethyl)(phenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide free base, m.p. 145-148 °C
(j) N-(4-(2-(((3,4-dichlorophenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide free base, m.p. 111-114 °C
Example 24
N-(4-(3-((phenylamino)carbonyl)propyl)phenyl)-2-thiophenecarboximidamide
(a) 4-(3-((phenylamino )carbonyl)propyl)aniline
A stirred solution of 4-(4-nitrophenyl)butyric acid (5.0 g; 0.023 moles) in 20 ml of thionyl chloride was refluxed for 4 hours. The solvent was evaporated and the crude acid chloride. 2.5g, was added dropwise to a stirred solution of aniline (2.0 g; 0.02 moles) in 30 ml of tetrahydrofuran and 10 ml of triethylamine and the reaction was then stirred 18 hours. The triethylamine hydrochloride was removed by filtration and 50 ml of ethyl acetate was added to the organic phase. The organic phase was washed with 1 × 100 ml of 1 N hydrochloric acid and the dried over magnesium sulfate. The solvent evaporated to yield a yellow solid. The solid was dissolved in 100 ml of methanol and 250 mg of 10% palladium on carbon was added, the reaction was hydrogenated over a 4 hour period. The product was found to be unreduced, and was then dissolved in 100 ml of methanol. 10 ml of a saturated solution of HCl in isopropanol was added, followed by 250 mg of 10% palladium on carbon. The mixture was hydrogenated for 4 hours. The catalyst was removed by filtration and the solvent evaporated. The residue was dissolved in 100 ml of hot water with a minimal amount of methanol, and the solution was then made basic with 50% sodium hydroxide solution. The mix was extracted with 150 ml of ethyl acetate, the extract was dried with magnesium sulphate and evaporated, giving solid 4-(3-(((phenyl)amino)carbonyl)propyl)aniline, yield 1.0 g, one spot on TLC.
(b) N-(4-(3-((phenylamino)carbonyl)propyl)phenyl)-2-thiophenecarboximidamide
To a stirred suspension of the product of step (a) (1.00 g; 0.0037 moles) in approximately 5ml of isopropanol was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (1.01g, 0.0035 moles). This mixture was refluxed for 1 hr and then allowed to cool giving solids. The product was filtered and allowed to dry under vacuum overnight giving N-(4-(3-((phenylamino)carbonyl)propyl)phenyl)-2-thiophenecarboximidamide. 1.76 g yield. m.p. 229-231 °C.
Example 25
The following compounds was prepared following a process analogous to that of
Example 24:
(a) N-(4-(3-((phenylmethylamino)carbonyl)propyl)phenyl)-2- thiophenecarboximidamide, m.p. 169-171 °C.
(b) N-(4-(3-((1-pyrrolidyl)carbonyl)propyloxy)phenyl)-2-thiophenecarboximidamide, m.p. 191-194 °C
(c) N-(4-(3-((4-morpholinyl)carbonyl)propyloxy)phenyl)-2-thiophenecarboximidamide, m.p. 136-138°C
(d) N-(4-(2-((phenylmethylamino )carbonyl)ethyl)phenyl)-2- thiophenecarboximidamide, m.p. 63-65°C
(e) N-(3-(2-((phenylamino)carbonyl)ethyl)phenyl)-2-thiophenecarboximidamide, m.p. 203-205°C
(f) N-(4-(3-((phenylamino)carbonyl)propyl)phenyl)-2-pyrrolecarboximidamide, m.p. 195-196°C
(g) N-(4-(3-((phenylamino )carbonyl)propyl)phenyl)-2- furocarboximidamide, m.p. 197-199°C
(h) N-(4-(3-((phenylamino)carbonyl)propyl)phenyl)-3-chloro-2-thiophenecarboximidamide. m.p. 141-144°C
(i) N-((3-((phenylamino)carbonyl)propyl)phenyl)-1-methylpyrrole-2-carboximidamide, m.p. 154-155°C
(j) N-(4-(3-(1-(4-methylpiperazinyl)carbonyl)propyl)phenyl)-2-thiophenecarboximidamide. m.p. 132-134 °C
Example 26
N-(4-(3-((1-pyrrolidyl)carbonyl)propyl)phenyl) thiophene-2-carboximidamidehydroiodide
(a) 4-(3-((1-pyrrolidinyl)carbonyl)propyl)aniline
4-(4-nitrophenyl)butyric acid (2.25 g, 0.01076 moles) was dissolved in 40 ml dichloromethane and cooled to -5 °C on an ice/acetone bath. Triethylamine (1.09 g, 0.01076 moles) and ethyl chloroformate (1.17 g, 0.01076 moles) were added and the mixture was stirred for 10 minutes before pyrrolidine (0.92 g, 0.01291 moles) was added dropwise whilst maintaining the temperature below 0 °C. After 10 minutes the cold bath was removed and the reaction stirred for 16 hours at room temperature. The dichloromethane solution was washed with 2 × 75 ml saturated sodium bicarbonate and 2 × 75 ml water. The dichloromethane layer was dried over magnesium sulfate and the solvent evaporated under vacuum to leave 2.19 g of a clear brown oil. The clear brown oil was reduced under 50 psi hydrogen; ethanol was the solvent and 10% palladium on carbon was used as a catalyst. After 4 hours the catalyst was filtered off and the solvent evaporated under vacuum to provide 4-(3-((1-pyrrolidinyl)carbonyl)propyl)aniline, an oil that solidified on standing (this was used as is).
(b) N-(4-(3-((1-pyrrolidyl)carbonynpropyl)phenyl)-2-thiophenecarboximidamide hydroiodide
S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (1.53 g 0.00538 moles) was added to the product of step (a) (1.50 g 0.00646 moles), in 6 ml of isopropanol and stirred at room temperature for 16 hours. The resulting suspension of solids was diluted with 50 ml isopropanol and the solids collected by filtration to give N-(4-(3-((1-pyrrolidyl)carbonyl)propyl)phenyl)-2-thiophenecarboximidamide hydroiodide, mp 213-216 °C. Example 27
The following compounds were prepared following a process analogous to of Example 26:
(a) N-(4-(3-((4-morpholinyl)carbonyl)propyl)phenyl)-2-thiophenecarboximidamide hydroiodide. m.p. 189-192 °C.
(b) N-(4-((phenylamino)carbonyl)phenyl)-2- thiophenecarboximidamide, m.p. 200-201°C
(c) N-(4-(2-((4-morpholinyl)carbonyl)ethyl)phenyl)-2-methylthiazole-4-carboximidamide. m.p. 280-281 °C Example 28
N-(4-(2-(((4-morpolinyl)carbonyl)amino )ethyl)phenyl)thiophene-2-carboximidamide hydroiodide
(a) 4-(2-(((4-morpolinyl)carbonyl)amino )ethyl) aniline hydrochloride
To a stirred solution of 4-nitrophenethylamine hydrochloride (4.0 g; 0.24 moles) in 50 ml of tetrahydrofuran was added 10 ml of triethylamine. To this was added 4-morpholinecarbonyl chloride (3.6 g; 0.024 moles) dropwise in 20 ml of
tetrahydrofuran and the reaction stirred for 6 hours. The triethylamine salt was removed by filtration, and the organic phase was washed with 1 × 100 ml of 1 N hydrochloric acid. The organic phase was dried over magnesium sulfate;
evaporation of the solvent gave a crude oil. The crude oil was then dissolved in 250 ml of methanol, to this was added 250 mg of 10% palladium on carbon and the reaction hydrogenated for 4 hours. The catalyst was removed by filtration, and the solvent evaporated. To the residue was added 150 ml of ethyl acetate and hydrochloric acid gas was then added to make the salt. Upon cooling 4-(2-(((4-morpolinyl)carbonyl)amino)ethyl)aniline hydrochloride, a pink solid, crystallized and was collected by filtration, 4.4 g. (b) 4-(2-(((4-morpolinyl)carbonyl)amino)ethyl)aniline
The product of step (a), 4.4 g, was dissolved in 200 ml of water. The mixture was made basic with 50 % sodium hydroxide solution, and extracted with 2 X 50 ml of ethyl acetate. The ethyl acetate extracts were combined, dried with magnesium sulfate, and evaporated in vacuo, giving a solid. The solid was dissolved in hot ethyl acetate and hexane, and crystals of 4-(2-(((4-morpolinyl)carbonyl)amino)
ethyl)aniline formed on cooling. Analysis: calculated C 62.63 H 7.68 N 16.85; found C 62.43 H 7.65 N 16.59.
(c) N-( 4-(2-(((4-morpolinyl)carbonyl)amino )ethyl)phenyl)-2-thiophenecarboximidamide hydroiodide
The product of step (b), 1.0 g, and S-methyl-2-thiophenethiocarboximide
hydroiodide (the product of Example 1, step (d)) 1.09 g, were combined in a minimal amount of isopropanol. The mixture was refluxed for one hour. The resulting solution was cooled, solids precipitated and were collected by fitration, giving N-( 4-(2-(((4-morpolinyl)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide hydroiodide, 0.95 g, m.p. 209-211 °C
Example 29
N-(4-(3-(((phenyl)amino)carbonyl)propyloxylphenyl)-2-thiophenecarboximidamide hydroiodide
(a) 4-(4-nitrophenoxy)butryic acid
Ethyl 4-bromobutyrate, 9.9 g, 4-nitrophenol, 7.0 g, and sodium carbonate, 6.0 g, were combined in 50 ml of DMF, and the mixture was warmed on a 100 C hot plate for four hours. The solids were removed by filtration, and washed with 20 ml of acetone, the filtrate was diluted to 400 ml with cold water, and extracted with a combination of 50 ml ethyl acetate and 50 ml of hexanes. The resulting organic layer was washed with 3 X 200 ml of 0.2 M potassium carbonate to remove unreacted nitrophenol. The resulting organic layer was evaporated in vacuo to give 11 g of yellow oil. The crude yellow oil was diluted with 200 ml of methanol, treated with 25 ml of 2 M sodium hydroxide, and stirred over night at room temperature. The mixture was evaporated in vacuo, and diluted with water to 250 ml. The solution was clairified with celite, and then acidified with 20 ml of 4 M hydrochloric acid. The resulting solids were collected by filtration, washed with water, and dried in vacuo to give 4-(4-nitrophenoxy)butryic acid, mp 116-118 °C. (b) 4-(3-(((phenyl)amino)carbonyl)propyloxy)aniline
A solution of 4-(4-nitrophenoxy)butryic acid, 4.0 g, in 20 ml of thionyl chloride was refluxed for four hours, and then the excess thionyl chloride was evaporated in vacuo. The crude acid chloride was the added to a solution of aniline, 1.68 g, and triethylamine, 10 ml, in 30 ml of THF, and the reaction was stirred for 18 hours. The solids were removed by filtration, and the filtrate was diluted with 50 ml of ethyl acetate. The solution was washed with 100 ml of 1 N hydrochloric acid, dried with magnesium sulfate, and evaporated to give a solid. The solid was disolved in 100 ml of methanol, and hydrogenated with with 10 % Pd/C for a total of 40 hours, giving 1.25 g of 4-(3-(((phenyl)amino)carbonyl)propyloxy)aniline, a white solid, M.S. (M+H)+= 271.
(c) N-(4-(3-(((phenyl)amino)carbonyl)propyloxy)phenyl)-2-thiophenecarboximidamide hydroiodide
The product of step (b), 1.0 g, and S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)), 1.01 g, were combined in a minimal amount of isopropanol and the mixture refluxed for one hour. The resulting clear solution was cooled, solids precipitated and were collected by filtration, giving N-(4-(3-(((phenyl)amino)carbonyl)propyloxy)phenyl)-2-thiophenecarboximidamide hydroiodide, 1.76 g, m.p. 229-231 °C.
Example 30
N-(4-(2-(((trifluoromethyl)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide
(a) 4-(2-(((trifIuoromethyl)carbonyl)amino)ethyl)nitrobenzene
To a stirred solution of 4-nitrophenethylamine hydrochloride (1.84 g, 9.10 mmol) and triethylamine (3.03 ml, 21.70 mmol) in methanol (12 ml) was added
trifluoroacetic anhydride (1.51 ml, 10.66 mmol) dropwise. After stirring for 1 minute, the solvent was removed at reduced pressure and the remaining residue was mixed with water and extracted with methylene chloride (3 X 20 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to yield a solid which was recrystallized from methylene
chloride/hexane to give 4-(2-(((trifluoromethyl)carbonyl)amino)ethyl)nitrobenzene as a white solid: 1.92 g (80% yield); m.p. 103-104 °C.
(b) 4-(2-(((trifluoromethyl)carbonyl)amino)ethyl)aniline
To a stirred solution of the product of step (a) (0.52 g, 1.98 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 1 hr, filtered through celite, and concentrated to give 4-(2-(((trifluoromethyl)carbonyl)amino)-ethyl)aniline which was homogeneous by TLC and used immediately in the next reaction.
(c) N-(4-(2-(((trifluoromethyl)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide
To a solution of the product of step (b) (0.30 g, 1.29 mmol) in isopropanol (6 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of
Example 1, step (d)) (0.37 g, 1.29 mmol). The mixture was stirred for 4 hr, turned into a solution of saturated NaCl (50 ml) and 50% NaOH (4 ml), and extracted with ethyl acetate (3 X 20 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered and concentrated to a solid which was recrystallized from hexane/ethyl acetate to yield N-(4-(2-(((trifluoromethyl) carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide as a slightly yellow solid: 0.19 g (43% yield), m.p. 181-182 °C.
Example 31
N-(4-(2-(((methyl)carbonyl)amino )ethyl)phenyl)-2-thiophenecarboximidamide
(a) 4-(2-(((methyl)carbonyl)amino)ethyl)nitrobenzene
The above compound was made by the mothod of Example 30 step (a) except that trifluoroacetic anhydride was replaced by acetic anhydride. 1.28 g of a pale yellow solid was obtained that was used immediately in the next reaction.
(b) 4-(2-(((methyl)carbonyl)amino )ethyl)aniline To a stirred solution of the product of step (a) (0.82 g, 3.94 mmol) in THF/MeOH (100 ml, 1:1) was added 4 ml of 1 N HCl and a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 4 hr, filtered through celite, and
concentrated to give a solid. The solid was turned into a solution of saturated Nad (50 ml) and 50% NaOH (4 ml), and extracted with ethyl acetate (3 X 20 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered and concentrated to a solid which was used immediately in the next reaction, (c) N-(4-(2-(((methyl)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide The above compound was prepared following the procedure of Example 30, step (c). After recrystallization from ethyl acetate/methanol, 0.56 g of a tan solid was obtained, mp. 186-187 °C.
Example 32
N-(4-(2-(((phenylmethyl)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide (a) 4-(2-(((phenylmethyl)carbonyl)amino)ethyl)nitrobenzene
The above compound was prepared following the procedure of Example 30, step
(a) except that trifluoroacetic anhydride was replaced by phenylacetyl chloride. 1.42 g of a pale yellow solid was obtained that was used immediately in the next reaction.
(b) 4-(2-(((phenylmethyl)carbonyl)amino)ethyl)aniline
The above compound was prepared by an analogous process to that described in
Example 8. step (b). The oil obtained was used immediately in the next reaction.
(c) N-(4-(2-(((phenylmethyl)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide
The above compound was prepared following the procedure of Example 30, step
(c). After recrystallization from ethyl acetate/methanol, 0.45 g of a tan solid was obtained, mp. 210-211 °C.
Example 33
N-(4-(2-(((phenyl)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide
(a) 4-(2-(((phenyl)carbonyl)amino)ethyl)nitrobenzene The above compound was prepared following the procedure of Example 30, step
(a) except that trifluoroacetic anhydride was replaced by benzoyl chloride. 1.77 g of a pale yellow solid was obtained that was used immediately in the next reaction.
(b) 4-(2-(((phenyl)carbonyl)amino)ethyl)aniline
The above compound was prepared by an analogous process to that described in Example 8, step (b). The oil obtained was used immediately in the next reaction.
(c) N-(4-(2-(((phenyl)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide The above compound was prepared following the procedure of Example 30, step (c). After recrystallization from ethyl acetate/methanol, 1.10 g of a tan solid was obtained, m.p. 196-197 °C.
Example 34
N-(4-(((phenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide
fa) N-(4-nitrophenyl)benzenecarboxirnidarnide
To a stirred solution of benzonitrile (25 ml) was added a catalytic amount of 4-dimethylaminopyridine. To this was added 4-nitroaniline hydrobromide (10:0 g, 0.57 moles) and the reaction then heated to 190 °C for six hours. The reaction mixture was allowed to cool and 25 ml isopropanol was added. A solid was collected by filtration to yield 8.6 g of N-(4-nitrophenyl)benzenecarboximidamide, m.p.. 240-241 °C
(b) N-(4-aminophenyl)benzenecarboximidamide
To a pressure bottle charged with the product of step (a) (8.6 g, 0.024 moles) in 200 ml of methanol was added 20 ml of isopropanol/HCl and 0.5 g of 10% palladium on carbon. The reaction was hydrogenated for six hours; the catalyst was removed by filtration and the solvent evaporated. To the residue was added 50 ml of isopropanol and 100 ml of ethyl acetate, the solid was slurried and then collected by filtration to yield 10.6 g of N-(4-aminophenyl)benzenecarboximidamide hydrochloride. The N-(4-aminophenyl)benzenecarboximidamide hydrochloride was dissolved in 100 ml of water and 20 ml of 50% sodium hydroxide. The aqueous phase was extracted (3x100 ml) of ethyl acetate, and dried over magnesium sulfate. Evaporation of the solvent gave solid product N-(4-aminophenyl)benzene carboximidamide, yield 7.6 g.
(c) N-(4-(((phenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide
To a stirred suspension of the product of step (b) (1.1g, 0.0052 moles) in 5 ml of isopropanol was added S-methyl-2-thiophenecarboxthioimide hydroiodide (the product of Example 1, step (d)) (1.5 g, 0.0054 moles) and the reaction was stirred for 48 hours. The solid was collected by filtration, this was dissolved in a solution containing 100 ml of water and 10 ml of 50% sodium hydroxide and the aqueous phase was extracted three times with ethyl acetate (100ml). The organic phase was dried over magnesium sulfate and subsequent evaporation of the solvent gave a crude oil. The crude oil was dissolved in 20 ml of methanol and HCl gas was added; upon standing a solid crystallized and was collected by filtration. The product, N-(4-(((phenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide, was dried at 80 °C for 24hrs. m.p. 317-318 °C
Example 35
The following compounds were prepared following a method analogous to that of
Example 34:
(a) N-N"-(1,4-phenylene)bis-2-thiophenecarboximidamide hydroiodide, m.p.
278-279 °C
(b) N-N"-(1,3-phenylene)bis-2-thiophenecarboximidamide. m.p. 219-220 °C
(c) N,N'-(1,3-phenylene)bis-2-chlorophenylcarboximidamide dimaleate, m.p.
200-201 °C
(d) N,N'-(1,4-phenylene)bis-3-chlorothiophene-2-carboximidamide free base, m.p. 247-248 °C
(e) N-(4-(((2-methoxyphenyl)iminocarbonyl)amino)phenyl)-2-thiophene
carboximidamide free base, m.p. 187-188 °C
(f) N-(4-(((Phenyl)iminocarbonyl)amino)phenyl)-3-chlorothiophene
-2-carboximidamide free base, m.p. 213-214 °C
(g) N-(4-(((Phenyl)iminocarbonyl)amino)phenyl)-3-thiophene
carboximidamide dihydrochloride, m.p. 323-324 °C (h) N-(3-(((phenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide m.p. 295-296 °C
(i) N-(4-(((4-chlorophenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamine dihydrochloride, m.p. 296-297 °C
(j) N-(4-(((2-chlorophenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide dioxalate, m.p. 166-167 °C
(k) N-(4-(((4-bromophenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide dioxalate. m.p. 236-237 °C
(1) N-(4-(((3-chloro-4-methylphenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide dihydrochloride, m.p. 294-294 °C
(m) N-(4-(((3,5-dimethoxyphenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide dioxalate, m.p. 226-227 °C
(n) N-(4-(((3,5-dichlorophenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide dioxalate, m.p. 237-238 °C
(o) N-(4-(((Phenyl)iminocarbonyl)amino)phenyl)-2-furancarboximidamide dioxalate m.p. 210-211 °C
(p) N-(4-(((3-methylphenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide free base m.p. 205-206 °C
(q) N-(4-(((3-Methoxyphenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide free base m.p. 194-195 °C
(r) N-(4-(((3-Bromophenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide dihydrobromide m.p. 293-294 °C
(s) N-(4-(((3-chlorophenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide dihydrochloride m.p. 310-311 °C
(t) N-(4-(((3-methylphenyl)iminocarbonyl)amino)phenyn-2-pyrrolecarboximidamide dihydrochloride m.p. 210-211 °C
(u) N-(4-(((4-chlorophenyl)iminocarbonyl)amino)phenyl)-2-pyrrolecarboximidamide difumarate m.p. 228-229°C Example 36 N-(4-(2-(((Phenylamino)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine hydroiodide
(a) N-(2-(4-Nitrophenyl)ethyl)N'phenyl urea
Prior to running the reaction, a 3.09g sample of 4-nitrophenylamine hydrochloride was dissolved in 20 mis water and treated with 30 mis 2N NaOH. The freebase was extracted with 2×75 mis diethyl ether. The ether layer was dried over magnesium sulfate, and the volume of the ether was reduced under vacuum to ~60 mis. To this solution was added 1.81g of phenyl isocyanate dropwise. The white solids that precipitated upon addition were stirred for three hours, then were collected by filtration and washed with ether. Air drying left 3.67g N-(2-(4-Nitrophenyl)ethyl)N'phenyl urea, m.p. 170-172 °C.
(b) N-(2-(4-aminophenyl)ethyl)N'phenyl urea
To a pressure bottle charged with 3.67g N-(2-(4-Nitrophenyl)ethyl)N'phenyl urea in 100 mis of a 50/50 volume mix of methanol/THF was added a catalytic amount of 5% Pd/C. The mix was hydrogenated under 50 psi hydrogen gas for 24 hours, the catalyst was filtered and TLC showed starting material and two lower Rf spots. The solvents were removed by evaporation in a vacuum and the resultant solid was taken up in methanol, and an excess of oxalic acid was added. The solution was quenched with ether and the precipitated white solids were collected by filtration. The solids were treated with 100 mis 2N NaOH, and the freebase was extracted with ethyl acetate; the organic layer was dried with magnesium sulfate and evaporated to leave a yellow solid; N-(2-(4-aminophenyl)ethyl)
N'phenyl urea (430 mg).
(c) N-(4-(2-(((Phenylamino)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine hydroiodide.
To a solution of 430mg N-(2-(4-Nitrophenyl)ethyl)N'phenyl urea slurried in 3 mis of isopropyl alcohol was added 435 mg of S-methyl-2-thiophenecarboxamide dihydroiodide (the product of Example 1, step (d)). The mix was stirred for 16 hrs at room temperature. The suspension was diluted in 25 mis isopropyl alcohol and the solids were collected by filtration to leave a yellow/tan solid. The solids were recrystallized from methanol/ether. Two batches were collected and combined to give 470 mg of N-(4-(2-(((Phenylamino)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine hydroiodide, m.p. 216-219°C.
Example 37
The following compound was made by a process analogous to that of Example 37: N-(4-(2-(((phenylamino)carbonyl)o 2-thiophenecarboximidamide, m.p. 222-224°C
Example 38
N-(4-((bis(phenylmethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide
(a) 4-((bis(phenylmethyl)amino)methyl)nitrobenzene
To 4-nitrobenylamine (1.61 g, 10.60 mmol) in DMF (25 ml) was added potassium carbonate (3.22 g, 23.30 mmol) followed by benzyl bromide (2.64 ml, 22.30 mmol). The mixture was allowed to stir for 2 days, dumped into water and extracted with ethyl acetate (3 X 50 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, concentrated and chromatographed over silica gel (20% ethyl acetate/hexane) to yield 4-((bis(phenylmethyl)amino)methyl) nitrobenzene: (1.64 g, 47%); M.S. (M+H)+ = 333.
(b) 4-((bisfphenylmethyl)amino)methyl) aniline
To the product of step (a) (0.56 g, 1.69 mmol) in AcOH (15 ml) was added Tin(II) chloride dihydrate (2.00 g, 19.03 mmol) followed by concentrated HCl (5 ml). The mixture was stirred for 20 hr, cooled to 0 °C, quenched with 50% NaOH, and extracted with ethyl acetate (3 X 50 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, concentrated and chromatographed over silica gel (30% ethyl acetate/hexane) to yield 4-((bis(phenylmethyl) amino)methyl)aniline: (0.29 g, 57%); M.S. (M+H)+= 303.
(c) N-(4-((bis(phenylmethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide To a solution of the product of step (b) (0.28 g, 0.93 mmol) in isopropanol (6 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (0.26 g, 0.93 mmol). The mixture was stirred for 14 hr, quenched with 2 N NaOH (2 ml) and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to a solid which was recrystallized from ethyl
acetate/hexane to yield N-(4-((bis(phenylmethyl)amino)methyl)phenyl)
-2-thiophenecarboximidamide as a white solid: (86 mg, 22%); m.p. 127-128 °C.
Example 39
The following compound was prepared following a process analogous to that of Example 8:
N-(4-(2-aminomethyl)phenyl)-2-thiophenecarboximidamide hvdrobromide. m.p.188-189 °C.
Example 40
N-(3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride
(a) 3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)nitrobenzene
To 3-nitrobenzyl chloride (2.00 g, 11.66 mmol) in DMF (25 ml) was added potassium carbonate (1.93 g, 13.96 mmol) followed by tetrahydroisoquinoline (1.55 g, 11.66 mmol). The mixture was allowed to stir for 4 hr, dumped into water and extracted with ethyl acetate (3 X 50 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to an oil. The oil was dissolved in ether and treated with IPA/ΗCl to afford
3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)nitrobenzene hydrochloride: (1.96 g, 55%); m.p. 196-197 °C.
(b) 3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)aniline hydrochloride
To a stirred solution of the product of step (a) (1.00g, 3.29 mmol) in THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 0.5 hr, filtered through celite, and concentrated to give 3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)aniline hydrochloride which was homogeneous by TLC and used immediately in the next reaction.
(c) N-(3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)phenyl)-2-thiophenecarboximidamide To a solution of the product of step (b) (0.90 g, 3.29 mmol) in isopropanol (3 ml)/DMF (1 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (0.94 g, 3.29 mmol). The mixture was stirred for 14 hr, quenched with 2 N NaOH (2 ml) and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and chromatographed over silica gel (8% methanol/methylene chloride) to yield the title compound as the free base. Treatment with IPA/HBr yielded
N-(3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)phenyl)-2-thiophenecarboximidamide as a white solid: (0.26 g, 16%); m.p. dec > 179 °C.
Example 41
N-(4-(4-((phenylmethyl)amino)butyl)phenyl)-2-thiophenecarboximidamide dimaleate
(a) 4-(4-nitrophenyl)-N-(phenylrnethyl)butylamide
A sample of 4-(4-nitrophenyl)butyric acid, 2.09 g, dissolved in 20 ml of
dichloromethane was treated with benzylamine, 1.07 g, giving suspended solids. The mix was treated with diphenylphosphorylazide, 2.75 g, and 20 ml of dioxane and on stirring for 4 hours it became clear. The mix was diluted with 100 ml of ethyl acetate and washed twice with 100 ml of 2 M potassium carbonate, then 100 ml of 1 M hydrochloric acid. The organic layer was dried with magnesium sulfate and evaporated to give solids. The solids were dissolved in 150 ml of cyclohexane and 50 ml of ethyl acetate, and cooled to give white solids; these solids were collected by filtration and air dried to give 4-(4-nitrophenyl)-N-(phenylmethyl)butylamide mp 133-135 °C
(b) 4-(4-aminophenyl)-N-(phenylmethyl)butylamide hydrochloride
A sample of the product of step (a), 0.80 g in 20 ml of ethanol and 20 ml of ethyl acetate was treated with 0.4 g of 5 % paladium on carbon and placed under 50 psi of hydrogen. TLC after one hour showed a new spot, Rf 0.2 with 15% acetone in methylenechloride. The mix was evaporated to dryness, and then treated with 30 ml of toluene. The residue was dissolved in 10 ml of THF and treated with 5 ml of 1 M lithium aluminium hydride in THF (Aldrich) giving a clear solution. After one hour at room temperature, 1 ml of 2M sodium hydroxide was added dropwise, followed by 10 g of anhydrous sodium sulfate. After stirring for 30 minutes, the mix was filtered and treated with hydrogen chloride gas and an oil formed. The mix was treated with 3 ml of isopropanol, and further hydrogen chloride gas, giving solids. The mix was cooled to -20 °C for 2 hours, then filtered and air dried to give 4-(4-aminophenyl)-N-(phenylmethyl)butylamide hydrochloride;
Chloride analysis: calc 20.78 found 20.64
(c) 4-(4-((phenylmethyl)amino)butyl)aniline dihydrochloride
A sample of the product of step (b) was suspended in 5 ml of THF and treated with 5 ml of 1 M lithium aluminium hydride in THF (Aldrich) giving a clear solution. The mixture was warmed to reflux for 5 hours, then cooled. The semisolid mass was diluted with diethyl ether to 20 ml, and then 1 ml of 2M sodium
hydroxide was added dropwise, followed by 4 cm3 of anhydrous sodium sulfate.
After stirring for 15 minutes, the mix was filtered and the solids were washed with 20 ml of diethyl ether. The combined filtrates were treated with hydrogen chloride gas and allowed to stand at room temperature. The solids that formed were collected by filtration and dried in vacuo to give 4-(4- (phenylmethyl)amino)butyl)aniline dihydrochloride; Chloride analysis: calc 21.66 found 21.63
(d) N-(4-(4-((phenylmethyl)amino )butyl)phenyl)-2-thiophenecarboximidamide dimaleate
A sample of the product of step (c), 0.50 g, and S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)), 0.44g were combined in 4 ml of isopropanol and warmed to 60 °C. After 2 hours, TLC with 15 % methanol in chloroform on silica showed that the starting aniline was mostly consumed, and that there had developed a new spot of lower Rf. The mix was diluted with 20 ml of 1M potassium carbonate, and extracted with ethyl acetate. The ethyl acetate extract was dried with 10 g of potassium carbonate and treated with 0.150 g of maleic acid, giving a gummy precipitate. TLC of the precipitate versus the supernatant showed the precipitate to be a mix of the starting amine and product, and that the supernatant contained mostly product. The supernatant was then treated again with 0.150 g of maleic acid, giving a gummy precipitate, and the remaining supernatant was decanted. The solids were dissolved in 5 ml of methanol and precipitated with 100 ml of diethylether. The resulting gummy precipitate was reacted with 1 ml of water, diluted with acetone to 200 ml giving a clear solution, diluted with diethyl ether to 275 ml and cooled to -20 °C. The solids were collected by filtration, washed with 20 ml of diethyl ether, and dried in vacuo to provide N-(4-(4-((phenylmethyl)amino)butyl)phenyl)-2-thiophenecarboximidamide dimaleate, m.p. 104-106 °C
Example 42
N-(4-((((2-thiophenyl)iminomethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide difumarate
(a) 4-aminomethylaniline
To a solution of 4-nitrobenzylamine hydrochloride (9.0g, 0.0477) in methanol (200ml) was added 20ml of IPA/HCl and a catalytic amount of 10% palladium on carbon. The mixture was hydrogenated at 50 psi for 4hrs, filtered through celite, concentrated to a solid. The above solid was then dissolved in 300ml of water and 20ml of 2N sodium hydroxide and extracted into methylene chloride (3×100ml). The combined extracts were dried over magnesium sulfate, filtered and
concentrated to give 4-aminomethylaniline as an oil (6.1g).
(b) N-(4-((((2-thiophenyl)iminomethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide difumarate
To a stirred solution of 4-aminomethylaniline (1.6g, 0.0013mmol) in (10ml) dimethylformamide and (10ml) of isopropanol was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (4.4g, 0.015mmol). The mixture the heated to 40 °C for 72 hrs. The reaction was diluted with 20% aqueous sodium hydroxide, and the solids collected by filtration to yield (2.5g). The fumaric acid salt was made from isopropanol and methanol, to yield (2.0g) of N-(4-(((2-thiophenyl)iminomethyl)amino)methyl)phenyl)-2- thiophenecarboximidamide difumarate, m.p. 200-201 °C
Example 43 The following compounds were prepared by a process analogous to that of Example 17:
(a) N-(3-(3-(1-pyrrolidinyl)propyl)phenyl)-phenylcarboximidamide dioxalate, m.p. 138-139 °C
(b) N-(4-(2-((4-methoxyphenylmethyl)amino)ethyl)phenyl)
-2-thiophenecarboximidamide free base, m.p. 144-145 °C
(c) N-(4-(2-((4-methylphenylmethyl)amino )ethyl)phenyl)-2-thiophenecarboximidamide monohydrochloride. m.p. 225-226 °C
(d) N-(3-(2-((3-phenylpropyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride m.p. 183-186 °C
(e) N-(3-(2-((2-methylphenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide free base m.p. 114-116 °C
(f) N-[4-(2-((1-indanyl)ethyl)amino)phenyl]-2-thiophenecarboximidamide dioxalate, m.p. 95 °C (dec)
(g) N-(4-(2-(((4-pyridyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide trihydrochloride m.p. >250°C
(h) N-(4-(2-(((2-thienyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide dioxalate m.p. 226-227°C Example 44
N-(3-(2-((2-phenylethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide
dihydrochloride
(a) N-(2-phenylethyl)-3-nitrophenylacetamide
2.50g (0.0138 moles) of 3-nitrophenylacetic acid were refluxed in 25mls of thionyl chloride. The solvents were evaporated and the residue taken up in 50mls of THF before 3.51 g (0.290 moles) of phenethylamine were added dropwise at 0 °C. The mix was stirred for 48 hours and the hydrochloride salt of the amine was filtered off as a white solid. The wash was evaporated to leave N-(2-phenylethyl)-3-nitrophenylacetamide, a dull orange oil, 4.48 g. The product was analyzed by MS and NMR.
(b) N-(2-phenylethyl)-2-(3-nitrophenyl)ethylamine To a stirred solution of the product of step (a), 4.48g, (0.0158moles) in 80ml dry THF was added 47.4 ml of 1M Borane/THF. The mix was heated to reflux for 3 hours and cooled before 10 ml of methanol was added carefully followed by 20 ml of 4N HCl. The solution was concentrated by evaporation under vacuum to leave a reddish liquid. The oil was basified with 2M NaOH and the product extracted with 3x50ml of EtOAc. The organic layers were combined, dried over magnesium sulfate and evaporated to leave an oil. The oil was dissolved in HCl/ isopropanol solution. White solids formed and were collected by filtration to give N-(2-phenylethyl)-2-(3-nitrophenyl)ethylamine, 2.63g, m.p. 196-200 °C.
(c) N-(2-phenylethyl)-N-(2-(3-nitrophenyl)ethyl)trifluoroacetamide
To a slurry of the product of step (b), 2.63g, (0.00857moles) in 40ml
dichloromethane was added 1.99g (0.0197 moles) of triethylamine and the mix was cooled to 0 °C before 2.34g (0.111 moles) of trifluoroacetic anhydride was added dropwise. After 45 minutes, the mixture was quenched with 50ml water and the product extracted with 3x50ml dichloromethane. The organic layers were combined, dried over magnesium sulfate and evaporated to leave N-(2-phenylethyl)-N-(2-(3-nitrophenyl)ethyl)trifluoroacetamide, 3.3g, as an oil.
(d) N-(2-phenylethyl)-N-(2-(3-aminophenyl)ethyl)trifluoroacetamide
To a solution of the product of step (c), 3.3g, in 75ml each of THF and methanol was added a catalytic amount of 10% Pd on carbon. After 1 hour under 50 psi hydrogen, the reaction was complete. The catalyst was filtered off and the solvents evaporated to leave N-(2-phenylethyl)-N-(2-(3-aminophenyl)ethyl)
trifluoroacetamide, 2.88g, as an oil.
(e) N-(3-(2-((2-phenylethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride
To a solution of the product of step (d), 2.88g (0.00857 moles) in 15 ml
isopropanol was added 2.94g of S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)). The mixture was stirred at room temperature for 16 hours then a solid yellow residue was filtered off and discarded. The wash was evaporated and the residue dissolved in minimal methanol; the solution was basified with 2M NaOH and heated to 50 °C for 30 minutes. The deprotected product was extracted with 3×50ml ethyl acetate, the organic layers were combined, washed with 2×50ml water, dried over magnesium sulfate and evaporated to leave an oil. The free base was dissolved in an isopropanol solution of HBr. Solids formed with the addition of ethyl acetate and cooling were collected by filtration to give 102 mg of N-(3-(2-((2-phenylethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide dihydrobromide salt. m.p. 137-139 °C.
Example 45
The following compounds were prepared by following a method analogous to that of Example 44:
(a) N-(4-(2-aminoethyl)phenyl)-2-pyrrolecarboximidamide dioxalate m.p. 145 °C (dec)
(b) (S)-N-(4-(2-((1-phenylethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride m.p. 197 °C dec
(c) (R)-N-(4-(2-((1-phenylethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide free base, m.p. 92-94 °C
(d) N-(3-(2-((4-phenylbutyl)amino )ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride, m.p. 136-139 °C Example 46
N-(4-(((phenylmethoxy)carbonyl)aminomethyl)phenyl)-2-thiophenecarboximidamide oxalate
(a) 4-(((phenylmethoxy)carbonynaminomethyl)mitrobenzene
A sample of 4-nitrobenzylamine hydrochloride, 5 g, and 200 ml of water was treated with sodium bicarbonate, 10 g. The mixture was treated with 50 ml of ethyl acetate, and then benzyl chloroformate, 4 ml. After 4 hours, the mix was treated with 200 ml of hexanes, and the precipitated solids were collected by filtration. The crude product was dissolved in 150 ml of hot methanol, filtered, diluted with 250 ml of water, and cooled. The resulting solids were collected to give
4-(((phenylmethoxy)carbonyl)aminomethyl)nitrobenzene, m.p. 92-93 °C.
(b) 4-(((phenylmethoxy)carbonyl)aminomethyl)aniline The product of step (a), 6.0 g was treated with 10 ml of acetic acid and 100 ml of methanol. The mixture was treated with platinum sulfide on carbon, 0.97 g, and treated with 50 psi of hydrogen gas; after 20 hours, the mixture was filtered and evaporated in vacuo. The residue was dissolved in 50 ml of ether, and diluted with hexanes to 200 ml. The mixture was then stirred for five days and filtered to give 4-(((phenylmethoxy)carbonyl)aminomethyl)aniline, m.p. 60-64 °C
(c) N-(4-(((phenylmethoxy)carbonyl)ammomethyl)phenyl)-2-thiophenecarboximidamide oxalate
The product of step (b), 0.89 g, and S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)), 1.0 g, were combined in 6 ml of isopropanol, and stirred at 30 °C. After 4 hours, the mixture was precipitated with ether, giving gummy solids which were taken up in 100 ml of hot water, treated with cellite and filtered. The mix was cooled, giving gummy white solids which were treated with 50 ml of ethyl acetate and 5 g sodium bicarbonate. The ethyl acetate layer was dried with magnesium sulfate, and cooled to -20 °C. The mix was then treated with hexanes, and failed to give crystals. The mix was evaporated in vacuo, and the crude free base, 0.7 g, was dissolved in 40 ml of warm isopropanol and treated with oxalic acid dihydrate, 0.26 g. On cooling and treatment with 150 ml of ether a tacky precipitate resulted. After stirring overnight at room temperature, the resulting solids were collected by filtration to yield
N-(4-(((phenylmethoxy)carbonyl)aminomethyl)phenyl)-2-thiophene carboximidamide oxalate, m.p. 150-160 °C
Example 47
N-(4-(2-((phenylmethyl)amino)ethoxy)phenyl)-2-thiophenecarboximidamide hydroiodide
(a) 4-nitrophenoxy-N-(phenylmethyl)acetamide
A sample of 4-nitrophenoxy-N-(phenylmethyl)acetic acid hydrazide (Lancaster), 4.22 g, was treated with 20 ml of 1 M aqueous HCl and 200 ml of ethyl acetate. The mix was cooled to 10 °C, and then 1.38 g of sodium nitrite in 20 ml of water was added over 2 minutes. The mix was stirred for 5 minutes, the layers were separated, and the ethyl acetate layer was dried with sodium sulfate. The ethyl acetate solution was treated with 5 ml of benzylamine, giving a prompt precipitate formation. After 20 minutes the mix was washed with 100 ml of saturated sodium carbonate, then 100 ml of 1 M HCl (aqueous). The ethyl acetate layer was then evaporated. The solids were dissolved in 50 ml of acetone, and precipitated with water. The solids were collected by filtration to provide 4-nitrophenoxy-N-(phenylmethyl)acetamide, m.p. 125-126 °C,, 3.76 g.
(b) 4-aminophenoxy-N-(phenylmethyl)acetamide
A sample of the product of step (a), 3.74 g, was taken up in 100 ml of methanol and 100 ml of ethyl acetate. The mix was treated with 0.4 g of 10 % palladium on carbon and placed under 50 psi hydrogen. After one hour the mix was filtered, and concentrated in vacuo to provide crude 4-aminophenoxy-N-(phenylmethyl) acetamide: CHN calculated: C 70.29, H 6.29, N 10.93, found C 69.97, H 6.3, N 10.90
(c) 4-(2-((phenylmethyl)amino)ethoxy) aniline
A solution of 3.2 g of the product of step (b) in 40 ml of dry THF under N2 was treated with 40 ml of 1 M diborane in THF. The mix was warmed to reflux for three hours, treated with 40 ml of 6M aqueous HCl, and refluxed for 2 hours. The filtrate was concentrated under vacuo to 150 ml. The cloudy mix was treated with 100ml of crushed ice and neutralised with 50 % NaOH, and the resulting fine solids were collected, washed with water, and dried by infrared to give 4-(2-((phenylmethyl)amino)ethoxy)aniline, MS = 243, 98 % by capillary electrophoresis (d) N-(4-(2-((phenylmethyl)amino)ethoxy)phenyl)-2-thiophenecarboximidamide hydroiodide
A sample of 4-(2-((phenylmethyl)amino)ethoxy)aniline, 0.81 g-and S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)), 1.42 g were combined in 10 ml of isopropanol and stirred for 7 hours at room
temperature. The resulting white solids were collected by filtration, washed with 10 ml of isopropanol, and dried in vacuo to provide white solids, N-(4-(2-((phenylmethyl)amino)ethoxy)phenyl)-2-thiophenecarboximidamide hydroiodide, m.p. 193-195 °C. Example 48
N-[4-(((Diphenylamino)carbonyl)amino)phenyl]-2-thiophenecarboxamidine hydrochloride
(a) 4-[Diphenylamino(carbonyl)amino]aniline
To a stirred solution of 1,4-phenylenediamine (1.00 g, 9.25 mmol) and
triethylamine (1.29 ml, 9.25 mmol) in methylene chloride (50 ml) was added diphenylcarbamyl chloride (2.14 g, 9.25 mmol). After stirring for 14 hr, the mixture was dumped into water and extracted with methylene chloride (3 X 20 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, concentrated and chromatographed over silica gel (80% ethyl acetate/hexane) to yield 4-[diphenylamino(carbonyl)amino]aniline: (0.49 g, 17%); M.S. (M+H)+ = 304.
(b) N-[4-(((Diphenylamino)carbonyl)amino)phenyl]-2-thiophenecarboxarnidine hydrochloride
To a solution of the product of step (a) (0.49 g, 1.62 mmol) in isopropanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (0.46 g, 1.62 mmol). The mixture was stirred for 48 hr, dumped into basic water and extracted with ethyl acetate ( 3 X 30 ml). The combined extracts were washed with water, dried over magnesium sulfate, filtered, and concentrated to an oil. Treatment with IPA/HCl yielded N-[4- (diphenylamino(carbonyl)amino]phenyl-2-thiophenecarboxamidine hydrochloride as a white solid: (24 m g, 3.3%); m.p. 210-211 °C.
Example 49
N-(3-((benzoyl)amino)phenyl)-2-thiophenecarboximidamide oxalate
(a) N-(3-nitrophenyl)benzamide
To a solution of 7.5 g (54 mmol) of 3-nitroaniline in a biphasic solution consisting of 100 ml of methylene chloride and 100 ml of 20% potassium carbonate was added dropwise 6.0 ml (52 mmol) of benzoyl chloride in 25 ml of methylene chloride. The reaction mixture was allowed to stir overnight and the organic phase was separated and washed with dilute hydrochloric acid. The solvent was concentrated to give 3.83 g (32%) of the title compound, MS 243 (M+H).
(b) N-(3-aminophenyl)benzamide
This compound was prepared following a process analogous to that of Example 30 step (b). MS 213 (M+H).
(c) N-(3-((benzoyl)amino)phenyl)-2-thiophenecarboximidarnide oxalate
This compound was prepared following the procedure of Example 30, step (b). The free base was converted to the oxalate salt in isopropanol. MS 323 (M+H). Example 50
N-(4-((benzoyl)amino)phenyl)-2-thiophenecarboximidarnide hydroiodide
(a) N-(3-nitrophenyl)benzamide
This compound was prepared following a process analogous to that of Example 49, step (a). MS 243 (M+H).
(b) N-(4-aminophenyl)benzamide
This compound was prepared following a process analogous to that of Example 30, step (b). MS 213 (M+H).
(c) N-(4-((benzoyl)amino)phenyl)-2-thiophenecarboximidarnide hvdroiodide
This compound was prepared following the procedure of Example 26, step (b) and was recrystallized from water, m.p. 234-5 °C.
Example 51
N-(3-(((phenylamino )carbonyl)amino)phenyn-2-thiophenecarboximidamide oxalate
(a) N-phenyl-N'-(3-nitrophenyl) urea
To a solution of 5.0 g (36 mmol) of m-nitroaniline in 40 ml of ether was added 5.0 ml (47 mmol) of phenylisocyanate. The solution was stirred for 6 hours. The product was filtered to afford 9.2 g (99%) of the title compound, MS 258 (M+H).
(b) N-phenyl-N'-(3-aminophenyl) urea
This compound was prepared by a process analogous to that of Example 30, step (b). Slurring the isolated product in ether afforded a solid product, m.p. 199-202 °C. (c) N-(3-(((phenylamino)carbonyl)amino)phenyl)-2-thiophenecarboximidamide oxalate
This compound was prepared following the procedure of Example 30, step (c). The free base was converted to the oxalate salt in isopropanol, 208-210 °C.
Example 52
N-(3-(((4-phenoxylbutyl)amino)carbonyl)phenyl)-2-thiophenecarboximidamide oxalate
(a) 3-nitro-N-(4-phenoxybutyl)benzamide
This compound was prepared following a process analogous to that of Example 49, step (a). MS 315 (M+H).
(b) N-((3-(4-phenoxylbutyl)amino)carbonyl)aniline hydrochloride
A solution of 7.8 g (25 mmol) N-4-phenoxybutyl-3-nitrobenzamide and 1 g of 5% palladium on carbon in 120 ml of isopropanol with hydrogen chloride added was hydrogenated at 45 psi for 3 hr. The catalyst was filtered off and the solvent was concentrated to give 6.7 g (84%) of the title compound, MS 285 (M+H).
(c) N-(3-(((4-phenoxylbutyl)amino)carbonyl)phenyl)-2-thiophenecarboximidamide oxalate
The above compound was first converted to the free base and the title compound was prepared using the procedure of Example 30, step (c). The free base of the title compound was then converted to the oxalate salt in isopropanol. MS 394 (M+H), m.p. 154-6 °C.
Example 53
N-(3-(((4-phenylbutyl)amino )carbonyl)phenyl)-2-thiophenecarboximidamide oxalate
(a) 3-nitro-N-(4-phenylbutyl)benzamide
This compound was prepared following a process analogous to that of Example 49, step (a). MS 299 (M+H).
(b) 3-amino-N-(4-phenylbutyl)benzamide hydrochloride
This compound was prepared following a process analogous to that of Example 52, step (b). MS 273 (M+H). (c) N-(3-(((4-phenylbutyl)amino)carbonyl)phenyl)-2-thiophenecarboximidamide oxalate
This compound was prepared following the procedure of Example 30, step (c) except an equivalent of triethylamine was also added. The free base was converted to the oxalate salt in isopropanol, MS 376 (M+H), m.p. 118-120 °C.
Example 54
N-(4-((((benzyl)amino)carbonyl)methyl)phenyl)-2-thiophenecarboximidamide
(a) N-benzyl-(4-nitro)phenylacetamide
This compound was prepared following a process analogous to that of Example 49, step (a), m.p. 172-82 °C.
(b) N-benzyl-(4-amino)phenylacetamide
This compound was prepared following the procedure of Example 17, step (d), m.p. 137-140 °C.
(c) N-(4-((((benzyl)amino)carbonyl)methyl)phenyl)-2-thiophenecarboximidamide This compound was prepared following the procedure of Example 30, step (c), m.p. 157-161 °C.
Example 55
N-(4-(2-(1-pyrrolidinyl)ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride
(a) N-pyrrolidinyl-(4-nitrophenyl)acetic acid
To a solution of 3.12 g (43.9 mmol) of pyrrolidine in a biphasic solution consisting of 100 ml of methylene chloride and 100 ml of 20% potassium carbonate was added dropwise 7.3 g (36.5 mmol) of 4-nitrophenylacetyl chloride in 25 ml of methylene chloride. The reaction mixture was allowed to stir overnight and the organic phase was separated and washed with dilute hydrochloric acid. The solvent was concentrated to give 6.26 g (73%) of the title compound, m.p. 103-5 °C.
(b) 4-(2-(1-pyrrolidinyl)ethyl)nitrobenzene
This compound was prepared following the procedure of Example 17, step (c). MS 221 (M+H).
(c) 4-(2-(1-pyrrolidinyl )ethyl)aniline This compound was prepared following the procedure of Example 34, step (c). MS 191 (M+H).
(d) N-(4-(2-(1-pyrrolidinyl)ethyl)phenyl)-2-thiophenecarboximidamide
dihydrochloride
This compound was prepared following the procedure of Example 18, step (b). The dihydrobromide salt was crystallised from isopropanol and ether, MS 300 (M+H).
Example 56
N-(4-(2-(1-piperidinyl)ethyl)phenyl)-2-thiophenecarboximidamide dihvdrochloride
(a) N-piperidinyl-(4-nitrophenyl)acetic acid
This compound was prepared following the procedure of Example 56, step (a), m.p. 105-7 °C.
(b) N-(4-(2-(1-piperidinyl)ethyl)nitrobenzene
This compound was prepared following the procedure of Example 17, step (c), MS 235 (M+H).
(c) N-(4-(2-(1-piperidinyl)ethyl)aniline
This compound was prepared following the procedure of Example 34, step (c). The hydrochloride salt was converted to the free base as an oil, MS 205 (M+H).
(d) N-(4-(2-(1-piperidinyl)ethyl)phenyl)-2-thiophenecarboximidamide
dihvdrochloride
This compound was prepared following the procedure of Example 34, step (d).
The dihydrochloride salt was crystallised from isopropanol and ether, m.p. 256-61
°C.
Example 57
N-(4-(3-(1-pyrrolidinyl)propyl)phenyl)-2-thiophenecarboximidamide dioxalate
(a) N-pyrrolidinyl-(4-nitrophenyl)propenamide
This compound was prepared following the procedure of Example 55, step (a), MS 247 (M+H).
(b) 4-(2-(1-((pyrolidinyl)carbonyl)ethyl)aniline This compound was prepared following the procedure of Example 34, step (c). MS 219 (M+H).
(c) 4-(3-(pyrolidinyl)propyl)aniline dihydrochloride
This compound was prepared following the procedure of Example 17, step (c). The dihydrochloride salt from ethanol, m.p. 262-5 °C.
(d) N-(4-(3-(1-pyrrolidinyl)propyl)phenyl)-2-thiophenecarboximidamide dioxalate This compound was prepared following the procedure of Example 18, step (b). The dioxalate salt was prepared from ethanol and ether, m.p. 86-92 °C. Example 58
N-(4-(3-(1-piperidinyl)propyl)phenyl)-2-thiophenecarboximidamide dioxalate
(a) N-piperidinyl-(4-nitrophenyl)propenamide
This compound was prepared following the procedure of Example 55, step (a), m.p.
168-71 °C.
(b) 4-(2-(1-((piperidinyl)carbonyl)ethyl)aniline
This compound was prepared following the procedure of Example 34, step (c). MS
233 (M+H).
(c) N-(4-(2-(1-piperidinyl)propyl)aniline
This compound was prepared following the procedure of Example 17, step (c), m.p. 180-5 °C.
(d) N-(4-(3-(1-piperidinyl)propyl)phenyl)-2-thiophenecarboxirnidamide dioxalate This compound was prepared following the procedure of Example 17, step (e). The dioxalate salt was prepared from ethanol and ethyl acetate, MS 328 (M+H). Example 59
N-(4-(2-(2-(1,2,3,4-tetrahydro)isoquinolyl)ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride
(a) 4-nitro-N-(2-isoquinolyl)phenylacetamide
To a solution of 4-nitrophenylacetic acid (5.43 g 930 mmol) and 1,2,3,4-tetrahydroisoquinoline (5.6 g, 42 mmol) in methylene chloride (200 ml) was added
1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (6.13 g, 32 mmol). The reaction mixture was allowed to stir for 18 hr. The reaction mixture was washed with dilute hydrochloric acid and dilute sodium hydroxide, dried, and the solvent was concentrated to give a sohd. Trituration with ether gave the title compound, m.p. 137-9 °C.
(b) N-(4-(2-(2-(1,2,3,4-tetrahydro)isoquinolyl)ethyl)nitrobenzene
This compound was prepared following the procedure of Example 17, step (c), m.p. 97-102 °C.
(c) N-(4-(2-(2-(1,2,3,4-tetrahydro)isoquinolyl)ethyl)aniline
This compound was prepared following the procedure of Example 34, step (c), m.p. 300 °C (dec).
(d) N-(4-(2-(2-(1,2,3,4-tetrahydro)isoquinolyl)ethyl)phenyl)-2-thiophenecarboximidamide dihydrochloride
This compound was prepared following the procedure of Example 18, step (b). The dihydrobromide salt was prepared from ethanol and ethyl acetate, MS 362 (M+H).
Example 60
N-(4-((((phenylmethyl)amino)methylcarbonyl)amino )phenyl)-2-thiophenecarboximidamide free base
(a) N-(4-nitrophenyl)-2-chloroacetamide
4-nitroaniline (13.8 g) in ethyl acetate (200 ml) was treated with triethyl amine (15 ml) and then treated in portions with chloroacetyl chloride (8 ml). The resulting mixture was stirred for 10 minutes. The mixture was then treated with water (200 ml) and ethyl acetate (100 ml). The mixture was warmed until all solids were dissolved, and the layers separated. The ethyl acetate layer was then concentrated to 100 ml whilst hot, and cooled to room temperature. The next day the mixture was filtered, and the solids washed with ethyl acetate and air dried to give N-(4-nitrophenyl)-2-chloroacetamide, m.p. 183-185 °C, 14.83 g.
(b) 4-((((phenylmethyl)amino)methylcarbonyl)amino)nitrobenzene
The compound of step (a) (4.28 g) and benzylamine (2.5 ml) were combined in DMF (10 ml) with potassium carbonate (3.2 g) and stirred at room temperature for 3 hours. The solids were filtered off, and washed with methanol (2 X 10 ml). The combined filtrates were slowly diluted with water to 150 ml to give yellow solids, which were collected by filtration, and air dried to give 4-((((phenylmethyl)amino)methylcarbonyl)amino)nitrobenzene, MS 286 (M+H).
(c) 4-((((phenylmethyl)(trifluoromethylcarbonyl)amino)methylcarbonyl)
aminolnitrobenzene
The compound of step (b) (4.9 g) trifluoroacetic anhydride (2.5 ml) and
triethylamine (2.5 ml) were combined in ethyl acetate (50 ml), and the mixture with suspended solids was warmed to 50 °C overnight. The mixture was then washed with water (50 ml), filtered to remove solids, and the ethyl acetate layer was evaporated. The residue was taken up in ether (150 ml) and cooled to -20 °C overnight. The solids were collected by filtration to give 4-((((phenylmethyl)(trifluoromethylcarbonyl)amino)methylcarbonyl)-amino)-nitrobenzene, MS (M+H) = 282.
(d) 4-((((phenylmethyl)(trifluoromethylcarbonyl)amino )methylcarbonyl)amino )aniline The compound of step (c) (3.8 g) was dissolved in ethyl acetate (50 ml) and ethanol (50 ml). The mixture was hydrogenated at 50 psi with palladium on carbon for 4 hours. The mixture was filtered and evaporated in vacuo to give white solids, 4-((((phenylmethyl)(trifluoromethylcarbonyl)amino)methylcarbonyl)amino)-aniline, MS (M+H)=352.
(e) N-(4-((((phenylmethyl)amino)methylcarbonynamino)phenyl)-2-thiophenecarboximidamide free base
The compound of step (d) (1.05 g) and S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1 step (d)) (0.85 g) were treated with methanol (2 ml). After 15 minutes the solids had dissolved and the mixture was blown down with nitrogen to remove methanethiol. TLC with 10 % isopropanol in chloroform on silica showed starting amine consumed and new spot of lower Rf. The mixture was dissolved in methanol (6 ml), and treated with potassium
carbonate (1.1 g). The TLC with 15 % methanol in chloroform on silica showed incomplete hydrolysis, so an additional 1.1 g of potassium carbonate was added. After 2 hours the conversion was complete, and the mix was filtered to remove solids. The next day the filtrate was treated with 0.65 g of maleic acid, diluted with ether and stirred overnight. The solids that were collected were not the desired product. The filtrate was further diluted with hexane, and washed with water. The aqueous layer was treated with 1 M potassium carbonate, and extracted with ethyl acetate. The ethyl acetate was evaporated in vacuo, and the residue taken up in 20 ml of methanol. The solution was treated slowly with water until solids precipitated, the solids were collected by filtration and dried at 40 °C under vacuum to give N-(4-((((phenylmethyl)amino)methylcarbonyl)amino)phenyl)-2-thiophenecarboximidamide, free base, m.p. 161-163 °C.
Example 61
N-(4-(2-(((2-Furanyl)methyl)amino )ethyl)phenyl)-2-thiophenecarboximidamide dioxalate
(a) 4-Nitrophenyl acetyl chloride
To 4-nitrophenyl acetic acid (30 g) was added thionyl chloride (100 ml). The mix was heated to reflux under nitrogen and stirred for two hours. The excess thionyl chloride was evaporated under vacuum, and the remaining oil was azeotropically dried with toluene. The resulting oil crystallized upon standing to leave 4-nitrophenyl acetyl chloride (35 g).
(b) 4-(2-(((2-Furanynmethyl)amino )ethyl)nitrobenzene hydrochloride
To a stirred solution of furfurylamine (1.32 g) in methylene chloride (125 ml) at °C was added triethyl amine (2.36 ml), followed by the dropwise addition of a solution of the compound of step (a) (3.0 g) in methylene chloride (10 ml). The mixture was stirred at 0 °C for 15 minutes. The mixture was poured into water (150 ml) and the crude products extracted with methylene chloride (2 X 100 ml). The organic layers were collected, dried (MgSO4), filtered and concentrated. The resulting sohds were taken up in a solution of 7% methanol/methylene chloride, and purified on a silica gel column eluted with the same solvent. The product was collected and concentrated. The solid was taken up in THF (50 ml) and treated with 1M Borane/THF (50 ml). The solution was refluxed for 15 hours. The mixture was cooled to 0 °C and was slowly made acidic with 4N hydrochloric acid. The mixture was reheated to reflux and stirred for 4 hours. The excess acid and THF was evaporated under vacuum, and the remaining slurry was taken up in water (100 ml) and ethyl acetate (100 ml), made basic with 50% sodium hydroxide, and extracted with ethyl acetate (3 X 125 ml). The organic layers were collected, dried (MgSO4), filtered and concentrated. The crude product was purified on a silica gel column eluted with 10% methanol/methylene chloride. The product was collected and concentrated. The remaining solids were taken up in isopropyl alcohol (25 ml), and treated with saturated IPA/HCl (10 ml). The white solids were filtered and washed with isopropyl alcohol to give 4-(2-(((2-furanyl)methyl)amino)ethyl) nitrobenzene hydrochloride (2.9 g).
(c) 4-(2-(((2-furanyl)methyl)amino)ethyl) aniline dihvdrochloride.
To a stirred solution of the compound of step (b) (2.46 g) in acetic acid (100 ml) was added of zinc dust (3.3 g) in one portion. The mixture was stirred for 10 minutes. The zinc was filtered and the excess acid evaporated under vacuum. The remaining solids were taken up in water (100 ml) and ethyl acetate (100 ml), made basic with 50% sodium hydroxide, and extracted with ethyl acetate (3 X 125 ml). The organic layers were collected, dried (MgSO4), filtered and concentrated. The remaining oil was taken up in isopropyl alcohol (25 ml) and treated with saturated IPA/HCl (10 ml). The white solids were filtered and washed with isopropyl alcohol to leave 4-(2-(((2-furanyl)
methyl)amino)ethyl) aniline dihydrochloride (1.50 g).
(d) N-(4-(2-(((2-Furanyl)methyl)amino )ethyl)phenyl)-2-thiophenecarboximidamide dioxalate
To a stirred suspension of the compound of step (c) (1.5 g) in DMF (15 ml) was added pyridine (0.42 ml) followed by of S-methyl-2-thiophenecarboxamide hydroiodide (the product of Example 1 step (d)) (1.51 g). The mixture was heated to 50 °C and stirred for 48 hours. The mixture was then diluted in 100 ml water and made basic with excess 50% sodium hydroxide. The crude product was extracted with ethyl acetate (3 X 100 ml). The organic layers were collected and washed with water (2 × 200 ml). The organic layer was dried (MgSO4), filtered and concentrated. The crude product was purified on a silica gel column eluted with 20% methanol/methylene chloride. The product was collected and concentrated to an oil, which was taken up in isopropyl alcohol and treated with 2.5 equivalents of oxalic acid. The white sohds were filtered and washed with ether to leave N-(4-(2-(((2-Furanyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide dioxalate (580 mg) m.p. decomposes >220 °C.
Example 62
The following compounds were made following a process analogous to that of Example 61:
(a) N-(4-(2-(((2-Pyridyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide trihydrochloride. m.p. decomposes >250 °C.
(b) N-(4-(2-(((2-Thiophenyl)methyl)amino)ethhl)phenyl)-2-thiophenecarboximidamide dioxalate, m.p. decomposes >226 °C. Example 63
N-(4-((amino )carbonyl)phenyl)-2-thiophenecarboximidamide hydroiodide
This compound was prepared following the procedure of Example 26, step (b). The salt was recrystallized from 30% isopropanol in water, m.p. 236 °C (dec). Example 64
N-(4-(((2-thienyl)carbonyl)amino)phenyl)-2-thiophenecarboximidamide oxalate
(a) N-(4-nitrophenyl)-2-thiophenecarboxamide
This compound was prepared using the procedure described for Example 26, step
(a), MS 249 (M+H).
(b) N-(4-amino)aniline-2-thiophenecarboxamide
This compound was prepared using the procedure described for Example 17, step
(d). MS 219 (M=H).
(c) N-(4-(((2-thienyl)carbonyl)amino)phenyl)-2-thiophenecarboximidamide oxalate
This compound was prepared following the procedure of Example 7, step (c). The free base was converted to the oxalate salt in isopropanol, m.p. 231-3 °C. Example 65
N-[4-((((Diphenylamino)carbonyl)amino)methyl)phenyl]-2-thiophenecarboxamidine oxalate
(a) 4-((((Diphenylamino)carbonyl)amino)methyl)nitrobenzene
To a stirred solution of 4-nitrobenzylamine hydrochloride (1.04 g, 5.51 mmol) and triethylamine (1.56 ml, 11.22 mmol) in methylene chloride (10 ml) was added diphenylcarbamyl chloride (1.40 g, 6.07 mmol). After stirring for 5 hr, the mixture was dumped into water and the layers separated. The aqueous layer was further extracted with methylene chloride (3 X 20 ml). The combined extracts were washed with water, dried (MgSO4), filtered, and concentrated to yield a solid which was recrystallized from ethyl acetate/hexane/methanol to give
4-((((diphenylamino)carbonyl)amino)-methyl)nitrobenzene as a white solid: 1.37 g (72% yield); m.p. 137-138 °C.
(b) 4-((((Diphenylamino)carbonyl)amino )methyl)aniline
To a stirred solution of the compound of step (a) (1.37 g, 3.94 mmol) in
THF/MeOH (100 ml, 1:1) was added a catalytic amount of 10% Pd/C. The mixture was hydrogenated at 50 psi for 1 hr, filtered through celite, and concentrated to give 4-((((diphenylamino)carbonyl)amino)methyl)aniline which was homogeneous by TLC and used immediately in the next reaction.
(c)
N-[4-((((Diphenylamino)carbonyl)amino)methyl)phenyl]-2-thiophenecarboxamidine oxalate
To a solution of the compound of step (b) (1.24 g, 3.90 mmol) in isopropanol (10 ml) was added S-methyl-2-thiophenethiocarboximide hydroiodide (1.06 g, 3.70 mmol). The mixture was stirred for 18 hr, dumped into basic water and extracted with chloroform ( 3 X 30 ml). The combined extracts were washed with water, dried (MgSO4), filtered, concentrated, and chromatographed over silica (6% methanol/methylene chloride) to an oil which solidified upon standing. A small amount was isolated as the oxalate salt: (48 mg); m.p. (dec) 150 °C.
Example 66 N-(4-((((2-thiophenyl)iminomethyl)amino)methyl)phenyl)-2-thiophenecarboxamidine difumarate
a) 4-(aminomethyl)aniline
To a solution of 4-nitrobenzylamine hydrochloride (9.0 g, 4.7 mmol) in methanol (200 ml) was added a catalytic amount of 10% palladium on carbon. The mixture was hydrogenated at 50 psi for 4 hours, filtered through celite, and concentrated to give a crude oil. The oil was dissolved in water (100 ml), and 20% sodium hydroxide (20 ml), was extracted twice with dichloromethane, the organic layer dried (MgSO4), filtered and was concentrated to yield (6.1g) of 4-(aminomethyl)aniline.
b) N-(4-((((2-thiophenyl)iminomethyl)amino)methyl)phenyl)-2-thiophenecarboxamidine difumarate
A mixture of the compound of step (a) (1.6 g 1.3 mmol) and S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (4.4 g, 1.5 mmol) in of DMF (10 ml) was warmed to 40 °C for 72 hours. The mixture was then diluted with 20% aqueous sodium hydroxide, and the solid collected by filtration to yield (2.5g) of crude N-(4-((((2-thiophenyl)iminomethyl)amino)methyl)phenyl)-2-thiophenecarboxamidine. The difumarate salt was made from methanol and isopropanol. m.p. 200-201 °C.
Example 67
Following a process analogous to that of Example 66, the following compound was prepared:
(a) N-(4-((((2-thiophenyl)iminomethyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine difumarate m.p. 200-201 °C.
Example 68
N-(4-((((3-methylphenyl)iminomethyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine difumarate
a) N-(4-(2-aminoethyl)phenyl)-2-thiophenecarboxamidine To a solution of 4-aminoethyl aniline dihydrochloride (1.4 g, 6.6 mmol) and S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)) (2.2 g, 7.9 mmol) in DMF (10 ml) was added pyridine (0.52 g, 6.6 mmol). The mixture was stirred at 40 °C for 24 hours, diluted with 20% aqueous sodium hydroxide, extracted twice with dichloromethane, dried (MgSO4), filtered and concentrated to give N-(4-(2aminoethyl)phenyl)-2-thiophenecarboxamidine (4.1g) as an oil.
b) N-(4-((((3-methylphenyl)iminomethyl)amino )ethyl)phenyl)-2-thiophenecarboxamidine difumarate
To a solution of the compound of step (a) (2.0 g, 8.2 mmol) was added S-methyl-(3-methylphenyl)thiocarboximide hydroiodide (2.8 g, 9.2 mmol) in isopropanol (10 ml). The mixture was stirred at 40 °C for 18 hours, diluted with 20% aqueous sodium hydroxide, and extracted twice with ethyl acetate. The organic layer was washed with water (100 ml), dried (MgSO4) filtered and concentrated to give an oil. The difumarate salt was made from methanol, isopropanol, and ethyl acetate to yield N(4-((((3-methylphenyl)iminomethyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine difumarate: m.p. 200-201 °C.
Example 69
Following a process analogous to that of Example 68, the following compound was prepared:
(a) N-(3-((((2-thiophenyl)iminomethyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine difumarate, m.p. 211-212 °C. Example 70
N-(4-(2-((pyrimidin-2-yl)aminolethyl)phenyl)-2-thiophenecarboxamide
dihydrochloride
a) [2-(4-nitrophenyl)ethyl]pyrimidi-2-ylamine
To a solution of 4-nitrophenethylamine hydrochloride (2.0 g, 9.8 mmol) in
dimethylformamide (20 ml) was added potassium carbonate (10 g) and 2-chloropyrimidine (1.6 g, 1.4 mmol). The mixture was heated to 100 °C for 24 hours, diluted with water (300ml), extracted twice with ethyl acetate, dried (MgSO4), filtered and concentrated to yield a crude solid. The monohydrochloride salt was made from ethyl acetate, isopropanol to yield (2.4g) of [2-(4-nitrophenyl)ethyl] pyrimidi-2-ylamine hydrochloride.
b) [2-(4-aminophenyl)-ethyl]pyrimidi-2-ylamine
To a solution of the compound of step (a) in acetic acid (100 ml) was added zinc dust (3.0 g). The reaction mixture was stirred for 30 minutes, filtered and concentrated. The residue was partitioned with 20% aqueous sodium hydroxide and dichloromethane and the organic layer was dried (MgSO4), filtered and concentrated to yield 1.3g of [2-(4-aminophenyl)-ethyl]pyrimidi-2-ylamine.
c) N-(4-(2-((pyrimidin-2-yl)amino)ethyl)phenyl)-2-thiophenecarhoxamide
dihydrochloride
To a solution of the compound of step (b) (1.3 g, 6.6 mmol) in (10 ml) of dimethylformamide was added S-methyl-2-thiophenethiocarboximide hydroiodide (the product of Example 1, step (d)). The reaction was stirred for 72 hours, diluted with 20% sodium hydroxide and extracted twice with ethyl acetate. The combined extracts were washed twice with water, dried (MgSO4), filtered and concentrated. The hydrochloride salt was made from methanol and isopropanol to yield N-(4-(2-((pyrimidin-2-yl)amino)ethyl)phenyl)-2-thiophenecarboxamide dihydrochoride. m.p. 191-192 °C.
Example 71
N-(4-(2-((phenylmethyl)amino)ethoxy)-2-fluoro-phenyl)-2-thiophenecarboximidamide a) 3-fluoro-4-nitrophenoxyacetic acid
A sample of 3-fluoro-4-nitrophenol (5.18 g) and potassium carbonate (10 g) was treated with DMF (20 ml). Ethyl bromoacetate (5 ml) was then added, and the mixture was stirred at 22 °C. After two hours the mixture was treated with methanol (20 ml) and water (40 ml) and allowed to stir. After an additional two hours, the mixture was diluted with water to 200 ml and the solids filtered off. The filtrate was acidified and the solids collected to give 3-fluoro-4-nitrophenoxyacetic acid, m.p. 90-92 °C. b) N-phenylmethyl-3-fluoro-4-nitrophenoxyacetamide
A sample of the compound of step (a) (2.84 g) was dissolved in dry THF (100 ml), then methylmorpholine (1.45 ml) was added and the mix stirred at 0 °C. Ethyl chloroformate, (1.26 ml) was added, and the mixture stirred for 2 minutes.
Benzylamine (1.45 ml) was added, and the mixture as stirred at 0 °C. After 15 minutes the mixture was diluted slowly with water to 220 ml and stirred at 0 °C. The resulting solids were collected and washed with water then air dried to give N-phenylmethyl-3-fluoro-4-nitrophenoxyacetamide, m.p. 128.5-130 °C.
(c) N-(4-(2-((phenylmethyl)amino)ethoxy)-2-fluoro-phenyl)-2-thiophenecarboximidamide
The product of step (b) was converted to N-(4-(2-((phenylmethyl)amino)
ethoxy)-2-fluoro-phenyl)-2-thiophenecarboximidamide free base following a process analogous to that of Example 19, steps (c) and (d); m.p. 105-107 °C. Example 72
N-(4-(2-((phenylmethyl)(methyl)amino)ethyl)phenyl)trifluoroacetimidamide
4-(2-((phenylmethyl)(methyl)amino)ethyl)aniline dihydrochloride (prepared following method of Example 19, steps (a)-(c)) (1.03 g) was dissolved in water (25 ml), treated with 50% sodium hydroxide (5 ml), and extracted with ethyl ether. The extract was dried (NaOH), and evaporated to provide free base, 0.72 g. The free base was then treated with trifluoroacetimidamide, and warmed to 100 °C. After one hour, toluene (5 ml) was added to improve stirring. The mixture was cooled after 2 hours, and water (30 ml) was added, and the mixture was stirred. After 15 minutes, the water was decanted from the resulting semisolid tan residue. The residue was recrystallised from a methanol and water mixture (125 ml), giving N-(4-(2-((phenylmethyl)(methyl)amino)ethyl)phenyl)-trifluoroacetimidamide, as a tan solid, m.p. 105-107 °C.

Claims

Claims
1. A compound of formula I
Figure imgf000085_0001
wherein
D represents phenyl, pyridinyl or a 5 membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, S and N, which three groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, halogen and perfluoroalkyl C1 to 6; or perfluoroalkyl C1 to 6;
R1 represents hydrogen, alkyl C1 to 6 or halogen;
R2 represents -X(CH2)nZCONR3R4, -X(CH2)nNHCO(CH2)sNR3R4,
-X(CH2)PNR3R4, -X(CH2)nNHCOR5 or -(CH2)qNHC(NH)R6;
R3 and R4 independently represent hydrogen, alkyl C1 to 6, -(CH2)rA, -(CH2)mOA or -CH(CH3)(CH2)tA;
or -NR3R4 together represent 1-indanyl, piperonylamino-, piperidinyl, morpholinyl, pyrrolidinyl, 1,2,3,4-tetrahydroisoquinolinyl; or piperazinyl optionally 4-substituted by alkyl C1 to 6;
R5 represents alkyl C1 to 6, perfluoroalkyl C1 to 6, -(CH2)rA or
-O(CH2)wA;
A represents phenyl, pyridinyl, pyrimidinyl, or a 5 membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, S and N, which four groups are optionally substituted by one or more groups selected from alkyl C1 to 6, halogen, nitro, cyano and trifluoromethyl;
R6 represents phenyl, pyridinyl or a 5 membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, S and N, which three groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, halogen and perfluoroalkyl C1 to 6; or perfluoroalkyl C1 to 6;
n and r independently represent an integer in the range 0 to 6 inclusive; p and w independently represent an integer in the range 1 to 5 inclusive;
m represents an integer in the range 2 to 5 inclusive;
q and t independently represent an integer in the range 0 to 5 inclusive;
s represents an integer in the range 1 to 3 inclusive;
X represents O or a bond;
Z represents O, NR7 or a bond;
R7 represents hydrogen or alkyl C1 to 6;
provided that:
(a) when D contains a heteroatom, it is not connected to the remainder of the compound of formula I through the heteroatom;
(b) when R2 represents -X(CH2)nZCONR3R4 and neither X nor Z represent a bond, then n represents an integer in the range 2 to 6 inclusive;
(c) when R2 represents -X(CH2)nNHCO(CH2)sNR3R4 or -X(CH2)nNHCOR5, and X represents O, then n represents an integer in the range 2 to 6 inclusive; (d) when R2 represents -X(CH2)pNR3R4 and X represents O, then p represents an integer in the range 2 to 5 inclusive;
(e) when R2 represents -(CH2)qNHC(NH)R6, R1 represents hydrogen, D represents phenyl and R6 represents phenyl, then q does not represent 0;
(f) when R2 represents -(CH2)qNHC(NH)R6, R1 represents hydrogen, D and R6 represent 2-chlorophenyl, then q does not represent 0;
(g) when R2 represents -(CH2)qNHC(NH)R6, R1 represents hydrogen, D ,and R6 represent 3-pyridinyl, then q does not represent 0; and
(h) when R2 represents -(CH2)qNHC(NH)R6, R1 represents hydrogen, D and R6 represent 4-pyridinyl, then q does not represent 0;
or a pharmaceutically acceptable salt thereof.
2. A compound as claimed in claim 1, wherein D represents phenyl, thiophene, pyrrole, furan or thiazole which five groups are optionally substituted by one or more groups selected from alkyl C1 to 6, alkoxy C1 to 6, halogen or perfluoroalkyl C1 to 6.
3. A compound as claimed in claim 1 or claim 2, wherein D represents thiophene, furan or pyrrole.
4. A compound as claimed in any one of the preceding claims wherein R2 represents -X(CH2)pNR3R4 or -(CH2)qNHC(NH)R6.
5. A compound as claimed in any one of the preceding claims wherein R2 represents -X(CH2)pNR3R4, X represents a bond and either -NR3R4 represents
1,2,3,4-tetrahydroisoquinolinyl or 1-indanyl or one of R3 and R4 represents -(CH2)rA and the other represents hydrogen or methyl.
6. A compound as claimed in any one of the preceding claims wherein R2 represents -X(CH2)pNR3R4, p represents an integer in the range 1 to 3 inclusive, one of R3 and R4 represents -(CH2)rA and the other represents hydrogen or methyl, r represents 1 or 2 and A represents phenyl optionally substituted by one or more groups selected from alkyl C1 to 6 and halogen.
7. A compound as claimed in any one of claims 1 to 4 wherein R2 represents -(CH2)qNHC(NH)R6, q represents 0, 1 or 2 and R6 represents phenyl or thiophene, which two groups are optionally substituted by one or more groups selected from alkyl C1 to 6 and halogen.
8. A compound as claimed in any one of claims 1 to 4 and claim 7 wherein R2 represents -(CH2)qNHC(NH)R6 and q represents 0.
9. A compound of formula I, as claimed in claim 1, which is:
N-(4-(2-((phenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(1-((phenylmethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(1-((phenethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-((2-chlorophenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-((3-fluorophenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide; N-(4-(2-(((2-methylphenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(methylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-aminoethyl)phenyl)-2-thiophenecarboximidamide;
N-((4-morpholinylmethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(((phenylmethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(((2,6-dichlorophenyl)methyl)amino)ethyl)phenyl)-2-thiophene carboximidamide;
N-(4-(2-(((2-bromophenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-((Phenylmethyl)amino)ethyl)phenyl)-3-thiophenecarboximidamide;
N-(4-(2-((2,6-dichlorophenylmethyl)amino)ethyl)phenyl)
-3-thiophenecarboximidamide;
N-(4-(2-aminoethyl)phenyl)-3-thiophenecarboximidamide dihydrobromide;
N-(4-(2-((2,6-dichlorophenylmethyl)amino)ethyl)phenyl)-2-furanocarboximidamide;
N-(3-(3-(1-pyrolidinyl)propyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-aminoethyl)phenyl)-2-furocarboximidamide dioxalate;
N-(4-((1-piperidinyl)methyl)phenyl)-2-thiophenecarboximidamide;
N-(4-((1-pyrrolidinyl)methyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(((phenylmethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide;
N-(3-((amino)methyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-((phenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine;
N-(3-(2-(Ethylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(3-((Phenylethyl)amino)propyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-(((2-Bromophenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-(Phenylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(Ethylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(2-Propylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(1-Propylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(t-Butylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(n-Butylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-(Methylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-(1-Propylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-(t-Butylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-(2-Propylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-aminoethyl)phenyl)-2-thiophenecarboximidamide; N-(3-(2-(Dimethylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-(Diethylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-(2-(1,2,3,4-Tetrahydro)isoquinolinyl)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(3-(2-(1,2,3,4,-tetrahydro)isoquinolyl)propyl)phenyl)-2-thiophene
carboximidamide;
N-(3-(2-(((2-Chlorophenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(3-((Phenylmethyl)amino)propyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(((3-Chlorophenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine;
N-(4-(2-(((4-Chlorophenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine;
N-(4-(2-(((3-Chlorophenyl)methyl)amino)ethyl)phenyl)-3-chlorothiophene- 2-carboximidamide;
N-(3-(2-((N-Phenylmethyl-N-methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-((N-Phenylmethyl-N-methyl)amino)ethyl)phenyl)-2-thiophene
carboximidamide;
N-(3-(2-(((3-Chlorophenyl)methyl)amino)ethyl)phenyl)-2-thiophene
carboximidamide;
N-(3-(2-(((3-fluorophenyl)methyl)amino)ethyl)phenyl)-2-thiophene carboximidamide;
N-(4-(3-(((3-Chlorophenyl)methyl)amino)propyl)phenyl)-2-thiophene
carboximidamide;
N-(4-(3-((phenylmethyl-N-methyl)amino)propyl)phenyl)-2-thiophene
carboximidamide;
N-(4-(3-((phenylamino)carbonyl)propyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(3-((phenylmethylamino)carbonyl)propyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(3-((1-pyrrolidyl)carbonyl)propyloxy)phenyl)-2-thiophenecarboximidamide;
N-(4-(3-((4-morphhlinyl)carbonyl)propyloxy)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-((phenylmethylamino)carbonyl)ethyl)phenyl)-2-thiophenecarboximidamide; N-(3-(2-((phenylamino)carbonyl)ethyl)phenyl)-2-thiophenecarboximidamide; N-(4-(3-((phenylamino)carbonyl)propyl)phenyl)-2-pyrrolecarboximidamide;
N-(4-(3-((phenylamino)carbonyl)propyl)phenyl)-2-furocarboximidamide;
N-(4-(3-((phenylamino)carbonyl)propyl)phenyl)-3-chloro-2-thiophenecarboximidamide;
N-((3-((phenylamino)carbonyl)propyl)phenyl)-1-methylpyrrole-2-carboximidamide;
N-(4-(3-(1-(4-methylpiperazinyl)carbonyl)propyl)phenyl)-2-thiophene
carboximidamide;
N-(4-(3-((1-pyrrolidyl)carbonyl)propyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(3-((4-morphohnyl)carbonyl)propyl)phenyl)-2-thiophenecarboximidamide;
N-(4-((phenylamino)carbonyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-((4-morpholinyl)carbonyl)ethyl)phenyl)-2-methylthiazole-4-carboximidamide;
N-(4-(2-(((4-morpolinyl)carbonyl)amino)ethyl)phenyl)thiophene-2-carboximidamide ;
N-(4-(3-(phenylaminocarbonyl)propyloxy)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(((trifluoromethyl)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(((methyl)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(((phenylmethyl)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(((phenyl)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-((phenyliminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide;
N-N"-(1,4-phenylene)bis-2-thiophenecarboximidamide;
N-N"-(1,3-phenylene)bis-2-thiophenecarboximidamide;
N,N'-(1,3-phenylene)bis-2-chlorophenylcarboximidamide;
N,N'-(1,4-phenylene)bis-3-chlorothiophene-2-carboximidamide;
N-(4-(((2-methoxyphenyl)iminocarbonyl)amino)phenyl)-2-thiophene
carboximidamide;
N-(4-(((Phenyl)iminocarbonyl)amino)phenyl)-3-chlorothiophene-2-carboximidamide;
N-(4-(((Phenyl)iminocarbonyl)amino)phenyl)-3-thiophenecarboximidamide;
N-(3-(((phenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide;
N-(4-(((4-chlorophenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamine; N-(4-(((2-chlorophenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide; N-(4-(((4-bromophenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide;
N-(4-(((3-chloro-4-methylphenyl)iminocarbonyl)amino)phenyl)-2-thiophene carboximidamide;
N-(4-(((3,5-dimethoxyphenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide;
N-(4-(((3,5-dichlorophenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide;
N-(4-(((Phenyl)immocarbonyl)amino)phenyl)-2-furancarboximidamide;
N-(4-(((3-methylphenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide;
N-(4-(((3-Methoxyphenyl)iminocarbonyl)amino)phenyl)-2-thiophene
carboximidamide;
N-(4-(((3-Bromophenyl)immocarbonyl)amino)phenyl)-2-thiophenecarboximidamide;
N-(4-(((3-chlorophenyl)iminocarbonyl)amino)phenyl)-2-thiophenecarboximidamide; N-(4-(((3-methylphenyl)immocarbonyl)amino)phenyl)-2-pyrrolecarboximidamide;
N-(4-(((4-chlorophenyl)iminocarbonyl)amino)phenyl)-2-pyrrolecarboximidamide;
N-(4-(2-(((Phenylamino)carbonyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine;
N-(4-(2-(((phenylamino)carbonyl)oxy)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-((bis(phenylmethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-aminomethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(4-((phenylmethyl)amino)butyl)phenyl)-2-thiophenecarboximidamide;
N-(4-((((2-thiophenyl)iminomethyl)amino)methyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(3-(1-pyrrolidinyl)propyl)phenyl)-phenylcarboximidamide;
N-(4-(2-((4-methoxyphenylmethyl)amino)ethyl)phenyl)
-2-thiophenecarboximidamide;
N-(4-(2-((4-methylphenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-((3-phenylpropyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-((2-methylphenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide; N-[4-(2-((1-indanyl)ethyl)amino)phenyl]-2-thiophenecarboximidamide;
N-(4-(2-(((4-pyridyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(((2-thienyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-((2-phenylethyl)ammo)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-aminoethyl)phenyl)-2-pyrrolecarboximidamide;
(S)-N-(4-(2-((1-phenylethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
(R)-N-(4-(2-((1-phenylethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(2-((4-phenylbutyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(((phenylmethoxy)carbonyl)aminomethyl)phenyl)-2-thiophene
carboximidamide;
N-(4-(2-((phenylmethyl)amino)ethoxy)phenyl)-2-thiophenecarboximidamide;
N-(4-(((diphenylamino)carbonyl)amino)phenyl)-2-thiophenecarboxamidine;
N-(3-((benzoyl)amino)phenyl)-2-thiophenecarboximidamide;
N-(4-((benzoyl)amino)phenyl)-2-thiophenecarboximidamide;
N-(3-(((phenylamino)carbonyl)amino)phenyl)-2-thiophenecarboximidamide;
N-(3-(((4-phenoxylbutyl)amino)carbonyl)phenyl)-2-thiophenecarboximidamide;
N-(3-(((4-phenylbutyl)amino)carbonyl)phenyl)-2-thiophenecarboximidamide;
N-(4-((((benzyl)amino)carbonyl)methyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(1-pyrrolidinyl)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(1-piperidinyl)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(3-(1-pyιτolidinyl)propyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(3-(1-piperidinyl)propyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(2-(1,2,3,4-tetrahydro)isoquinolyl)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-((((phenylmethyl)amino)methylcarbonyl)amino)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(((2-furanyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(((2-Pyridyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(((2-Thiophenyl)methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-3-((aminocarbonyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(((2-thienyl)carbonyl)amino)phenyl)-2-thiophenecarboximidamide; N-[4-((((Diphenylamino)carbonyl)amino)methyl)phenyl]-2-thiophenecarboxamidine;
N-(4-((((2-thiophenyl)iminomethyl)amino)methyl)phenyl)-2-thiophenecarboxamidine;
N-(4-((((2-thiophenyl)iminomethyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine; N-(4-((((3-methylphenyl)immomethyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine;
N-(3-((((2-thiophenyl)iminomethyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine;
N-(4-(2-((pyrimidin-2-yl)amino)ethyl)phenyl)-2-thiophenecarboxamide;
N-(4-(2-((phenylmethyl)amino)ethoxy)-2-fluoro-phenyl)-2-thiophene
carboximidamide;
N-(4-(2-((phenylmethyl)(methyl)amino)ethyl)phenyl)trifluoroacetimidamide;
N-(4-(2-((ethyl)(phenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-((propyl)(phenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-((1,1-dimethylethyl)(phenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-((3,4-dichlorophenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-((3,5-bistrifluoromethylphenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(3-(ethylamino)propyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-(diethylamino)ethyl)phenyl)-2-thiophenecarboximidamide;
N-(4-(2-((3-chlorophenylmethyl)amino)ethyl)phenyl)-benzenecarboximidamide;
N-(4-(2-((3-chlorophenylmethyl)amino)ethyl)phenyl)-3-chlorothiophene-2-carboximidamide;
N-(4-(2-((4-methylphenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboxamidine;
N-(4-(2-(piperonylamino)ethyl)phenyl)-2-thiophenecarboxamidine;
or a pharmaceutically acceptable salt of any one thereof.
10. A pharmaceutical formulation including a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable diluent or carrier.
11. A compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.
12. Use of a compound of formula I, as defined in claim 1, without provisos (e) to (h), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of neurodegenerative disorders or of migraine or for the prevention and reversal of tolerance to opiates and diazepines or for the treatment of drug addiction.
13. A method of treatment of neurodegenerative disorders or of migraine or of tolerance to opiates and diazepines or of drug addiction which comprises
administering a therapeutically effective amount of a compound of formula I, as defined in claim 1, without provisos (e) to (h), or a pharmaceutically acceptable salt thereof, to a person suffering from such a condition.
14. A process for the preparation of a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, which comprises:
(a) preparing a compound of formula I, by reacting a corresponding compound of formula II
Figure imgf000094_0001
wherein D is as defined in claim 1 and L is a leaving group,
with a compound of formula III
Figure imgf000094_0002
wherein R1 and R2 are as defined in claim 1,
(b) preparing a compound of formula I, by reacting a corresponding compound of formula IV
Figure imgf000094_0003
wherein D is as defined in claim 1,
with a compound of formula V
Figure imgf000095_0003
wherein R1 and R2 are as defined in claim 1 and HA is an acid,
(c) preparing a compound of formula I in which R2 represents
-X(CH2)nZCONR3R4, -X(CH2)nNHCO(CH2)sNR3R4 or -X(CH2)pNR3R4 and at least one of R3 and R4 represents alkyl C1 to 6, -(CH2)rA, -(CH2)mOA or
-CH(CH3)(CH2)tA by reacting a corresponding compound of formula I in which one or both of R3 and R4 represents hydrogen with a compound of formula VI,
Figure imgf000095_0004
wherein R8 represents alkyl C1 to 6, -(CH2)Λ -(CH2)mOA or -CH(CH3)(CH2)tA and L is a leaving group,
(d) preparing a compound of formula I in which R2 represents
-(CH2)qNHC(NH)R6 by reacting a corresponding compound of formula VII
Figure imgf000095_0002
wherein D, R1 and q are as defined in claim 1,
with a compound of formula VIII
Figure imgf000095_0001
wherein R6 is as defined in claim 1 and L is a leaving group,
(e) preparing a compound of formula I in which R2 represents
-(CH2)qNHC(NH)R6 by reacting a corresponding compound of formula IX
Figure imgf000096_0006
wherein D, R1 and q are as defined in claim 1 and HA is an acid, with a compound of formula X
Figure imgf000096_0005
wherein R6 is as defined in claim 1,
(f) preparing a compound of formula I in which R2 represents
-X(CH2)nZCONR3R4 by reacting a corresponding compound of formula XI,
Figure imgf000096_0004
wherein D, R1, X, n, Z and L are as defined in claim 1,
with a compound of formula XII,
Figure imgf000096_0003
wherein R3 and R4 are as defined in claim 1,
(g) preparing a compound of formula I in which R2 represents
-X(CH2)nNHCO(CH2)sNR3R4, by reacting a compound of formula XIII
Figure imgf000096_0001
wherein D, R1, X and n are as defined in claim 1,
with a compound of formula XIV
Figure imgf000096_0002
wherein R3, R and s are as defined in claim 1 and L is a leaving group, (h) preparing a compound of formula I in which R2 represents -X(CH2)nNHCOR5, by reacting a compound of formula XIII with a compound of formula XV
Figure imgf000097_0004
wherein R5 is as defined in claim 1 and L is a leaving group,
(i) preparing a compound of formula I in which R2 represents
-X(CH2)nZCONR3R4 and Z represents NR7 by reacting a corresponding compound of formula I in which R2 represents -X(CH2)nZCONR3R4 and Z represents -NH with a compound of formula XVI
Figure imgf000097_0003
wherein R7 is as defined in claim 1 and L is a leaving group,
(j) preparing a compound of formula I in which R2 represents -X(CH2)pNR3R4, and p is not less than 2, by reduction of a compound of formula XVII
Figure imgf000097_0002
wherein D, X, R1, R3, R4 and p are as defined in claim 1,
(k) preparation of a compound of formula I wherein R2 represents
-X(CH2)pNR3R4 and both R3 and R4 represent hydrogen, by reduction of a corresponding compound of formula XVIII
Figure imgf000097_0001
wherein R1, D, p and X are as defined in claim 1,
(1) preparing a compound of formula I wherein R2 represents
-X(CH2)nZCONR3R4, Z represents O or NR7 and R3 represents hydrogen by reacting a compound of formula XIX
Figure imgf000098_0005
wherein R1, D, X and n are as defined in claim 1 and Z represents O or NR7, with a compound of formula XX
Figure imgf000098_0004
wherein R4 is as defined in claim 1,
(m) preparing a compound of formula I wherein R2 represents
-X(CH2)nNHCOR5 and R5 represents -O(CH2)wA by reacting a compound of formula XXI
Figure imgf000098_0001
wherein R1, D, X and n are as defined in claim 1,
with a compound of formula XXII
Figure imgf000098_0002
wherein A and w are as defined in claim 1,
(n) preparing a compound of formula I wherein R2 represents
-X(CH2)nZCONR3R4 and Z represents O or NR7 by reacting a compound of formula XIX with a compound of formula XXIII
Figure imgf000098_0003
wherein R3 and R4 are as defined in claim 1,
(o) preparing a compound of formula I wherein R2 represents -X(CH2)pNR3R4, R3 represents hydrogen and p represents an integer 2 to 5, by reduction of a compound of formula XXIV
Figure imgf000099_0004
wherein R1, R4, D, X and p are as defined in claim 1,
(p) preparing a compound of formula I wherein R2 represents -X(CH2)pNR3R4, one of R3 and R4 represents hydrogen, and the other represents -(CH2)rA in which r represents an integer 2 to 6, by reduction of a compound of formula XXV
Figure imgf000099_0003
wherein R1, A, D, r and p are as defined in claim 1,
(q) preparing a compound of formula I wherein R2 represents -X(CH2)pNR3R4, one of R3 and R4 represents hydrogen, and the other represents -(CH2)mOA, by reduction of a compound of formula XXVI
Figure imgf000099_0002
wherein R1, A, D, p and m are as defined in claim 1,
(r) preparing a compound of formula I wherein R2 represents -X(CH2)pNR3R4, one of R3 and R4 represents hydrogen, and the other represents -(CH2)rA in which r represents an integer 2 to 6, by reduction of a compound of formula XXVII
Figure imgf000099_0001
wherein R1, A, D, p and r are as defined in claim 1, or
(s) preparing a compound of formula I wherein R2 represents -X(CH2)pNR3R4, one of R3 and R4 represents hydrogen, and the other represents -(CH2)mOA, by reduction of a compound of formula XXVIII
Figure imgf000100_0001
wherein R1, A, D, p and m are as defined in claim 1,
and where desired or necessary converting the resultant compound of formula I, or another salt thereof, to a pharmaceutically acceptable salt thereof, or vice versa.
PCT/GB1994/001767 1993-08-12 1994-08-12 Amidine derivatives with nitric oxide synthetase activities WO1995005363A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AT94923776T ATE231126T1 (en) 1993-08-12 1994-08-12 AMIDINE DERIVATIVES WITH NITROGEN OXIDE SYNTHEASE ACTIVITY
DE69432019T DE69432019T2 (en) 1993-08-12 1994-08-12 AMIDINE DERIVATIVES WITH NITROGEN OXIDE SYNTHEASE ACTIVITY
SK163-96A SK16396A3 (en) 1993-08-12 1994-08-12 Amidine derivatives with nitric oxide synthetase activities
JP7506814A JPH09501918A (en) 1993-08-12 1994-08-12 Amidine derivative having nitric oxide synthase activity
AU73875/94A AU682381B2 (en) 1993-08-12 1994-08-12 Amidine derivatives with nitric oxide synthetase activities
BR9407515A BR9407515A (en) 1993-08-12 1994-08-12 Compound pharmaceutical formulation use of the compound processes for the treatment of neurodegenerative or migraine disorders or for the prevention and reversal of tolerance to opiates and diazepines or for the treatment of drug addiction and for the preparation of the compound
RU96104356A RU2130017C1 (en) 1993-08-12 1994-08-12 Amidine derivatives, a method of their synthesis and a drug based on said showing a property to inhibit activity of nitrogen oxide (v) synthetase
EP94923776A EP0713483B1 (en) 1993-08-12 1994-08-12 Amidine derivatives with nitric oxide synthetase activities
US08/586,761 US5807885A (en) 1993-08-12 1994-08-12 Amidine derivatives with nitric oxide synthetase activities
PL94312961A PL180081B1 (en) 1993-08-12 1994-08-12 Amidine derivatives exhibiting activity of nitrogen oxide synthetase
NO960534A NO306459B1 (en) 1993-08-12 1996-02-09 Amidine derivatives with nitric oxide synthetase activities, pharmaceutical preparation and use of the amidine derivatives
FI960628A FI960628A (en) 1993-08-12 1996-02-12 Amidine derivatives with nitric oxide synthetase activities

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB939316806A GB9316806D0 (en) 1993-08-12 1993-08-12 Pharmaceutically active compounds
GB9316806.0 1993-08-12
GB939319835A GB9319835D0 (en) 1993-09-25 1993-09-25 Pharmaceutically active compounds
GB9319835.6 1993-09-25
GB9325410.0 1993-12-11
GB939325410A GB9325410D0 (en) 1993-12-11 1993-12-11 Pharmaceutically active compounds
GB9401580A GB9401580D0 (en) 1994-01-27 1994-01-27 Pharmaceutically active compounds
GB9401580.7 1994-01-27
GB9411700.9 1994-06-10
GB9411700A GB9411700D0 (en) 1994-06-10 1994-06-10 Pharmceutically active compounds

Publications (1)

Publication Number Publication Date
WO1995005363A1 true WO1995005363A1 (en) 1995-02-23

Family

ID=27517202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1994/001767 WO1995005363A1 (en) 1993-08-12 1994-08-12 Amidine derivatives with nitric oxide synthetase activities

Country Status (18)

Country Link
US (2) US5807885A (en)
EP (1) EP0713483B1 (en)
JP (1) JPH09501918A (en)
AT (1) ATE231126T1 (en)
AU (1) AU682381B2 (en)
BR (1) BR9407515A (en)
CA (1) CA2169280A1 (en)
CZ (1) CZ29996A3 (en)
DE (1) DE69432019T2 (en)
FI (1) FI960628A (en)
HU (1) HUT75876A (en)
IL (1) IL110643A (en)
NO (1) NO306459B1 (en)
NZ (1) NZ269571A (en)
PL (1) PL180081B1 (en)
RU (1) RU2130017C1 (en)
SK (1) SK16396A3 (en)
WO (1) WO1995005363A1 (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031195A1 (en) * 1994-05-11 1995-11-23 Jes Olesen Use of no scavengers, inhibitors or antagonists in the treatment of migraine
WO1996001817A1 (en) * 1994-05-07 1996-01-25 Astra Aktiebolag Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
WO1997006158A1 (en) * 1995-08-10 1997-02-20 Astra Aktiebolag Bicyclic amidine derivatives useful in therapy
WO1997009982A1 (en) * 1995-09-14 1997-03-20 Nippon Kayaku Kabushiki Kaisha Nitrogen monoxide synthetase inhibitor comprising 2-aminopyridines as active ingredient
WO1997017344A1 (en) * 1995-11-07 1997-05-15 Astra Aktiebolag Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
WO1997046515A1 (en) * 1996-06-04 1997-12-11 Chugai Seiyaku Kabushiki Kaisha Substituted benzenes having nos inhibitory effects
US5721247A (en) * 1994-09-20 1998-02-24 Astra Aktiebolag Isothiourea derivatives useful in therapy
US5786364A (en) * 1995-02-11 1998-07-28 Astra Aktiebolag Bicyclic isothiourea derivatives useful in therapy
FR2761066A1 (en) * 1997-03-24 1998-09-25 Sod Conseils Rech Applic NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO1998050372A1 (en) * 1997-05-02 1998-11-12 Schering Aktiengesellschaft Substituted heterocycles and their use in medicaments
FR2764889A1 (en) * 1997-06-20 1998-12-24 Sod Conseils Rech Applic NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US5854234A (en) * 1993-10-21 1998-12-29 G. D. Searle & Co. Amidino dervatives useful as nitric oxide synthase inhibitors
US5883251A (en) * 1995-04-20 1999-03-16 G. D. Searle & Co. Azepine derivatives useful as nitric oxide synthase inhibitors
US5929085A (en) * 1996-11-06 1999-07-27 Astra Aktiebolag Amidine and isothiourea derivatives, compositions containing them and their use as inhibitors of nitric oxide synthase
US5958958A (en) * 1997-07-22 1999-09-28 G.D. Searle & Co. 1,2,4-oxa diazolino and 1,24-oxa diazolidion heterocycles as useful nitric oxide synthase inhibitors
EP0949242A1 (en) * 1996-12-24 1999-10-13 Chugai Seiyaku Kabushiki Kaisha Aromatic amine derivatives having nos inhibitory effect
FR2783519A1 (en) * 1998-09-23 2000-03-24 Sod Conseils Rech Applic Phenyl amidines have NO synthase and lipidic peroxidase inhibiting activity for treating cardiovascular, cerebrovascular, peripheral and central nervous system, muscular, neuromuscular and other disorders
WO2000017191A2 (en) * 1998-09-23 2000-03-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) N-(iminomethyl)amine derivatives, their preparation, their use as medicines and compositions containing them
EP1043312A1 (en) * 1997-11-04 2000-10-11 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds having nos inhibitory activities
US6133306A (en) * 1995-01-13 2000-10-17 The General Hospital Corporation Methods of inhibiting neurodegerative diseases
US6140322A (en) * 1995-11-07 2000-10-31 Astra Aktiebolag Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
US6166030A (en) * 1997-05-05 2000-12-26 Astra Aktiebolag Compounds
FR2801053A1 (en) * 1999-11-16 2001-05-18 Sod Conseils Rech Applic NOVEL AMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
WO2001046171A1 (en) * 1999-12-20 2001-06-28 Astrazeneca Ab Amidine derivatives which are inhibitors of nitric oxide synthase
WO2001046170A1 (en) * 1999-12-20 2001-06-28 Astrazeneca Ab Amidine derivatives which are inhibitors of nitric oxide synthase
WO2001049656A1 (en) * 2000-01-07 2001-07-12 Sun Ho Park Novel aliphatic amide having anticancer property
US6274593B1 (en) 1997-05-01 2001-08-14 Smithkline Beecham P.L.C. Substituted tetrahydro isoquinolines as modulators of dopamine D3 receptors
WO2001068585A1 (en) * 2000-03-14 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. Novel amide compounds
FR2812198A1 (en) * 2000-07-28 2002-02-01 Sod Conseils Rech Applic AMIDINE DERIVATIVES INHIBITORS OF PHOSPHATASES cdc25
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
WO2002020511A1 (en) * 2000-09-05 2002-03-14 Astrazeneca Ab Amidine derivatives which are inhibitors of nitric oxide synthase
US6414154B1 (en) 1998-05-20 2002-07-02 Smithkline Beecham P.L.C. Tetraisoquinoline derivatives as modulators of dopamine D3 receptors
US6489323B1 (en) 1998-06-10 2002-12-03 G.D. Searle & Co. Heterobicyclic and tricyclic nitric oxide synthase inhibitors
US6489322B1 (en) 1997-05-05 2002-12-03 Astrazeneca Ab Amidine derivatives as inhibitors of nitric oxide synthase
DE10162114A1 (en) * 2001-12-12 2003-06-26 Schering Ag New N-phenyl (hetero)aryl-carboximidamides are potent nitrogen monoxide synthase inhibitors, useful e.g. for treating neurodegenerative, cardiovascular, autoimmune and/or inflammatory diseases
US6586454B2 (en) * 1997-03-24 2003-07-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US6605607B1 (en) 1998-10-08 2003-08-12 Smithkline Beecham P.L.C. Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
US6649589B1 (en) 1998-09-25 2003-11-18 A+ Science Ab (Publ) Use of certain drugs for treating nerve root injury
US6750254B2 (en) 1997-07-03 2004-06-15 The United States Of America As Represented By The Department Of Health And Human Services Nitric oxide-releasing amidine—and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
US6770636B2 (en) * 2000-08-18 2004-08-03 Boehringer Ingelheim Pharma Kg Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines
US6809088B2 (en) * 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2014086790A1 (en) 2012-12-05 2014-06-12 Istituto Europeo Di Oncologia S.R.L. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
US9040558B2 (en) 2004-12-31 2015-05-26 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527391A (en) * 2000-03-16 2003-09-16 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） Novel heterocyclic or benzene derivative of lipoic acid, its production method and its use as a medicament
DZ3415A1 (en) 2000-08-31 2002-03-07 Chiron Corp GUANIDINOBENZAMIDES AS MC4-R AGONISTS.
UA75093C2 (en) * 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
ATE348097T1 (en) * 2001-04-09 2007-01-15 Chiron Corp GUANIDINE COMPOUNDS AS MELANOCORTIN-4 RECEPTOR (MC4-R) AGONISTS
US6514960B1 (en) 2001-08-27 2003-02-04 Hedonist Biochemical Technologies Co., Ltd. Use of bismuth subgallate in inhibition of production of nitric oxide synthase
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US20050124652A1 (en) * 2002-02-04 2005-06-09 Rustum Boyce Guanidino compounds
US20030207814A1 (en) * 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
JP2005524649A (en) * 2002-02-25 2005-08-18 カイロン コーポレーション Intranasal administration of MC4-R agonist
EP1551834B1 (en) 2002-05-23 2010-08-25 Novartis Vaccines and Diagnostics, Inc. Substituted quinazolinone compounds
FR2842808B1 (en) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic NOVEL ARYLIMIDAZOLA DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS
US7625909B2 (en) * 2003-05-23 2009-12-01 Novartis Vaccines And Diagnostics, Inc. Substituted quinazolinone compounds
EP1686996A4 (en) * 2003-11-19 2008-11-12 Novartis Vaccines & Diagnostic Quinazolinone compounds with reduced bioaccumulation
US7914705B2 (en) * 2005-01-10 2011-03-29 Robert Eliot Sisson Flowable electrical conductive liquid
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
US9000007B2 (en) 2011-09-27 2015-04-07 Dr. Reddy's Laboratories Ltd. 5-benzylaminomethyl-6-aminopyrazolo [3, 4 -B] pyridine derivatives as cholesteryl ester-transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
RU2480452C1 (en) * 2012-01-11 2013-04-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА Минздрава России) Method of producing n-4-nitrophenylbenzamidine
US8735606B2 (en) * 2012-08-30 2014-05-27 Northwestern University Thiophene-2-carboximidamide based selective neuronal nitric oxide inhibitors
US10377698B2 (en) 2015-03-30 2019-08-13 University Of Innsbruck Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production
RU2684117C1 (en) * 2018-10-29 2019-04-04 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный химико-фармацевтический университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России) Method for producing n-(naphthalene-2-yl)benzamidine
RU2694263C1 (en) * 2019-02-14 2019-07-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный химико-фармацевтический университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России) Analgesic and anti-inflammatory agent with antimicrobial activity
US20220280644A1 (en) * 2019-08-09 2022-09-08 University Of Utah Research Foundation "TRPswitch" - A STEP FUNCTION CHEMO-OPTOGENETIC LIGAND

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004024A1 (en) * 1989-09-13 1991-04-04 Board Of Regents, The University Of Texas System Arginine antagonists for inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
EP0446699A1 (en) * 1990-02-26 1991-09-18 Merrell Pharmaceuticals Inc. Inhibitors of nitric oxide biosynthesis
WO1992004054A1 (en) * 1990-08-30 1992-03-19 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY, PORTLAND, OREGON, and THE UNIVERSITY OF OREGON, EUGENE, OREGON, Johnson Hall, University of Oregon Substituted amidines having high binding to the sigma receptor and the use thereof
WO1992016666A1 (en) * 1991-03-22 1992-10-01 Cornell Research Foundation, Inc. N6-(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
EP0547558A1 (en) * 1991-12-16 1993-06-23 Washington University Use of aminoguanidine for the manufacture of a medicament for inhibiting nitric oxide formation
WO1993013055A1 (en) * 1991-12-24 1993-07-08 The Wellcome Foundation Limited Amidino derivatives and their use as nitric oxide synthase inhibitors
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity
WO1993024126A1 (en) * 1992-05-28 1993-12-09 Cornell Research Foundation, Inc. Substituted arginines and substituted homoarginines and use thereof
WO1994012163A1 (en) * 1992-11-25 1994-06-09 Abbott Laboratories 2-nitroaryl and 2-cyanoaryl compounds as regulators of nitric oxide synthase
WO1994012165A2 (en) * 1992-11-27 1994-06-09 The Wellcome Foundation Limited Enzyme inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299081A (en) * 1963-09-13 1967-01-17 Merck & Co Inc Chemical processes for preparing nu-substituted amidines
NL135043C (en) * 1963-10-11
GB1188956A (en) * 1967-07-14 1970-04-22 Delalande Sa N-Substituted Aromatic Amidines and process for obtaining same
GB1180629A (en) * 1967-07-14 1970-02-04 Delalande Sa Di-Amidines derived from Aromatic Diamines and process for obtaining same
US3669974A (en) * 1971-03-25 1972-06-13 Usv Pharma Corp N,n1-disubstituted benzamidines
DE2321330A1 (en) * 1973-04-27 1974-11-07 Bayer Ag AZOLYL-AMIDINES, THE PROCESS FOR THEIR MANUFACTURING AND THEIR USE AS HERBICIDES
US3988474A (en) * 1974-11-06 1976-10-26 The Dow Chemical Company N,N'-dialkyl-halobenzamidines as antidepressants
NL7908922A (en) * 1979-12-12 1981-07-16 Akzo Nv CARBOXIMIDAMIDE DERIVATIVES.
JPS5857357A (en) * 1981-09-30 1983-04-05 Daikin Ind Ltd Fluorine-containing amidine and its preparation
IT1211138B (en) * 1981-12-01 1989-09-29 Ausonia Farma Srl ANTI-HYPERTENSIVE COMPOUND PROCEDURE FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS.
EP0097463A3 (en) * 1982-06-16 1985-05-15 Beecham Group Plc Amidine derivatives
JPS60130561A (en) * 1983-12-16 1985-07-12 Torii Yakuhin Kk Amidine derivative and cardiotonic agent containing the same
US4634705A (en) * 1984-06-06 1987-01-06 Abbott Laboratories Adrenergic amidines
IE62023B1 (en) * 1989-01-02 1994-12-14 Boots Co Plc Therapeutic agents
JPH02229147A (en) * 1989-03-03 1990-09-11 Nissan Chem Ind Ltd Fluorine-containing compound
US5286752A (en) * 1991-09-10 1994-02-15 Sterling Winthrop Inc. Antiarrhythmic diarylamidines
BR9307903A (en) * 1992-11-23 1996-08-27 Dry Dock Ind Inc Retainer for receiving threaded fasteners and a retainer manufacturing method
ES2132393T3 (en) * 1993-03-23 1999-08-16 Astra Ab GUANIDINE DERIVATIVES USEFUL IN THERAPEUTICS.

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004024A1 (en) * 1989-09-13 1991-04-04 Board Of Regents, The University Of Texas System Arginine antagonists for inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
EP0446699A1 (en) * 1990-02-26 1991-09-18 Merrell Pharmaceuticals Inc. Inhibitors of nitric oxide biosynthesis
WO1992004054A1 (en) * 1990-08-30 1992-03-19 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY, PORTLAND, OREGON, and THE UNIVERSITY OF OREGON, EUGENE, OREGON, Johnson Hall, University of Oregon Substituted amidines having high binding to the sigma receptor and the use thereof
WO1992016666A1 (en) * 1991-03-22 1992-10-01 Cornell Research Foundation, Inc. N6-(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
EP0547558A1 (en) * 1991-12-16 1993-06-23 Washington University Use of aminoguanidine for the manufacture of a medicament for inhibiting nitric oxide formation
WO1993013055A1 (en) * 1991-12-24 1993-07-08 The Wellcome Foundation Limited Amidino derivatives and their use as nitric oxide synthase inhibitors
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity
WO1993024126A1 (en) * 1992-05-28 1993-12-09 Cornell Research Foundation, Inc. Substituted arginines and substituted homoarginines and use thereof
WO1994012163A1 (en) * 1992-11-25 1994-06-09 Abbott Laboratories 2-nitroaryl and 2-cyanoaryl compounds as regulators of nitric oxide synthase
WO1994012165A2 (en) * 1992-11-27 1994-06-09 The Wellcome Foundation Limited Enzyme inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S.MONCADA ETAL.: "Nitric oxide: Physiology,Pathophysiology, and Pharmacology", PHARMACOL.REV.., vol. 43, no. 2, 1991, pages 109 - 142 *

Cited By (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071906A (en) * 1993-10-21 2000-06-06 G. D. Searle & Co. Imidino piperidine derivatives useful as nitric oxide synthase inhibitors
US5854234A (en) * 1993-10-21 1998-12-29 G. D. Searle & Co. Amidino dervatives useful as nitric oxide synthase inhibitors
US6448286B1 (en) 1993-10-21 2002-09-10 G.D. Searle & Co. Imino pyrrolidine derivatives useful as nitric oxide synthase inhibitors
US6046211A (en) * 1993-10-21 2000-04-04 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
US5807886A (en) * 1994-05-07 1998-09-15 Astra Aktiebolag Bicyclic amidine dervatives as inhibitors of nitric oxide synthetase
WO1996001817A1 (en) * 1994-05-07 1996-01-25 Astra Aktiebolag Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
US6117898A (en) * 1994-05-07 2000-09-12 Astra Aktiebolag Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
AU682768B2 (en) * 1994-05-07 1997-10-16 Astra Aktiebolag Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
WO1995031195A1 (en) * 1994-05-11 1995-11-23 Jes Olesen Use of no scavengers, inhibitors or antagonists in the treatment of migraine
US6265441B1 (en) 1994-05-11 2001-07-24 Jes Olesen Use of no scavengers, inhibitors of antagonists in the treatment of migraine
US5721247A (en) * 1994-09-20 1998-02-24 Astra Aktiebolag Isothiourea derivatives useful in therapy
US6133306A (en) * 1995-01-13 2000-10-17 The General Hospital Corporation Methods of inhibiting neurodegerative diseases
US5786364A (en) * 1995-02-11 1998-07-28 Astra Aktiebolag Bicyclic isothiourea derivatives useful in therapy
US5883251A (en) * 1995-04-20 1999-03-16 G. D. Searle & Co. Azepine derivatives useful as nitric oxide synthase inhibitors
WO1997006158A1 (en) * 1995-08-10 1997-02-20 Astra Aktiebolag Bicyclic amidine derivatives useful in therapy
WO1997009982A1 (en) * 1995-09-14 1997-03-20 Nippon Kayaku Kabushiki Kaisha Nitrogen monoxide synthetase inhibitor comprising 2-aminopyridines as active ingredient
US6140322A (en) * 1995-11-07 2000-10-31 Astra Aktiebolag Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
WO1997017344A1 (en) * 1995-11-07 1997-05-15 Astra Aktiebolag Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
WO1997046515A1 (en) * 1996-06-04 1997-12-11 Chugai Seiyaku Kabushiki Kaisha Substituted benzenes having nos inhibitory effects
US5929085A (en) * 1996-11-06 1999-07-27 Astra Aktiebolag Amidine and isothiourea derivatives, compositions containing them and their use as inhibitors of nitric oxide synthase
EP0949242A1 (en) * 1996-12-24 1999-10-13 Chugai Seiyaku Kabushiki Kaisha Aromatic amine derivatives having nos inhibitory effect
US6331553B1 (en) 1996-12-24 2001-12-18 Chugai Seiyaku Kabushiki Kaisha Aromatic amine derivatives having NOS inhibiting action
EP0949242A4 (en) * 1996-12-24 2004-09-08 Chugai Seiyakukabushiki Kaisha Aromatic amine derivatives having nos inhibitory effect
US6340700B1 (en) 1997-03-24 2002-01-22 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
FR2761066A1 (en) * 1997-03-24 1998-09-25 Sod Conseils Rech Applic NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US6599903B2 (en) * 1997-03-24 2003-07-29 Societe De Conseils De Recherches D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US6586454B2 (en) * 1997-03-24 2003-07-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
WO1998042696A1 (en) * 1997-03-24 1998-10-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
US6809088B2 (en) * 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US6630461B2 (en) * 1997-03-24 2003-10-07 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl) amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US7122535B2 (en) * 1997-03-24 2006-10-17 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
CZ297562B6 (en) * 1997-03-24 2007-02-07 Societe De Conseils De Recherches Et D'applications Scientifiques (S. C. R. A. S.) Novel 2-(iminomethyl)aminophenyl derivatives, process of their preparation, their use as medicaments and pharmaceutical compositions in which they are comprised
US6274593B1 (en) 1997-05-01 2001-08-14 Smithkline Beecham P.L.C. Substituted tetrahydro isoquinolines as modulators of dopamine D3 receptors
US6191127B1 (en) 1997-05-02 2001-02-20 Schering Aktiengesellschaft Substituted heterocycles and their use in medicaments
WO1998050372A1 (en) * 1997-05-02 1998-11-12 Schering Aktiengesellschaft Substituted heterocycles and their use in medicaments
US6166030A (en) * 1997-05-05 2000-12-26 Astra Aktiebolag Compounds
US6489322B1 (en) 1997-05-05 2002-12-03 Astrazeneca Ab Amidine derivatives as inhibitors of nitric oxide synthase
WO1998058934A1 (en) * 1997-06-20 1998-12-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same
CZ299237B6 (en) * 1997-06-20 2008-05-28 Société De Conseils De Recherches Et D'applications Scientifiques (S. C. R. A. S.) 2-(iminomethyl)phenyl derivatives, process of their preparation and use as medicaments and pharmaceutical composition containing thereof
FR2764889A1 (en) * 1997-06-20 1998-12-24 Sod Conseils Rech Applic NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
AU737964B2 (en) * 1997-06-20 2001-09-06 Ipsen Pharma S.A.S. New derivatives of 2-(iminomethyl) amino-phenyl,their preparation, their use as medicaments and the pharmaceutical compositions containing them
US6750254B2 (en) 1997-07-03 2004-06-15 The United States Of America As Represented By The Department Of Health And Human Services Nitric oxide-releasing amidine—and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
US6911478B2 (en) 1997-07-03 2005-06-28 The United States Of America As Represented By The Department Of Health And Human Services Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
US5958958A (en) * 1997-07-22 1999-09-28 G.D. Searle & Co. 1,2,4-oxa diazolino and 1,24-oxa diazolidion heterocycles as useful nitric oxide synthase inhibitors
US6136829A (en) * 1997-07-22 2000-10-24 G.D. Searle & Co. Oxathiadiazole derivatives usful as iNOS inhibitors
US6414005B1 (en) 1997-11-04 2002-07-02 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds having nos inhibitory activities
EP1043312A1 (en) * 1997-11-04 2000-10-11 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds having nos inhibitory activities
EP1043312A4 (en) * 1997-11-04 2001-01-17 Chugai Pharmaceutical Co Ltd Heterocyclic compounds having nos inhibitory activities
US6414154B1 (en) 1998-05-20 2002-07-02 Smithkline Beecham P.L.C. Tetraisoquinoline derivatives as modulators of dopamine D3 receptors
US6489323B1 (en) 1998-06-10 2002-12-03 G.D. Searle & Co. Heterobicyclic and tricyclic nitric oxide synthase inhibitors
KR100746762B1 (en) * 1998-09-23 2007-08-06 소시에떼 드 꽁세이으 드 르세르세 에 따블리까시옹 시앙띠피끄 (에스.세.에르.아.에스.) New Derivatives of Amidines, Their Preparation, Their Use as Medicaments and the Pharmaceutical Compositions Containing Them
FR2783519A1 (en) * 1998-09-23 2000-03-24 Sod Conseils Rech Applic Phenyl amidines have NO synthase and lipidic peroxidase inhibiting activity for treating cardiovascular, cerebrovascular, peripheral and central nervous system, muscular, neuromuscular and other disorders
WO2000017190A2 (en) * 1998-09-23 2000-03-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same
WO2000017190A3 (en) * 1998-09-23 2000-10-26 Sod Conseils Rech Applic Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same
FR2784678A1 (en) * 1998-09-23 2000-04-21 Sod Conseils Rech Applic NOVEL N- (IMINOMETHYL) AMINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6482822B1 (en) * 1998-09-23 2002-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) N-(iminomethyl)amines derivatives, their preparation, their use as medicines and compositions containing them
WO2000017191A3 (en) * 1998-09-23 2000-10-26 Sod Conseils Rech Applic N-(iminomethyl)amine derivatives, their preparation, their use as medicines and compositions containing them
CZ299664B6 (en) * 1998-09-23 2008-10-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Novel N-(iminomethyl)amine derivatives, their use and pharmaceutical composition in which the derivatives are comprised
EP1318149A1 (en) * 1998-09-23 2003-06-11 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing them
WO2000017191A2 (en) * 1998-09-23 2000-03-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) N-(iminomethyl)amine derivatives, their preparation, their use as medicines and compositions containing them
US6653312B1 (en) 1998-09-23 2003-11-25 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same
AU766373B2 (en) * 1998-09-23 2003-10-16 Ipsen Pharma S.A.S. Novel amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same
US6649589B1 (en) 1998-09-25 2003-11-18 A+ Science Ab (Publ) Use of certain drugs for treating nerve root injury
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US6605607B1 (en) 1998-10-08 2003-08-12 Smithkline Beecham P.L.C. Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
US6770669B1 (en) 1999-11-16 2004-08-03 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Amidine derivatives, preparation and use thereof as medicines
FR2801053A1 (en) * 1999-11-16 2001-05-18 Sod Conseils Rech Applic NOVEL AMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
WO2001036407A1 (en) * 1999-11-16 2001-05-25 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Novel amidine derivatives, preparation and use thereof as medicines
WO2001046171A1 (en) * 1999-12-20 2001-06-28 Astrazeneca Ab Amidine derivatives which are inhibitors of nitric oxide synthase
WO2001046170A1 (en) * 1999-12-20 2001-06-28 Astrazeneca Ab Amidine derivatives which are inhibitors of nitric oxide synthase
KR20010068667A (en) * 2000-01-07 2001-07-23 박선호 Novel aliphatic amide having anticancer property
WO2001049656A1 (en) * 2000-01-07 2001-07-12 Sun Ho Park Novel aliphatic amide having anticancer property
WO2001068585A1 (en) * 2000-03-14 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. Novel amide compounds
WO2002009686A2 (en) * 2000-07-28 2002-02-07 Societe De Conseils De Recherches Et D'applications Scientifique (S.C.R.A.S.) Cdc25 phosphatase inhibitors
FR2812198A1 (en) * 2000-07-28 2002-02-01 Sod Conseils Rech Applic AMIDINE DERIVATIVES INHIBITORS OF PHOSPHATASES cdc25
WO2002009686A3 (en) * 2000-07-28 2003-10-09 Sod Conseils Rech Applic Cdc25 phosphatase inhibitors
US7196084B2 (en) 2000-07-28 2007-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Cdc25 phosphatase inhibitors
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
US6770636B2 (en) * 2000-08-18 2004-08-03 Boehringer Ingelheim Pharma Kg Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines
WO2002020511A1 (en) * 2000-09-05 2002-03-14 Astrazeneca Ab Amidine derivatives which are inhibitors of nitric oxide synthase
DE10162114A1 (en) * 2001-12-12 2003-06-26 Schering Ag New N-phenyl (hetero)aryl-carboximidamides are potent nitrogen monoxide synthase inhibitors, useful e.g. for treating neurodegenerative, cardiovascular, autoimmune and/or inflammatory diseases
WO2003053914A1 (en) * 2001-12-12 2003-07-03 Schering Aktiengesellschaft Novel amidine derivatives and the use of the same in pharmaceuticals
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US9040558B2 (en) 2004-12-31 2015-05-26 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2014086790A1 (en) 2012-12-05 2014-06-12 Istituto Europeo Di Oncologia S.R.L. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a

Also Published As

Publication number Publication date
IL110643A0 (en) 1994-11-11
PL180081B1 (en) 2000-12-29
IL110643A (en) 1998-07-15
NO960534L (en) 1996-04-11
AU682381B2 (en) 1997-10-02
EP0713483B1 (en) 2003-01-15
RU2130017C1 (en) 1999-05-10
JPH09501918A (en) 1997-02-25
BR9407515A (en) 1997-01-07
DE69432019D1 (en) 2003-02-20
SK16396A3 (en) 1996-09-04
NO960534D0 (en) 1996-02-09
US5807885A (en) 1998-09-15
FI960628A0 (en) 1996-02-12
FI960628A (en) 1996-02-12
NZ269571A (en) 1996-11-26
AU7387594A (en) 1995-03-14
HUT75876A (en) 1997-05-28
US6030985A (en) 2000-02-29
CZ29996A3 (en) 1996-09-11
NO306459B1 (en) 1999-11-08
DE69432019T2 (en) 2003-11-27
CA2169280A1 (en) 1995-02-23
PL312961A1 (en) 1996-05-27
HU9600310D0 (en) 1996-04-29
EP0713483A1 (en) 1996-05-29
ATE231126T1 (en) 2003-02-15

Similar Documents

Publication Publication Date Title
EP0713483B1 (en) Amidine derivatives with nitric oxide synthetase activities
EP0690851B1 (en) Guanidine derivatives useful in therapy
EP0820991B1 (en) Cycloalkyl derivatives as bone resorption inhibitors and vitronectin receptor antagonists
US5721247A (en) Isothiourea derivatives useful in therapy
EP0759027B1 (en) Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
JP4231403B2 (en) Urea derivatives with antiproteolytic activity
US5786364A (en) Bicyclic isothiourea derivatives useful in therapy
SK281442B6 (en) Bicyclic amidine derivatives, method of preparing thereof, pharmaceutical compositions containing theses derivatives and their use
AU2002214035A1 (en) Substituted alkyldiamines as inhibitors of plasmepsin or related proteases
RU2155761C2 (en) Bicyclic derivatives of amidine, method of their synthesis, pharmaceutical composition and method of inhibition of nitrogen oxide synthetase activity
IL115482A (en) Bicyclic amidine derivatives, their preparation and pharmaceutical compositions containing them
CZ388999A3 (en) Compounds
HUT77376A (en) Bicyclic amidine derivatives, process for their preparation, pharmaceutical compositions containing the same and their use
NZ290918A (en) Bicyclic amidines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94193688.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 269571

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 08586761

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PV1996-299

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 16396

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2169280

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 960628

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1994923776

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994923776

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1996-299

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1996-299

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1994923776

Country of ref document: EP